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Background. Cardiovascular diseases (CVDs) are the main cause of morbidity and 
mortality due to non-communicable diseases worldwide. Together with the already 
known CVDs risk factors related to lifestyle and genetic background, it is well recognized 
the importance of fetal life. The fetus can adapt to adverse intrauterine conditions to 
ensure survival. However, these conditions induce alterations in fetal development, 
which result, later in life, in an increased susceptibility to develop CVDs and its risk 
factors, particularly hypertension. This is known as Fetal Programming of Hypertension 
(FPH). Despite the efforts carried out so far, the mechanisms underlying the 
predisposition to FPH are not completely understood although some have been 
proposed to explain the relationship between poor fetal growth and later hypertension 
development. Two of the proposed mechanisms are the alteration of the renin-
angiotensin system (RAS) and an activation of sympathetic nervous system (SNS). 
However, the possible relationship between these two systems and their contribution 
to vascular functional and structural alterations in FPH is still to be addressed.  
In this Thesis the following hypothesis is postulated: “suboptimal nutrition during fetal 
life induces hypertension in male rats, at least in part, through an alteration in vascular 
sympathetic neurotransmission, and cross-talk with RAS”. The aim of this Thesis was to 
evaluate in a rat model of FPH if the vascular SNS and the RAS are altered, their interplay 
in vascular sympathetic neuromodulation, and contribution to arterial remodelling. 
Additionally, the SNS, vascular remodelling and hemodynamic alterations have been 
compared to those found in spontaneously hypertensive rat (SHR), a rat model of 
essential hypertension. The specific aims were to evaluate in male rats the influence of 
fetal undernutrition on: 1) hemodynamic parameters, mesenteric artery remodelling 
and sympathetic neurotransmission, comparing with SHR model, and 2) RAS alterations, 
assessing vascular expression of enzymes and receptors, circulating levels of angiotensin 
II (Ang II) and effect on sympathetic neurotransmission. Methods. This study was 
conducted in offspring from an experimental model of fetal programming in Sprague 
Dawley rats, induced by 50% restriction of maternal intake during the second half of 
pregnancy (Maternal Undernutrition, MUN), using as control, offspring from rats fed ad 









control the Wistar Kyoto (WKY) rat. The following parameters were assessed in 6 month 
old male offspring: 1) hemodynamic parameters  (intra-arterial measurements in 
anesthetized rats and tail-cuff plethysmography); 2) arterial remodelling  
(histomorphometric analysis of mesenteric artery, MA); 3) sympathetic innervation 
(fluorescence immunohistochemistry in MA); 4) sympathetic neurotransmission and the 
neuromodulatory role of Ang II (3H-noradrenaline release by electrical field stimulation); 
5) plasma determination of Ang II (ELISA); 6) expression of RAS enzymes (renin, 
angiotensin converting enzyme (ACE) and ACE2) and receptors (AT1, AT2, Mas and MrgD) 
by RT-PCR in MA; 7) RAS receptors distribution in the adventitia of MA (fluorescence 
immunohistochemistry); 8) Localization of NADPH oxidase, the main enzyme 
responsible for ROS production, in the adventitia of MA (fluorescence 
immunohistochemistry) . Results. Fetal nutrient restriction induces: 1) hypertension; 2) 
inward hypertrophic remodelling with fibrosis of MA; 3) higher immunoreactivity for 
tyrosine hydroxylase (sympathetic nerves marker); 4) higher noradrenaline release and 
uptake; 5) higher tonic facilitation by endogenous Ang II through presynaptic AT1 
receptors; 6) higher RNA expression of ACE1 and ACE2; 7) higher RNA expression of AT1 
receptors and lower levels of AT2, Mas and MrgD receptors; 7) higher immunoreactivity 
for NADPH oxidase in the adventitia layer. Conclusions. Adult males exposed to fetal 
undernutrition exhibit vascular sympathetic innervation hypertrophy and 
hyperactivation of sympathetic neurotransmission, at least in part, related to facilitation 
by Ang II through AT1 receptors. These modifications may be responsible for the 
observed remodelling and fibrosis through oxidative damage. All of these findings 
contribute to increase vascular resistance and consequently, to hypertension. The 
sympathetic alterations and vascular remodelling alterations found in FPH are similar to 













Antecedentes. Las enfermedades cardiovasculares (ECV) son la principal causa de 
morbilidad y mortalidad por enfermedades no transmisibles en el mundo. Junto con los 
factores de riesgo clásicos relacionados con el estilo de vida y antecedentes genéticos, 
se conoce la importancia de la vida fetal en el desarrollo de ECV. Ante un ambiente 
intrauterino adverso, el feto se adapta para asegurar la supervivencia. Sin embargo, 
estas condiciones inducen alteraciones en su desarrollo, lo que conduce a una mayor 
susceptibilidad para desarrollar ECV y sus factores de riesgo -particularmente 
hipertensión- en etapas posteriores de la vida. Esto se conoce como programación fetal 
de la hipertensión (FPH). A pesar de los esfuerzos, los mecanismos subyacentes a la 
programación fetal no se comprenden completamente, aunque se han propuesto 
algunos para explicar la relación entre un crecimiento fetal deficiente y el desarrollo 
posterior de hipertensión. Dos de los mecanismos propuestos son la alteración del 
sistema renina-angiotensina (SRA) y la activación del sistema nervioso simpático (SNS). 
Sin embargo, la posible relación entre estos dos sistemas y su contribución a las 
alteraciones vasculares funcionales y estructurales en la FPH aún no se ha abordado. En 
esta Tesis se postula la siguiente hipótesis: "la nutrición subóptima durante la vida fetal 
induce hipertensión en ratas machos, al menos en parte, a través de una alteración en 
la neurotransmisión simpática vascular, a través de una interacción con el SRA". El 
objetivo de esta Tesis fue evaluar en un modelo de FPH en rata si el SNS vascular y el 
SRA están alterado, si existe interacción entre ambos sistemas en la neuromodulación 
simpática vascular y la contribución de estas alteraciones al remodelado vascular. 
Además, las alteraciones hemodinámicas, el remodelado vascular y las modificaciones 
del SNS se han comparado con las encontradas en ratas espontáneamente hipertensas 
(SHR), un modelo de rata de hipertensión esencial. Los objetivos específicos fueron 
evaluar en ratas machos la influencia de la desnutrición fetal en: 1) parámetros 
hemodinámicos, el remodelado y la neurotransmisión simpática de la arteria 
mesentérica (AM), comparando los resultados con el modelo SHR de hipertensión 
esencial y 2) las alteraciones en el SRA, evaluando la expresión de enzimas y receptores, 
niveles circulantes de angiotensina II (Ang II) y su posible efecto sobre la 









modelo experimental de programación fetal, en ratas Sprague Dawley, inducida por una 
restricción del 50% de la ingesta materna durante la segunda mitad de la gestación 
(Maternal Undernutrition, MUN), utilizando como control, descendientes de ratas 
alimentadas ad libitum (CONTROL). Las ratas SHR se utilizaron como modelo de rata de 
hipertensión esencial, siendo su control la rata Wistar Kyoto (WKY). Los siguientes 
parámetros se evaluaron en descendientes macho de 6 meses de edad: 1) parámetros 
hemodinámicos (medida intra-arterial en ratas anestesiadas y pletismografía en la cola; 
2) remodelado vascular (análisis histomorfométrico de AM) ; 3) inervación simpática 
(inmunohistoquímica de fluorescencia y microscopia Confocal en AM); 4) 
neurotransmisión simpática en la AM y el papel neuromodulador de Ang II 
(experimentos de liberación de 3H-noradrenalina por estimulación eléctrica); 5) 
determinación plasmática de Ang II (ELISA); 6) expresión de enzimas del SRA (renina, 
enzima convertidora de angiotensina (ACE1) y ACE2) y receptores (AT1, AT2, Mas y MrgD) 
por RT-PCR en AM; 7) distribución de receptores del SRA en la adventicia arteria 
mesentérica  (immunohistoquímica de fluorescencia); 8) la presencia de NADPH oxidasa, 
la enzima principal responsable de la producción de ROS, en la adventicia de la AM 
(immunohistoquímica de fluorescencia y microscopia Confocal). Resultados. La 
restricción de nutrientes en la etapa fetal induce: 1) hipertensión; 2) remodelado 
hipertrófico de tipo “inward” con fibrosis en la AM; 3) mayor immuno-reactividad para 
tirosina hidroxilasa (marcador de inervación simpática); 4) mayor liberación y absorción 
de noradrenalina; 5) facilitación tónica por Ang II endógena a través de receptores 
presinápticos AT1; 6) mayor expresión de ARN de las enzimas ACE1 y ACE2; 7) mayor 
expresión de ARN de los receptores AT1 y menor de los receptores AT2, Mas y MrgD; 7) 
mayor immunoreactividad para NADPH oxidasa en la capa de adventicia. Conclusiones. 
En la etapa adulta, los machos expuestos a desnutrición fetal muestran una hipertrofia 
de la inervación simpática vascular e hiperactivación de la neurotransmisión simpática, 
al menos en parte, relacionada con alteraciones del SRA vascular. Estas modificaciones 
pueden ser responsables del remodelado y la fibrosis vascular a través de daño 
oxidativo. Todas estas alteraciones contribuyen a aumentar la resistencia vascular y, en 
consecuencia, contribuir al desarrollo de hipertensión. Las alteraciones del SNS y del 
























I. CARDIOVASCULAR DISEASES 
 
Cardiovascular diseases (CVDs) are considered non-communicable chronic diseases and 
are the result of a combination of genetic, physiological, environmental and behaviours 
factors. CVDs comprise disorders of the heart and of blood vessels, including those 
supplying the heart muscle, the brain, the kidney, the arms and legs, among others. The 
most important acute cardiovascular events occur mainly because a blockage that 
prevents blood from flowing to the heart or brain. In the heart, atherosclerosis or 
abnormal blood clots, can lead to a thrombus and cut off or reduce the blood flow to 
part of the heart muscle. This is known as Coronary Heart Disease. When the blood flow 
to the heart is cut off, the decrease in oxygen and nutrients supply damages the heart 
tissue resulting in a heart attack. In the brain, a reduction of blood flow can lead to a 
stroke. A stroke can be ischemic when a blood vessel that irrigates the brain gets 
blocked, usually from a blood clot or atherosclerosis, or hemorrhagic, when a blood 
vessel within the brain bursts. Hemorrhagic stroke is most often caused by uncontrolled 
hypertension. In addition to acute cardiovascular events, CVDs also lead to chronic 
alterations, like Congestive Heart Failure (reduced pumping capacity of the heart), atrial 
fibrillation (uncoordinated atrial activation) and Chronic Kidney Failure (reduced 
capacity of the kidneys to carry out their function). High blood pressure (BP) also plays 
a key role in the development of these chronic CVDs [1].  
 
i. EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES 
CVDs are the number one cause of morbidity and mortality in the world, and are 
responsible for 49% of mortality in Europe, being ischemic heart disease and stroke the 















FIGURE 1| Causes of deaths in Europe in 2016 in males (A) and females (B). Source: World Health 
Organization Mortality Database. 
 
In Iberian Peninsula the scenario is very similar. In both Spain and Portugal CVDs are the 
first cause of death, according to the last national statistical records (Figure 2). These 




FIGURE 2| Mortality national rate by cardiovascular diseases in Spain in 2017 (A) and in Portugal between 
2011 and 2017 (B) and its distribution through the country. Results are presented as a percentage of 













Despite of the numerous efforts taken so far to revert these numbers, unfortunately, 
they have not been reduced over the years. Therefore, the role of prevention become 
even more important, namely by controlling the possible risk factors associated with 
CVDs [3]. These risk factors can be classified as modifiable and non-modifiable. Non 
modifiable risk factors are those we cannot change. They include inheritance-positive 
family history, age and sex. CVDs are more frequent in men over age 45 and women 
over 55 years. The delay in the occurrence of CVDs in women, after menopause, is 
related to the protective effects exerted by female sex hormones on the cardiovascular 
system. On the other hand, modifiable risk factors are those we can influence by 
changing unhealthy lifestyle habits such as: smoking, harmful use of alcohol, insufficient 
physical activity, and high fat diets leading to obesity. In addition, some diseases such as 
elevated BP, hyperlipidaemia and diabetes are also important modifiable risk factors 
that can be controlled [2, 4].  
 
ii. HYPERTENSION AS RISK FACTOR FOR CARDIOVASCULAR DISEASES 
Hypertension is defined as Systolic Blood Pressure (SBP) values ≥140 mmHg and/or 
diastolic BP (DBP) values ≥90 mmHg [5]. It can be classified into several degrees: High 
normal, Grade 1, Grade 2 and Grade 3 hypertension. The risk to develop a CVDs depends 
on the level of hypertension as well as the number of other CVDs risk factors. As so, risk 
can be stratified, simplifying the diagnosis and treatment decisions (Figure 3). 
According to the World Health Organization (WHO), an estimated 1.13 billion people 
worldwide have hypertension, most (two-thirds) living in low- and middle-income 
countries. In Europe, the prevalence of hypertension in different countries seems to be 
about 30–45% of the overall population, with a steep increase with ageing [4].  
During the last 2 decades, the number of diagnosed hypertensive patients has increased, 
as shown in the figure below regarding prescription of antihypertensive drugs (Figure 
4). However, it is important to mention that a considerable percentage of hypertensive 














FIGURE 3| Stratification of total cardiovascular risk in categories of low, moderate, high and very high. 
RF: risk factors; OD: organ damage; SBP: systolic blood pressure; DBP: diastolic blood pressure; HT: 
hypertension; CVD: cardiovascular disease; CKD: chronic kidney disease. Source: Kjeldsen, 2018  
 
 
FIGURE 4| Antihypertensive drug prescriptions in 2000 (blue) and 2013 (red) in Europe. Source: European 













Hypertension may be classified as primary -of unknown origin- or secondary -with a 
known etiology, including renal, vascular, and endocrine causes. Primary, also known as 
essential hypertension, accounts for 90-95% of adult cases. As so, the majority of 
hypertensive patients exhibit an undefined etiology for a sustained increase in BP.  
Since 2003, the Global Burden of Disease Study, organized by the WHO, has pointed 
hypertension as the most important global risk factor for morbidity and mortality. 
Indeed, hypertension is the strongest modifiable risk factor associated with the most 
important CVDs related to the generation of vascular damage in the heart, brain and 
kidneys;  namely, coronary heart disease, heart failure, atrial fibrillation, left ventricular 
hypertrophy, cerebral stroke and renal failure [7].  
Nowadays, more than 100 commercial drugs and drug combinations are available for 
treating hypertension. However, a substantial proportion of the hypertensive 
population has uncontrolled or suboptimally controlled hypertension [8], a fact that 
contributes to the growing global burden of CVDs [9].  
 
iii. MODEL OF ESSENTIAL HYPERTENSION  
Due to the complexity of the pathophysiology of hypertension, experimental animal 
models are very useful for investigating specific factors that may be involved in the 
development or maintenance of the disease [10, 11].  
The spontaneously hypertensive rat (SHR) strain was developed by Okamoto's group, by 
selecting and crossing rats of the Wistar Kyoto (WKY) strain that presented high BP [12]. 
The SHR rat is a good model for the study of human essential hypertension since it shares 
some physio-pathological similarities. Among them, a genetic predisposition to high BP 
without a specific etiology, an increase in peripheral total resistance and a similar 
response to drugs with BP lowering effects.  Besides, there is evidence of alterations in 
vascular sympathetic neurotransmission, remodelling, oxidative stress and RAS, also 
present in human essential hypertension. Finally, there is a sexual dimorphism in the 
development of hypertension, with higher BP values in male rats. Based on these 
features the SHR was the chosen model of essential hypertension to perform 












II. MECHANISMS IMPLICATED IN HYPERTENSION 
 
The origin of essential hypertension is still unknown; however multiple mechanisms are 
recognized to be involved in the physiopathology of this disease. Among them, vascular 
remodelling, alterations in renin-angiotensin system (RAS), sympathetic nervous system 
(SNS), and oxidative stress are briefly described below, due to their importance in this 
work.  
 
i. VASCULAR REMODELLING 
Blood vessels are capable of structural changes in a dynamic process called vascular 
remodelling, which involves cell growth, death, phenotypic change and migration, as 
well as deposition of collagen, fibronectin, and other components of the extracellular 
matrix [13]. Vascular remodelling is also accompanied by altered vascular tone 
(decreased relaxation and/or increased contraction), associated with mild inflammation 
and fibrosis [14, 15]. Vascular remodelling can be a physiological process to adapt blood 
vessels to new hemodynamic or humoral conditions. However, in the end, it may be 
deleterious and contribute to CVDs development. 
 
a. Vascular Wall 
Blood vessels are an intrinsic part of cardiovascular system since they are the structures 
through which blood flows throughout the body. All blood vessels follow the same 
general histological structure. Nevertheless, they present differences that histologically 
differentiate arteries from veins (Figure 5).  
The vascular wall is formed by 3 different tunicas or layers. The vascular layer that is in 
direct contact with the blood flow is the tunica intima (commonly called the intima 
layer), made up mainly of endothelial cells. The next layer is the tunica media (known as 
the media layer), with vascular smooth muscle cells (VSMC) and connective tissue. The 
outermost layer is known as the tunica adventitia (the adventitia layer), and it is 













FIGURE 5| Schematic representation of the vascular wall (A) and histological representative images of an 
artery and a vein (B). All layers of the vascular wall are represented (adapted from Pearson Education 
Inc., 2014). 
 
As the thickness of vein walls is typically much less than the diameter of the lumen (i.e., 
proportionately much thinner than arteries carrying a similar volume), veins tend to 
appear flattened or collapsed in cross-section of histological preparations (in contrast to 
arteries, which tend to appear more round) (Figure 5B).  
The intima is the inner layer of a blood vessel, consisting in a very thin lining of simple 
squamous endothelial cells supported by a similarly thin layer of connective tissue. In 
arteries this layer is composed of an elastic membrane lining, and smooth endothelium 
that is covered by elastic tissue [17]. The endothelium has key physiological roles to 
regulate blood vessels function since endothelial cells are situated at a critical location, 
between the blood and all other body cells. Endothelial cells secrete substances which 












crucial, since damage can lead to atherosclerosis, abnormal clotting, and reduced 
vasodilatation.  
The media is the middle layer of a blood vessel and, in most arteries, it is the thickest of 
the three tunics. The thickness of the media is generally proportional to the overall 
diameter of the vessel. The media of arteries is generally thicker than the media of veins 
of comparable diameter. The media consists of VSMC and elastic tissue in varying 
proportions.  Elastic arteries have the highest proportion of elastic tissue while muscular 
arteries have the highest proportion of VSMC [17]. In most vessels, VSMC are arranged 
circumferentially, so the plane of section across an artery can be deduced by the 
orientation or shape of VSMC nuclei. The media elastic tissue is organized in concentric 
lamellas which alternate with VSMC forming the lamellar unit, which is the functional 
unit of the vessel wall. The number of lamellar units is directly proportional to the 
tension supported by the wall, and is maximal in the aorta. 
The adventitia is the outer layer of the artery, composed of connective tissue with 
collagen and elastic fibres. The fibres of adventitial connective tissue tend to be more 
concentric around the vessel, and often somewhat denser than the surrounding 
connective tissue (fascia).  In some blood vessels, the adventitia contains sympathetic 
innervation, and, in large arteries this layer harbours vasa vasorum, small vessels which 
supply oxygen and nutrients to the arterial wall. The adventitial layer is surrounded by 
adipose tissue that secrets adipokines, that also regulate the tone of the vessel [17].  
 
b. Importance of the tunicas in vascular remodelling 
VSMC are the most abundant cell type in the arterial wall and are essential in 
maintaining vessel structure and function, and so, playing a key role in arterial 
remodelling [18]. VSMC display a high degree of plasticity [19]. Under physiological 
conditions, VSMC have a contractile phenotype, which facilitates the contraction and 
dilation of the vasculature and, in turn, regulates the blood flow. Upon biological stress 
signals or vascular injury, VSMC respond by losing contractility markers and differentiate 













The adventitia has been mostly disregarded as participating in the development of 
vascular disease, whereas the media and intima have been seen as the predominate 
layers involved in the formation of atherosclerotic plaques and vascular remodelling 
[21].  Historically, it has been described as a purely structural asset to the arterial wall, 
presenting a support function for the underlying layers of the vessel, because the most 
common cell in the adventitia, the fibroblast, was seen mostly as a producer of the 
extracellular matrix (collagen types I and III) [22]. However, this has changed as multiple 
studies over the past decade have strongly refuted the idea that the adventitia plays 
only a passive role in the vasculature. Indeed, some studies demonstrate that adventitia 
is the most complex compartment of the vessel that integrates key regulators of vessel 
wall function [23, 24]. Moreover data demonstrate that wall changes in the adventitia 
occur early in the course of vascular disease development, before changes are seen in 
the intima or the media [21]. In the literature the influence of intima to media layers and 
vice versa is well established: endothelial cells can release mediators that alter the tonus 
of VSMC and VSMC can also influence the activity of endothelial cells [25]. Recent data 
has also highlight the interplay of intima with adventitia since endothelial cells have 
been shown to release mediators able to alter vascular sympathetic tonus [25-27]. 
 
c. Classification of arteries 
Since arteries play a major role in nourishing organs with blood and nutrients, they are 
always under high pressure. To accommodate this stress, in the media layer of larger 
arteries, they present an abundance of elastic tissue and less smooth muscle. When an 
artery reaches a particular organ, it undergoes further division into smaller vessels, 
which have more smooth muscle and less elastic tissue. As the diameter of the blood 
vessels decreases, the velocity of blood flow also diminishes. 
There are two main types of arteries found in the body: the elastic and the muscular 
arteries. Muscular arteries include the anatomically named arteries like the brachial 
artery, the radial artery, and the femoral artery for example. Muscular arteries contain 
more VSMC in the tunica media than the elastic arteries. Elastic arteries are larger 












more elastic tissue in the tunica media. This feature allows to maintain a relatively 
constant pressure gradient along the cardiac cycle. 
Muscular arteries branch into small diameter arteries with fewer VSMC layers called 
resistance arteries. They contribute significantly to the creation of the resistance to flow 
and regulation of blood flow through the degree of the contraction of the VSMC and 
lumen narrowing. Resistance arteries divide into arterioles, which contain only 1 VSMC 
layer and these branch into meta-arterioles and capillaries, which have the role of 
exchange nutrients and gas [17]. 
 
d. Classification of vascular remodelling 
As stated above, blood vessels undergo structural changes, which modify their geometry 
and composition. According to the alterations in lumen size, vascular remodelling can 
be classified as outward or inward remodelling, if lumen expands or narrows, 
respectively. According to changes in wall cross sectional area, it can be classified as 
hypertrophic (increased), hypotrophic (decrease) or eutrophic (no change) (Figure 6) 











FIGURE 6| Types of vascular remodelling according to geometrical changes. Different types of arterial 
remodelling can be distinguished: hypotrophic (left column), eutrophic (center column) and hypertrophic 












In addition, an important parameter is the wall thickness/lumen, since it has been 
demonstrated in resistance arteries from human subjects that an increase in wall/lumen 
ratio, is associated with higher risk of adverse cardiovascular events [28, 29]. 
Vascular remodelling characteristics are different depending on the underlying 
pathophysiology (e.g., aneurysms, essential or secondary hypertension, diabetes, etc.) 
and arterial site (e.g., central elastic arteries or peripheral resistance arteries) [14].  In 
resistance arteries, the main characteristic is a decrease in lumen diameter and an 
increase in media thickness, sometimes resulting in hypertrophic or eutrophic 
remodelling. This alteration leads to an increase in total peripheral vascular resistance 
[30]. Large arteries however do not have the ability to constrict in response to stress, 
and therefore show outward hypertrophic or eutrophic remodelling, characterized by 
increased vessel diameter usually accompanied by thickened intima and media layers of 
the vascular wall [14].  
The thickening of the arterial wall may be caused by intima hyperplasia, media 
hypertrophy and hyperplasia of VSMC. Upon activation of VSMC by certain stimulus, 
they activate and change phenotype. This, in turn, alter their function and increase the 
deposition of extracellular matrix material. These changes in composition contribute to 
alterations in vascular function, both in active function of the endothelial and VSMC, and 
also in the mechanical behaviour of the arterial wall, particularly when collagen 
deposition is increased, leading to fibrosis [28, 31].  
 
e. Mechanisms implicated in hypertensive vascular remodelling 
Remodelling of large and small arteries contributes to the development and 
complications of hypertension (Figure 7) [15].  
Vascular remodelling can be a consequence of alterations in hemodynamic parameters. 
For example, sustained high BP can be a stimulus for wall growth or lumen reduction, 
since it would increase wall stress (wall stress=pressure x vessel diameter/2xwall 
thickness). This parameter has to remain relatively constant and, if increased, it may 
cause vessels rupture. Therefore, if pressure is increased for a long time, this stimulates 












wall stress to initial conditions [32]. Despite the fact that this is a physiological adaptive 
response, if a stimulus is chronically maintained, it will be deleterious for arterial 
function.  
In addition to alterations in hemodynamic conditions, several humoral factors can be 
implicated in vascular remodelling, such as reactive oxygen species (ROS), angiotensin II 
(Ang II), noradrenaline (NA), and several growth factors.  
ROS are well known to be involved in the pathogenesis of hypertension. Among other 
actions, they are implicated in vascular cell growth and death; specifically, superoxide 
anion (•O2-) induces proliferation and, hydrogen peroxide (H2O2), may induce apoptosis 
via a protein kinase C–dependent mechanism [33].  
Ang II also modulates apoptosis throughout the activation of angiotensin receptor type 
1 (AT1) and type 2 (AT2) [34, 35]. Ang II also mediates inflammation in the vasculature 
mainly by stimulation of •O2- production and subsequent activation of redox-dependent 
signalling cascades [15, 36]. Further proof of the role of AT1 receptors in vascular 
remodelling is found in studies which demonstrate that AT1 receptor antagonists regress 
vascular structural changes in hypertensive patients [36]. 
FIGURE 7| Pathophysiological mechanisms of arterial remodelling. Cross sectional schematic view of the 
arterial wall. (A) Normal situation. (B) Arterial remodelling. Arterial remodelling is characterized by 
thickening of the wall. Elastic fiber degradation, extracellular matrix calcification and collagen deposition 
lead to adaptation of the vascular wall. Abbreviations: TGF-β, transforming growth factor-beta; IL-1, 















ii. ENDOTHELIAL DYSFUNCTION 
Accumulating evidence has demonstrated that endothelial functions are essential to 
ensure proper maintenance of vascular homeostasis [37]. Endothelial cells are exposed 
to the shear stress resulting from blood flow and can convert mechanical stimuli into 
intracellular or biochemical signals (proliferation, apoptosis, migration, remodelling, 
etc.). In fact, the endothelium can modulate the vascular tone by synthesizing and 
releasing a variety of factors, including vasodilators, like prostaglandins, nitric oxide 
(NO), and endothelium-dependent hyperpolarization factors, as well as 
vasoconstrictors, such as endothelin-1, Ang II, thromboxane A2, and ROS. All these 
molecules influence vascular tone [14].  
A healthy endothelium presents an athero-protective capacity, through the promotion 
of vasodilation, its antioxidant and anti-inflammatory effects, as well as the inhibition of 
leukocyte adhesion and migration and VSMC proliferation and migration. Also, a healthy 
endothelium has anticoagulant and pro-fibrinolytic effects, as well as an inhibitory 
action on platelet aggregation [38]. All these aspects occur due to a balance between 
endothelium‐derived relaxing and contracting factors (Figure 8). Disturbance of this 
balance causes endothelial dysfunction and it is a hallmark of an extensive range of CVDs 
associated with pathological conditions toward vasoconstriction, thrombosis, and 









FIGURE 8| The balance between endothelium‐derived relaxing factors (EDRF) and endothelium‐derived 
contracting factors (EDCF). PGI2, prostacyclin; PGH2, Prostaglandin H2; TXA2, Thromboxane A2 (from 













Endothelial dysfunction has a critical role in the development of hypertension and 
contributes to the progression of organ damage [38, 39]. 
In hypertension, sustained elevation of systemic pressure in the microvasculature leads 
to premature aging and increased turnover of endothelial cells.  As a result, there is a 
disruption of multiple endothelial-dependent mechanisms that can contribute to 
maintain hypertension (Figure 9). Endothelial dysfunction is associated with a reduction 
of the NO bioavailability, either due to decreased production by NO synthases (NOS), or 
to increased destruction by ROS. 
Endothelial dysfunction in hypertension is also linked to impairment in the response of 
VSMC to vasodilators, elevated sensitivity of endothelial cells against vasoconstrictors, 
increased production of vasoconstrictor substances, or elevated shear stress. All these 
leads to functional changes in the vasculature with a predominant and deleterious 














FIGURE 9| Representative scheme of endothelial control of vascular tone. Vasodilator pathways include 
the prostacyclin, endothelium-derived hyperpolarization, angiotensin, and nitric oxide (NO) pathways 
that are additionally influenced by endothelin and superoxide production. Vasoconstrictor pathways 
include endothelin, adrenergic, angiotensin, and thromboxane pathways. Endothelial and smooth muscle 
membrane hyperpolarization has been depicted by an action potential symbol. α1, alpha 1-adrenergic 
receptor; α2, alpha 2-adrenergic receptor; ANG II, angiotensin II; AT1, angiotensin 1 receptor; AT2, 
angiotensin 2 receptor; β2, beta 2-adrenergic receptor; big ET, big endothelin; BKCa, large conductance 
calcium-activated potassium channel; Ca2+, molecular calcium; EET, epoxyeicosatrienoic acid; eNOS, 
endothelial nitric oxide synthase; ET, endothelin; ETA, endothelin A receptor; ETB, endothelin B receptor; 
Gi, inhibitory G protein; Gq, phospholipase C activating G protein; Gs, stimulatory G protein; IKCa, 
intermediate conductance calcium activated potassium channel; IP, prostacyclin receptor; IP3, inositol 
triphosphate; K+, molecular potassium; KIR, inward-rectifying potassium channel; Kv, voltage-gated 
potassium channel; Mas, angiotensin mas receptor; MEGJ, myoendothelial gap junction; Na/K, sodium 
potassium ATPase exchanger; NA, noradrenaline; O2·, superoxide; OONO-, peroxynitrite; PGI2, 
prostacyclin (also known as prostaglandin I2); prepro ET, prepro endothelin; SKCa, small-conductance 
calcium-activated potassium channel; SOD, superoxide dismutase; TP, thromboxane receptor; TXA2, 

















iii. RENIN-ANGIOTENSIN SYSTEM 
a. The RAS and vascular function 
The RAS is a very complex system with many peptides and receptors involved. Briefly, 
angiotensinogen is released from the liver and is cleaved in the circulation by the 
enzyme renin, secreted from the juxtaglomerular apparatus of the kidney, to form 
angiotensin I (Ang I). Then, Ang I is transformed to Ang II by angiotensin converting 
enzyme (ACE), which is expressed in high levels on the surface of endothelial cells in the 
pulmonary circulation [40, 41]. Ang II, considered as the most powerful active peptide 
of the RAS, acts on specific receptors: AT1 and AT2, being the AT1 receptor predominant.  
Recently, new peptides, enzymes and receptors with biological activity have been 
reported as components of the RAS [40-42]. Among them, the peptide angiotensin-(1-
7) (Ang 1-7), that is mainly formed directly from Ang II, by angiotensin converting 
enzyme 2 (ACE2), and the peptide alamandine. These peptides bind, respectively, to 
receptor Mas and Mas-related G protein coupled receptor D (MrgD), and counteract the 
main effects of Ang II through AT1 receptor (Figure 10).  
With these new findings the RAS is now classified in 2 axis, the classical and the non-
classical. The classical axis includes the renin/ACE/Ang II/AT1 receptor. The non-classical 
axis includes the ACE2/Ang 1-7 and alamandine/acting on Mas and MrgD receptors [40]. 
These 2 axis seem to have opposing actions on the cardiovascular system. The classical 
RAS axis releases Ang II, which promotes vasoconstriction and increase oxidative stress, 
fibrosis, and inflammation by activating AT1 receptor. The non-classical RAS axis leads to 
Ang 1-7 and alamandine acting on Mas and MrgD receptors, which cause an increase of 
NO bioavailability and a decrease of oxidative stress, through inhibition of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase [40]. Also these new RAS players 
seem to be protective avoiding remodelling and vascular wall structural alterations [41]. 
Therefore, dysregulation of the classical and non-classical RAS axis -either in the 
enzymes and subsequent peptide production or in the expression of the specific 












FIGURE 10| Identified angiotensin peptides and receptors in RAS signaling. ANG, angiotensin; ACE, 
angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; CarboxPep, carboxipeptidase; 
AminoPep, aminopeptidase; PRR, (pro)renin receptor;  AT1R, angiotensin type-1 receptor; AT2R, 
angiotensin type 2 receptor; AT4R, angiotensin type 4 receptor; MAS, Ang-(1-7) receptor Mas; MrgD, MAS 
related G-protein coupled receptor D (from Forrester et al., 2018). 
 
Experimental evidence also support the concept that local RAS is present in different 
organs including the heart and kidney, and in VSMC, contributing to local regulation of 
tissue and organ function [43]. Indeed, the synthesis of several components of the RAS 
in the heart and vessels, or their uptake from plasma, makes possible the synthesis of 
Ang II locally. Evidence demonstrate that angiotensinogen, ACE, Ang I, and Ang II are 
synthesized in the VSMC and the presence of renin has been found in these cells [43]. 
The origin of vascular renin, in vivo, might be related to local production or be related 
to its uptake from the circulation, which is known to play an important role in the 













b. RAS alterations in hypertension 
The RAS influences a large range of homeostatic and modulatory processes including 
regulation of salt and water balance, vasoconstriction, cell/tissue remodelling. 
Therefore, an alteration in RAS is linked to alterations in the cardiovascular system.  
In fact, the involvement of the RAS in the pathophysiology of hypertension has been 
known for many years and various components of the systemic RAS are pharmacological 
targets to treat CVDs, including renin inhibitors, ACE inhibitors, and AT1 receptor 
antagonists [44, 45]. All of these drugs are primarily designed to block and/or reduce 
the harmful effects of Ang II. There is, however, increasing evidence that in addition to 
Ang II, many other angiotensin peptides such as Ang III (Ang 2-8), Ang IV (Ang 3-8), Ang 
1-9 and Ang 3-7 have important physiologic effects. These new findings have opened 
new advances for the development of novel drugs targeting the RAS to better treat 
hypertension.  New strategies include gene therapy to suppress angiotensinogen at the 
RNA level, recombinant ACE2 protein, and novel bispecific designer peptides [46]. 
Below, there is information on the effects of the different RAS receptors, cantered on 
the role on vascular physiological and pathophysiological processes.  
 
c. RAS receptors 
AT1 Receptor 
The AT1 receptor is predominantly expressed in various tissues throughout the 
cardiovascular system including VSMC, endothelium, heart and kidney [47].  
The effects of AT1 receptor activation by Ang II varies depending on the tissue. Among 
other actions, Ang II binding to AT1 receptor leads to VSMC vasoconstriction and 
hypertrophy, cardiac myocyte hyperplasia, aldosterone release, renal sodium 
reabsorption and sympathetic nervous adrenergic facilitation in the SNS [48]. AT1 
receptor triggers several intracellular signalling pathways through the activation of 
various protein kinases (e.g. activation of phospholipase C, generation of inositol 
phosphate and Ca2+ release, mitogen-activated protein (MAP) kinase activation, etc.). 












vascular remodelling, promotion of tissue inflammation and fibrosis, increased oxidative 
stress and increased aldosterone production [47]. AT1 receptors in the VSMC once 
activated increase the intracellular pool of Ca2+, which in turn, lead to VSMC contraction. 
This vasoconstriction, ultimately, lead to an increase in BP [49]. 
AT1 receptor antagonists are an important pharmacological tool consistently used for 
the treatment of hypertension and diabetic nephropathy. 
 
AT2 Receptor 
AT2 receptor expression is very high in embryonic tissues and decreases shortly after 
birth in most organs. Nevertheless, lower AT2 receptor expression is maintained in 
kidneys, heart, blood vessels and brain [50, 51]. AT2 receptor has been shown to be 
constitutively expressed at a low level in the physiological state, but is markedly up-
regulated in certain cardiovascular disorders, including hypertension [52]. 
Although the physiological/pathophysiological roles of the AT2 receptor have not been 
fully clarified, there is an increasing interest in AT2 receptor functions in the 
cardiovascular system [53]. Current knowledge suggests that under normal physiologic 
conditions, AT2 receptor counterbalances the effects of AT1 receptor, inhibiting cell 
proliferation and differentiation, promoting vasodilation, and reducing inflammation 
and oxidative stress [51]. It is known that AT2 receptor stimulation causes vasodilation 
through endothelial nitric oxide synthase (eNOS) activation, among other molecules [53, 
54], and pharmacological stimulation of AT2 receptor promotes natriuresis and reduces 
BP [55]. Up-regulation in AT2 receptor expression has support their implication in wound 
healing, tissue remodelling and reduced inflammation [52].  
All of these beneficial effects have suggested the possibility that AT2 receptor agonist 
















The Mas receptor is a proto-oncogene that is expressed in brain, kidneys, heart and 
blood vessels of both humans and mice [57].  
Gene and pharmacological manipulation studies reveal that Mas receptor is involved in 
natriuretic, vasodilatory, antiproliferative and anti-inflammatory responses, and in BP 
lowering in various animal models of hypertension, such as salt-sensitive hypertension 
[58]. The most reported signalling pathways linked to Mas stimulation in the vasculature 
[59] and heart [60] are those related to prostaglandins, and NO production through 
activation of eNOS, highlighting the importance of the Ang 1-7/Mas axis as a putative 
regulator of endothelial function. 
 
MrgD Receptor 
Mas-related genes (Mrgs), a large family of G-protein coupled receptors (GPCRs), have 
been divided into subfamilies established by sequence homology (MrgA, MrgB, and 
MrgC), and some more single genes (MrgD, MrgE, MrgF, MrgG, MrgH, and Mas 1) [61].  
MrgD is widely expressed in sensory neurons in the dorsal root spinal ganglia, but it can 
be located in other organs in lower levels, namely in arteries and in the heart [41].  
The MrgD receptor ligand (alamandine) only differs from Ang 1-7 in one amino acid (an 
alanine instead of aspartate in the N-terminal domain). Therefore, the biological actions 
of these peptides are very similar. Alamandine and Ang 1-7 have been demonstrated to 
produce endothelial-dependent vasodilation, and were able to modulate the baroreflex 
sensibility facilitating bradycardia [42]. However, some different actions between these 
two peptides have also been reported. For example, while Ang 1-7 exhibits 
antiproliferative effects on tumour cells, this effect was not observed for alamandine 
[41, 62].  
In SHR, alamandine induced vasodilatation and demonstrate antihypertensive effects 
[62]. Besides, in isoproterenol-treated rats, almandine had pronounced cardioprotective 












orally, opens new perspectives for exploring the therapeutic potential of Ang 1–7–
related peptides in the treatment of CVDs [62]. 
 
 
iv. SYMPATHETIC NERVOUS SYSTEM 
The autonomic nervous system is a major regulator of the cardiovascular system. The 
SNS is the component of the autonomic nervous system that is responsible for 
controlling the human body’s reaction to situations of stress or emergency, while the 
parasympathetic nervous system is generally responsible for basal organ and system 
function. 
These two divisions regulate heart rate (HR) and BP in the short-term. Parasympathetic 
modulation decreases the HR and cardiac contractility, whereas activity of the 
sympathetic branch opposes these effects, and also regulates peripheral 
vasoconstriction. In fact, most blood vessels lack parasympathetic innervations and their 
diameter is regulated by SNS input, so that they have a constant state of sympathetic 
tone.  
The SNS has an integral role in the regulation of HR and contractility, vascular tone and 
fluid volume. The activation of SNS in the heart releases NA, a neurotransmitter that 
binds to adrenoceptors (primary β-adrenoceptors), increasing HR, contractility and 
velocity of electrical impulse conduction, resulting in an increased cardiac output and 
arterial BP. On the other hand, NA can also bind to α-adrenoceptors in the VSMC causing 
vasoconstriction, which also contributes to BP increase. α-adrenoceptors (1 and 2) are 
the main type of receptors in blood vessels, but β-adrenoceptors (few 1, 2 and also 
3) are also present in the vasculature [63, 64]. 
 
a. Vascular sympathetic neurotransmission 
In sympathetic nervous system, large axons, even those unmyelinated, are surrounded 
by a lipid-rich sheath of Schwann cells. The plasma membrane of these glial cells folds 












travel in individual channels in the Schwann cells, but when nerve fibres are small they 
can bundled together within a single channel [65]. 
In SNS, the majority of the postganglionic endings release NA. NA is synthesized inside 
the nerve axon, stored within vesicles, and then released by the nerve when an action 
potential travels down the sympathetic nerve. Briefly, the amino acid tyrosine, 
transported into the sympathetic nerve axon, is converted to DOPA by tyrosine 
hydroxylase (TH), a rate-limiting step for NA synthesis. DOPA is then converted to 
dopamine by DOPA decarboxylase. Dopamine is transported into vesicles then 
converted to NA by dopamine β-hydroxylase. When an action potential traveling down 
the axon depolarizes the membrane, it causes Ca2+ to enter the axon. Increased 
intracellular Ca2+ causes the vesicles to migrate to the axonal membrane and fuse with 
the membrane, which allows the NA to diffuse out of the vesicle. The NA binds to the 
postsynaptic receptor and stimulates the effector organ response. Once in the synaptic 
cleft, most of the NA (~90%) is transported back into the nerve terminal by a neuronal 
reuptake transport system. NA can also diffuses into capillaries and is carried out of the 
tissue by the circulation. Therefore, high levels of sympathetic activation in the body 
increase the plasma concentration of NA and its metabolites. However, some of the NA 
released is metabolized within the extracellular space before reaching the capillaries. 
Additionally, a small amount of NA (~5%) is taken up by the postsynaptic tissue and 
metabolized by catechol-O-methytransferase and monoamine oxidase (Figure 11) [66].  
Sympathetic vascular innervation varies widely among vascular beds. Generally, the 
density of sympathetic nerves increases as the arterial calibre decreases, so that small 
arteries have the densest innervation and, in these beds, sympathetic stimulation 












FIGURE 11| NA synthesis, storage, release and action. (Adapted from Cardiovascular Pharmacology 
Concepts, Richard E. Klabunde, Lippincott Williams & Wilkins, Second Edition) 
 
b. Alterations of the SNS in hypertension  
In hypertension, autonomic cardiovascular control is compromised, leading to a reduced 
parasympathetic tone and to an increased sympathetic influence to the heart and 
peripheral vessels [67]. Data from humans and experimental animal models of 
hypertension support the neurogenic hypothesis of hypertension, which considers 
sympathetic hyperactivation as the primary factor underlying the elevation of BP [68-
71]. Several studies have corroborate this by different means: 1) measuring circulating 
blood levels of the adrenergic neurotransmitters (adrenaline and NA), 2) quantifying 
efferent postganglionic muscle sympathetic nerve activity (SNA) in peripheral nerves or 
3) assessing regional NA and reuptake by adrenergic nerves with radiolabelled NA [67, 
72]. Although the main causes of sympathetic hyperactivation remain undefined, 
alterations of reflexes and/or metabolic factors have been proposed as candidates [71]. 
Nevertheless, it is known that excessive activation of SNS has numerous deleterious 
effects such as increased peripheral resistance, left ventricular hypertrophy, or 
alteration in renal function with retention of salt and water, thus, contributing to the 
development and/or maintenance of hypertension [67, 73-76]. Moreover, in vessels, an 
increased SNA is responsible for vascular remodelling related to VSMC hypertrophy and 













FIGURE 12| Schematic representation of the adverse cardiovascular and metabolic effects of sympathetic 
activation in hypertension. LVDD, left ventricular diastolic dysfunction; LVH, left ventricular hypertrophy 
(from G. Grassi et al., 2010). 
 
c. Role of Ang II in SNS 
It has long been proposed the existence of a bidirectional stimulatory interactions 
between Ang II and the SNS [78-80]. On one hand, renal sympathetic innervation is a 
major determinant of β1-adrenergic receptor-mediated renin release, thus contributing 
to the control of circulating Ang II levels. Consistent with this, renal denervation 
suppress efferent sympathetic outflow reducing circulating renin, Ang II and aldosterone 
in experimental animal models and in patients with resistant hypertension [79]. On the 
other hand, AT1 receptors are abundant at each synaptic relay of the autonomic nervous 
system to influence sympathetic and parasympathetic neurotransmission. Ang II 
enhances SNS neurotransmission by stimulating presynaptic release of NA from 
sympathetic nerves, facilitating sympathetic ganglionic transmission, inhibiting NA 
reuptake in nerve terminals, increasing the density of sympathetic innervation in 
cardiovascular organs, and enhancing vasoconstrictor responses to NA [80]. Emerging 
evidence suggests that activation of RAS (either through increased Ang II production, or 
enhanced AT1 receptor expression and signalling) contributes to sympathetic 













v. OXIDATIVE STRESS 
Oxidative stress refers to the imbalance between ROS synthesis and elimination by 
antioxidant systems, which leads to excessive oxidative processes in cells and tissues. 
This alteration can be either related to an excess in ROS production by specific enzymes, 
or a decrease in buffering capacity non-enzymatic antioxidants or elimination of ROS by 
specific enzymatic systems [82].  
Oxidative damage can induce alterations in the cardiovascular system and has been 
implicated in hypertension and other CVDs. Several ROS have been implicated in 
hypertension. Among them, one of the most important is •O2-, considered a primary 
ROS, from which other ROS can be generated. One of the main deleterious actions of 
•O2- in the vascular system is the reaction with NO, which generates the production of 
peroxynitrite (ONOO−). This is a much more stable ROS, which, in turn, promotes 
alterations of transcription factors, kinases, protein synthesis, and redox-sensitive 
genes. These changes induce functional and structural alterations in the vascular wall 
[83],  including excessive contractility, alterations in VSMC growth/death, monocyte 
migration, lipid peroxidation and inflammation. All these alterations are known to be 
deeply involved in the pathogenesis and progression of vascular damage in hypertension 
and other CVDs [83, 84]. In hypertension, major source of •O2- are xanthine oxidase, 
uncoupled eNOS, NADPH oxidase, cyclooxygenase (COX) and the mitochondrial 









FIGURE 13| Enzymatic sources of superoxide anion (·O2−). The major enzymes responsible for ROS 
generation in the vasculature include NAD(P)H oxidase, xanthine oxidase, and uncoupled NOS (from 












a. NADPH oxidases 
NADPH oxidases are a family of transmembrane enzymes capable of generating •O2- and 
it is the main enzyme system responsible for its production both in the vascular wall [87] 
and in the heart [88]. There are different isoforms of NADPH oxidase: Nox1, Nox2, Nox3, 
Nox4, Nox5, Duox1 and Duox2, being Nox2 the most abundant in the cardiovascular 
system. This isoform consists of 5 subunits: a stabilizing subunit (p22phox), several 
regulator subunits (p40phox, p47phox, p67phox) and the catalytic subunit (gp91phox), 
which transfers electrons.  
Activation of NADPH oxidase is regulated by many vasoactive hormones, growth factors 
(platelet-derived growth factor, transforming growth factors) and mechanical stimuli 
(shear stress and stretch) [85]. 
 
b.  Role of Ang II on vascular ROS generation 
Although NADPH oxidases are constitutive enzymes, Ang II represents one of the major 
vasoactive peptides involved in the regulation and activation of NADPH oxidase. Indeed, 
observations in experimental animals demonstrate that Ang II increases •O2- production 
by activation of NADPH oxidase in various vascular cell types, including VSMC, 
endothelial cells and fibroblasts [89, 90]. Vascular ROS production induced by Ang II 
takes place via AT1 receptors, which stimulates both the expression of NADPH oxidase 
subunits and the activation of the enzyme [36]. On the other hand, ROS may regulate 
AT1 receptor gene expression, which in turn modulates ROS production, thus creating a 













III. FETAL PROGRAMMING OF HYPERTENSION 
 
i. HYPOTHESIS 
Along with genetic and lifestyle factors (sedentary, unhealthy diet, tobacco), it is now 
established that some stress factors during fetal life contribute to the development, in 
adult age, of CVDs [92-94]. The fetus can adapt to adverse intrauterine conditions, as 
malnutrition, oxygen deprivation, placental insufficiency, exposure to excess 
glucocorticoids (GC) or toxic substances, to ensure survival [95]. However, these 
increased susceptibility to develop CVDs, a phenomenon named Developmental Origins 
of Health and Disease or fetal programming [96]. 
Dr. David Barker was the first to advocate the hypothesis, by demonstrating that 
adaptive responses of the fetus to maternal undernutrition leading to low birth weight 
(LBW), are associated with the development of coronary heart disease and hypertension 
in adult life [92, 97, 98]. Over the past years, several epidemiological studies in 
populations exposed to starvation and intrauterine stress have confirmed this 
association and validated Dr. Barker´s hypothesis. Thus, the association between LBW 
and increased cardiovascular risk, namely of increased BP is now well established. This 
process is known as fetal programming of hypertension (FPH) [99-102].  
 
ii. DETERMINANTS 
The inverse relationship observed between LBW and hypertension may be due to fetal 
alterations induced by exposure to a suboptimal environment during gestation [97]. 
During intrauterine period, tissues and organs go through critical stages of development 
and the fetus has high plasticity. This plasticity represents also a high sensibility to any 
alteration in the environmental factors around the fetus. Therefore, its development is 
not only determined by the fetal genome, but also by maternal health and by the 
placental capacity to supply nutrients and oxygen [103-105]. When the fetus is exposed 
to a suboptimal environment which compromises growth at this critical period of 












adaptive changes may lead to alterations in organ structure and function, with long term 
consequences. In particular, fetal exposure to stress conditions, has been demonstrated 
to lead to permanent alterations in the structure and function of key organs implicated 
in cardiovascular control resulting in increased risk for hypertension and CVDs 
development [95, 106]. Furthermore, the timing of the exposure to the adverse factor 
along gestation, mediates different fetal growth trajectories and the severity or nature 
of the long term cardiovascular alteration [107].  
Several adverse factors during intrauterine life have been demonstrated to contribute 
to inadequate fetal development and fetal programming. The most important are 
malnutrition [107, 108], oxygen deprivation [109-111], placental insufficiency [112], 
exposure to excess GC [113-115], toxic substances (alcohol, tobacco) [116-118] and 
environmental pollutants [119].   
 
a. Suboptimal fetal nutrition 
An inadequate nutrition of the fetus may occur due to maternal malnutrition or to 
inadequate placentation; both have been demonstrated to be well-known fetal insults 
responsible for FPH. 
Maternal malnutrition was proved to contribute to FPH in studies carried out in the 
offspring of women that suffered from starvation during pregnancy in periods of war 
[100, 120]. Later epidemiological studies carried out in different countries and in 
populations of different ethnic origin, in both men and women, have provided additional 
evidence that programming is a consequence of malnutrition, and is not the result of 
confounding variables [121-124].  
On the other hand, placenta is fundamental for fetus´ nutrition as it controls oxygen and 
nutrients supply, and also is the source of specific hormones involved in fetal growth 
and development [125]. To achieve these functions, placenta performs a remarkably 
diverse range of activities, including active and passive transport, endocrine secretion, 
immunological protection, and xenobiotic detoxification. As well as being 
multifunctional, the placenta is also an organ with high plasticity, capable of 












maternal insults [126]. An alteration in placenta´s function, as in of preeclampsia or 
placental insufficiency, may result in fetal development changes, and consequently, in 
LBW [125]. Both in humans and animal models, it has been demonstrated that a nutrient 
deficiency through the placenta, is associated with LBW and the development of CVDs 
in adulthood [127-129].  
It is important to highlight that maternal undernutrition seems to be the major cause of 
LBW in underdeveloped or developing countries, while in high-income societies, LBW is 
mostly related with prematurity or obstetric complications associated with delayed 
pregnancy. For example, placental insufficiency and pre-eclampsia, which cause 
placental hypoxia and fetal oxygen and nutrient delivery privation [130, 131], are 
conditions related with the increase in maternal age [132, 133] and with offspring 
hypertension in adult life [133]. 
 
b. Other Fetal Stress Factors  
In addition to an insufficient supply of nutrients, other stress factors, such as low oxygen, 
exposure to toxic substances, excess GC or environmental pollutants, can also affect 
fetal development, contributing to FPH [118, 119, 134]. 
Low oxygen access to the fetus is also associated with LBW and with programming of 
CVDs. Together with undernutrition, gestational hypoxia is the most clinically relevant 
fetal stress factor with important consequences for maternal health and responsible for 
offspring programming [135]. Low oxygen can be the consequence of placental 
insufficiency or of low hypobaric pressure, as occurs in high altitude pregnancies. In 
addition, exposure to maternal hypoxia during early gestation may have a profound 
influence on placentation. In fact, children born at high altitude are smaller and there is 
also higher incidence of preeclampsia [136]. The programming effects of oxygen 
deprivation during fetal life have also been demonstrated in experimental animals [111].   
A third group of stress factor are toxic substances, which even in low concentrations are 
known to induce fetal programming.  Maternal smoking during pregnancy has a number 
of well-known short-term adverse effects on offspring, such as shortened gestation and 












smoking may also have long-term health consequences. Exposure to tobacco smoke in 
utero was associated with hypertension in offspring [138, 139]. Alcohol consumption 
during the gestational period has also been related to LBW and preterm birth [116]. In 
addition to these life-style related substances, exposure during intrauterine life to 
environmental pollutants, present in soil, water or air, has also been demonstrated to 
induce fetal programming [140]. 
Excess GC exposure to the fetus may also limit fetal growth [141] and program the 
cardiovascular and endocrine systems [142]. This is clinically relevant, since women with 
risk of preterm delivery are treated with CG to improve fetal pulmonary function and 
reduce mortality. Besides, maternal psychological stress may abnormally elevate 
cortisol levels [143]. The placental enzyme, 11 β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2), inactivates GC and thus protects the developing fetus from the deleterious 
effects of excess GC [144]. However, this enzyme can be reduced in adverse conditions, 
such as undernutrition or hypoxia [144, 145], favoring cortisol access to the fetus and 
contributing to FPH.  
Finally, fetal overnutrition, due to maternal obesity or excess weight gain during 
gestation, is another stress factor important for FPH development. In fact, maternal 
obesity is associated with an increased risk for obstetric complications such as 
gestational diabetes mellitus, gestational hypertension, preeclampsia or pre-term 
delivery that can also contribute to FPH [146, 147]. Thus, in utero exposure to 
overnutrition programs the fetus for both metabolic disease later in life, and recent 
studies indicate that placental function may also be disrupted and contribute to long 
term health risk [148, 149].  
 
iii. EXPERIMENTAL ANIMAL MODELS 
Experimental data gathered in animal studies have been very valuable to understand 
the relationship between adverse intrauterine environment and increased susceptibility 
to hypertension. Many of these mimic the maternal causes of LBW such as maternal 












others mimic complications during pregnancy that are linked to increased cardiovascular 
risk in the offspring such as preeclampsia or gestational diabetes [96, 150].  
 
a. Animal Models of Fetal Undernutrition 
As it was already said, reduced fetal access to nutrients could be induced by decreasing 
the mother's nutritional intake during the gestational period or by reducing placental 
blood flow. A variety of animal species, including the mouse, rat and sheep, have been 
used to study this effect.  
Concerning the nutritional manipulation, the models employed differ, using various 
protein:lipid:carbohydrate ratios of the maternal diet during gestation, and varying 
timing and duration of dietary manipulation [151]. More specifically, the mother's diet 
can be modified by reducing the total caloric intake, the protein intake or some 
micronutrient in the diet, such as minerals or vitamins. Most of the FPH studies used a 
maternal general (caloric) undernutrition or a maternal low-protein diet animal models 
since both interventions resulted in significantly increased BP in the offspring [151]. 
General undernutrition (50 to 70% food restriction) during gestation in the rat programs 
a marked increase in BP associated with vascular dysfunction in the offspring in later life 
and, in mouse, programs an increase in BP associated with cardiac enlargement and an 
increase in coronary perivascular fibrosis [96]. Maternal protein restriction (8% versus 
18%) during gestation programs an increase in BP in adult rat offspring, mouse, sheep 
or cow, indicating that the long-term impact of nutritional insults during fetal life on 
later CVDs is not species-specific [96, 152]. 
Animal models of reduced uteroplacental perfusion during late gestation, mimicking 
placental insufficiency, also lead to an environment of undernutrition and hypertension 
in the LBW offspring [112, 152]. This can be achieved through surgical models, being the 
most common the maternal bilateral uterine vessel ligation [153]. This model, when 
initiated at day 18 of gestation in the rat, programs hypertension in male offspring 













The majority of the experimental studies in these animal models have evidenced the 
important influence of sex in FPH.  As so, male offspring develop hypertension by adult 
age, while females remain normotensive or develop milder forms of hypertension [155, 
156]. These sexual dimorphism has been proposed to be related to the protective effects 
of estrogens [157-159]. Estrogen has been proposed as key factor that contributes to 
female protection against FPH, due its capacity to interact with the RAS system, its 
antioxidant properties, and the effects of estrogens on eNOS expression and activity, 
increasing vasodilation [160].  Besides, the role of testosterone has also been suggested, 
because animals exposed to placental insufficiency exhibit higher levels of testosterone 
compared to controls, and castration completely abolished hypertension in male 
offspring with LBW [159]. The contribution of sex steroids in the developmental 
programming of hypertension may involve modulation of neurohormonal systems, 
particularly RAS [158-160]. 
In addition to the influence of sex steroids on the sexual dimorphism of FPH, the concept 
of sex of the placenta has also been put forward, and it has been suggested that the 
placenta nourishing female fetus could adapt better to adverse intrauterine 
environments, thus, contributing to the lower impact of FPH in females [161, 162]. 
Despite the fact that in animal models of FPH the role of sex has been well documented, 
in humans, this is not so evident. This discrepancy is likely related to differences in the 
age of the populations under study, and the confounding factor of menopause [156, 
157]. 
 
iv. POSSIBLE MECHANISMS IMPLICATED IN FETAL PROGRAMMING 
In the above experimental animal studies some mechanisms have been pointed out to 
contribute to hypertension development in the offspring. Among them, high BP is 
associated with alterations in blood vessels (remodelling, stiffening and endothelial 
dysfunction), heart (cardiomyocyte hypertrophy or intramyocardial fibrosis), and 
deficient renal activity (low nephron number, alterations in sodium handling, etc.) [101, 












[167, 168], RAS [169-171] and SNS [172-174], as well as alterations in the GC axis [101, 
113, 175, 176].  In the figure below, Figure 14, the proposed mechanisms underlying FPH 
that are most relevant for this work, are summarized. 
 
FIGURE 14| Schematic diagram of the mechanisms implicated in fetal programming of cardiovascular 
diseases. Adverse exposure to maternal insults during gestational life programs alterations in structure 
and physiology that contribute to the development of increased cardiovascular risk in later life (adapted 
from Alexander et al., 2015). 
 
a. Sympathetic Nervous System Hyperactivation 
Several lines of research, in humans and experiment animal models, point at the SNS as 
an important contributor to FPH.  
Numerous studies indicate that SNS activation is increased in LBW individuals [177-179]. 
In addition, increases in circulating catecholamines indicative of enhanced SNS 
activation are observed in LBW individuals and also in different experimental models of 
LBW [174, 180, 181]. 
Alterations in SNS control are also evidenced in several animal models of FPH, where 












184] and sympathetic hyperinnervation [173]. In addition to alterations at the peripheral 
level, data also indicates changes in central SNA [175, 183, 185].  
Excess cortisol levels may also contribute to FPH through the SNS. For example, in sheep 
fetuses, it has been shown that adrenal GC contribute to cardiovascular regulation by 
modulation of SNA and arterial baroreflex [186]. 
Taken together, data are consistent with a pathophysiological role of the SNS in FPH, 
with evidence indicating the occurrence of an increased SNA accompanied by 
morphological alterations.   
 
b. Alterations in the Renin-Angiotensin System 
RAS alterations are one of the common findings in different models of FPH. However, in 
humans exposed to adverse intrauterine conditions, information is scarce regarding the 
RAS. Nevertheless, it was reported that children born from preeclamptic pregnancies 
have increased circulating levels of aldosterone, a mineralocorticoid hormone which 
secretion is controlled by Ang II [187]. Also, boys with LBW exhibited a significant 
increase in ACE activity and circulating Ang II, which were associated with increased 
systolic BP [188]. However, this association was not found in girls, supporting the 
existence of sex differences in FPH also in humans. Indeed, RAS alterations associated 
with FPH seem to be age and sex-specific [156, 158]. 
Alterations of angiotensin receptors to FPH has been demonstrated in animals exposed 
to nutritional insults such as low-protein, high-fat or sugar diets [189-191] and toxics, 
such as nicotine [192, 193], or to CG [158]. ACE is other RAS player modified in FPH. Both 
pulmonary and plasma ACE activities seem to be increased in MUN adult rat offspring 
[194].  The role of Ang II  in experimental FPH, hypertension is further demonstrated by 
evidence that BP rise is controlled after treatment with ACE inhibitors or Ang II receptors 
antagonists [170, 194, 195] similarly to what occur in essential hypertension.  
Overall, experimental data are consistent and support the idea that RAS might be a 













c. Oxidative Stress 
Oxidative stress, defined as the imbalance between free radical producing systems and 
antioxidant defence systems of the body, is closely associated with inflammation [196], 
cardiovascular fibrosis and stiffness [31, 197] as well as endothelial dysfunction [14].  
It is plausible that it might be the common denominator of cardiovascular changes in 
FPH. Some data support this hypothesis: i) placental alterations associated with fetal 
stress generates ROS linked to ischemia-reperfusion that might affect the development 
and function of the fetal vessels [198]; ii) diets rich in antioxidants during gestation and 
lactation in rats confer cardiovascular protection in adults [199-203]; iii) elevated BP and 
vascular dysfunction are characterized by enhanced vascular superoxide anion 
production that is generated, at least in part, by NADPH oxidase in FPH animals models 
[112]. 
Numerous data suggest that oxidative stress is at the basis of obstetric and fetal 
complications associated with LBW and also an underlying mechanism in FPH. During 
pregnancy, ROS exert important functions in placentation and serve as a signalling 
molecule, allowing the normal progression of embryonic and fetal development. Since 
embryo and fetus have low antioxidant capacity, an excess production in ROS during the 
intrauterine period would lead to a pro-oxidative state compromising fetal growth [168]. 
Furthermore, oxidative stress is also at the basis of changes in the kidney, heart, blood 
vessels and cardiovascular control systems. Particularly in vessels, oxidative stress 
contributes to endothelial dysfunction, observed in animal models of fetal programming 
[96, 150]. Reduced NO bioavailability caused by superoxide anion is one of the 
alterations consistently found in animals exposed to various fetal stress factors, namely 
nutrient deficiency, hypoxia, excess GC, or placental insufficiency [168]. Another factor 
is the reduced antioxidant capacity, also detected in FPH animals [168, 204]. 
Interestingly, the presence of oxidative damage prior to BP elevation, supports a role of 













d. Epigenetic Modifications 
Epigenetics is the study of molecular processes occurring on and around the genome 
that regulate gene activity without changing the underlying DNA sequence [205].  
Accordingly, epigenetic changes modify the expression of specific genes without 
changing the sequence of an individual’s genome, and can be transmitted across 
generations.  
Epigenetics describes the micro-structure of DNA and its associated proteins, which may 
be modified to induce upregulation or downregulation of specific genes, by three closely 
related mechanisms: DNA methylation, chromatin remodelling, and histone 
modification [206].  Several studies implicate these mechanisms in fetal programming 
and in the transmission of alterations to future generations [168, 206], particularly 
implicating the RAS and oxidative stress. 
Considering the RAS, it had been demonstrated a methylation and an upregulation of 
mRNA and protein expressions of AT1 receptor gene associated with histone 
modifications in blood vessels of different animal models of FPH [207, 208]. In addition, 
in brains of FPH animal models was reported an upregulation of mRNA expression of 
angiotensinogen and ACE and a downregulation of mRNA levels of AT2 receptor [209]. 
Recently, it was presented the hypothesis that the expression of RAS components in the 
heart and VSMC might be induced by epigenetic factors activated during pregnancy 
[210]. This activation lead to the expression of renin and Ang II inside the cardiac and 
VSMC with consequent decrease of cell communication, impairment of metabolic 
cooperation, and changes in vascular smooth muscle contractility and dysfunction.  
Other epigenetic modifications demonstrated in the context of FPH are the 
hypomethylation of eNOS promoter found in human umbilical endothelium from LBW 













IV. MESENTERIC CIRCULATION 
The branches of the abdominal aorta are divided into parietal and visceral parts. The 
visceral arteries are in turn divided into paired and unpaired branches. There are three 
major unpaired branches: the celiac trunk, the superior and the inferior mesenteric 
artery. Each has several major branches supplying the abdominal organs: the superior 
mesenteric artery supplies the pancreas, small intestine and the colon, whereas the 











FIGURE 15| Schematic representation of splanchnic circulation. (From McGuire et al., 1993). 
 
The mesenteric circulation plays an important role in the maintenance of systemic BP, 
and regulation of tissue blood flow [211]. Actually, the entire splanchnic circulation can 
receive up to 60% of cardiac output and contains about one third of the total blood 
volume. Mesenteric arteries and veins have significant resistance and capacitance 
functions in the systemic circulation, respectively. In comparison to the mesenteric vein, 
mesenteric artery has a high resting basal tone mediated in part by a thicker layer of 
VSMC [212]. Constriction of the mesenteric artery is thought to increase total peripheral 
resistance in the systemic circulation. In contrast, the mesenteric vein contains fewer 
layers of VSMC and is a more compliant vessel.  The function of these low pressure 
vessels is to store significant quantities of blood that can be utilized to maintain the 












Sympathetic nerves innervating the splanchnic circulation are of upmost importance 
[213]. Mesentery arteries and veins are densely innervated by sympathetic nerve 
endings which play a critical role in the regulation of peripheral resistance and 
capacitance, respectively [214-217]. Indeed, when an increase in venomotor tone occurs 
in mesenteric vein, an increase in venous return/cardiac output also occur having a high 
relevance on hemodynamic [214].  
It is known that increased SNA to the splanchnic circulation may represent a common 
stage in the development of hypertension [213] . Various animal models of hypertension 
support the concept that vascular resistance changes in the splanchnic organs are similar 
in direction and magnitude to pressure changes. These resistance changes appear to 
result from increased responsiveness of the arterioles to a variety of constrictor 




























BASIS AND HYPOTHESIS OF THE STUDY  
 
 Hypertension is the primary risk factor for CVDs, a serious worldwide health 
concern and a significant healthcare burden.  
 Exposure to adverse fetal environments, leading to LBW, predisposes to 
hypertension development, being males more susceptible. This process is known 
as fetal programming of hypertension. 
 SNS and RAS hyperactivation and oxidative stress are common denominators in 
hypertension development. There is evidence of alterations in these systems 
associated with fetal programming. However, the relationship between these 
systems in the vascular wall have not been fully elaborated. 
 The classic conceptualization of the RAS has undergone significant revision with 
the discovery of new active peptides and receptors. Their role of in fetal 
programming remains largely unknown. 
 
Based on the above assumptions, the following hypothesis is postulated:  
Suboptimal nutrition during fetal life induces hypertension in male rats, at least in part, 
through an alteration in vascular sympathetic neurotransmission, and cross-talk with 



















The general aim of this thesis is to analyse if exposure to suboptimal nutrition during 
fetal life in rats induces alterations in vascular sympathetic neurotransmission and RAS, 
which may be implicated in hypertension development. To achieve this, an experimental 
rat model of fetal programming based on maternal undernutrition during gestation was 
used and male offspring at adult age were studied. Another aim of this work is to 
compare vascular alterations in sympathetic neurotransmission induced by fetal 
undernutrition and those present in essential hypertension. For this comparison SHR 















Specific aims:  
i. To evaluate the influence of fetal undernutrition on hemodynamic parameters: 
a. To analyse BP and HR in adult male rats exposed to fetal undernutrition. 
b. To compare the alterations in hemodynamic parameters induced by fetal 
undernutrition with those present in the SHR, a model of essential 
hypertension.  
ii. To assess the influence of fetal undernutrition on mesenteric artery 
remodelling : 
a. To determine morphological alterations 
b. To determine alterations in collagen content 
c. To compare the alterations induced by fetal undernutrition and essential 
hypertension. 
iii. To assess the influence of fetal undernutrition on vascular sympathetic 
neurotransmission  in the mesenteric artery: 
a. To determine alterations in sympathetic innervation. 
b. To determine alterations in NA release and uptake. 
c. To compare alterations induced by fetal undernutrition and essential 
hypertension. 
iv. To assess the influence of maternal undernutrition on RAS  
a. To assess alterations in plasmatic concentration of Ang II. 
b. To assess alterations in the expression of the main enzymes and 
receptors of the RAS in mesenteric arteries. 
c. To determine the location of RAS receptors in adventitial cells and 
sympathetic innervation. 
v. To determine the possible influence of RAS on sympathetic neurotransmission 
a. To assess the influence of Ang II on perivascular NA release and the 
receptors implicated. 
vi. To assess the influence of maternal undernutrition on vascular •O2- production. 




























I. EXPERIMENTAL ANIMAL MODELS 
 
i. ETHICAL CONSIDERATIONS 
In this thesis two different experimental animal models were used; a rat model of FPH 
and a rat model of essential hypertension, the SHR. The rats used were from the colony 
maintained at the animal house facility of the Universidad Autónoma de Madrid (UAM). 
All of the experimental procedures were approved by the Ethics Review Board of UAM 
(CEI63-1112-A097) and Comunidad Autónoma de Madrid (PROEX 199/15), and 
conformed to the Guidelines for the Care and Use of Laboratory Animals (National 
Institutes of Health publication no. 85-23, revised in 1996), the Spanish legislation (RD 
1201/2005) and the Directive 2010/63/EU on the protection of animals used for 
scientific purposes.  
 
ii. ANIMAL MODEL OF FETAL PROGRAMMING OF HYPERTENSION 
In this work was used an animal model of FPH based on maternal undernutrition during 
gestation in Sprague Dawley rats (MUN), as previously described [204, 219]. The rats 
were mated in a cuvette with a grid bottom on filter paper. The morning after the day 
of mating, the presence of a mucous vaginal plug on the floor of the cuvette indicated 
day 1 of gestation. At that time, the female was separated from the male and was 
housed individually in a bucket on aspen wood, with the following dimensions: 36.5 cm 
long, 21.5 cm wide and 18.5 cm high. The buckets were placed in rooms under controlled 
conditions with regulated temperature (19-23 °C), controlled relative humidity (35-45%) 
and 12/12 light/dark photoperiod. The animal health monitoring indicated that the rats 
were free from pathogens that may interact with any of the studied parameters.  
All the rats were fed with breeding diet (SAFE A03; Safe Augy, France) of the following 
composition: 51.7% carbohydrates, 21.4% protein, 5.1% lipids, 3.9% fiber, 5.7% minerals 

















Two study groups were established: a control group, with ad libitum feeding throughout 
pregnancy and lactation and a group with intake restriction during part of gestation. This 
last group of rats had ad libitum diet during the first half of the gestation (from day 1 to 
10) and then, they were fed with 50% of the intake of a pregnant rat (from day 11 until 
delivery). To determine the amount corresponding to the 50% of the normal intake, 
preliminary studies were carried out. These experiments showed that the maximum 
intake of a pregnant rat was 24 g/day. After delivery and through all the lactation period 
the mothers were fed ad libitum.  
Immediately after birth, the offspring was weighed individually and sexed, and the litter 
was standardized to 12 rats, 6 males and 6 females if possible. The rest of the litter was 
sacrificed with CO2. At the age of 6 months, male offspring from the two experimental 
groups were analysed: from rats exposed to maternal undernutrition during pregnancy 
(MUN) and from control rats with mothers fed ad libitum during pregnancy (CONTROL). 
Rats from at least 3 different litters were used for each experimental protocol. A 
schematic diagram showing the experimental model is shown in Figure 17.  
 
 
FIGURE 17| Experimental animal model of fetal programming of hypertension based on maternal 
undernutrition.  
 
iii. ANIMAL MODEL OF ESSENTIAL HYPERTENSION  
In the present work the SHR were wealso used, a well-known animal model of essential 
hypertension to make comparisons with the animal model of FPH induced by MUN. 
Since the SHR have been created by selective breeding of Wistar-Kyoto rats (WKY), the 
WKY was chosen as the control model, representing a normotensive state. Both WKY 

















II. IN VIVO EXPERIMENTAL PROCEDURES 
 
i. HEMODYNAMIC PARAMETERS IN ANESTHETIZED RATS 
Intra-arterial BP was assessed as previously described [220]. Briefly, the rats were 
anaesthetized with 37.5 mg/kg Ketamine hydrochloride and 0.25 mg/kg Medetomidine 
hydrochloride i.p. and placed on a heating blanket. The iliac artery was exposed and a 
catheter was inserted (filled with 0.9% saline solution with 1% heparin). The catheter 
was connected to a pressure transducer (Statham; Harvard Apparatus) and the 
transducer to a PowerLab system/8SP (ADInstruments), where the pressure wave was 
displayed. After cannulation the pressure was recorded for approximately 60 min and 
stored for later analysis of data. HR, DBP and SBP were measured in the chart, averaging 
over approximately 1 min of the last part of the recording period (Figure 18). 
 
 
FIGURE 18| Schematic representation of in vivo blood pressure measurement. After 60 minutes of 



















ii. TAIL-CUFF PLETHYSMOGRAPHY  
To evaluate hemodynamic parameters without the effect of anaesthesia the tail-cuff 
plethysmography was used. BP was analysed with a NIPREM 645 non-invasive BP 
acquisition system for rats (CIBERTEC, Madrid, Spain). The experiments were conducted 
in a quiet area at 22±2°C. Firstly, the rats were placed in a chamber at 37 °C for 10-15 
min to induce vasodilatation. Thereafter, they were placed inside a soft support in the 
darkness to prevent excessive movement. A pulse sensor and a pressure cuff were place 
around the tail for BP recordings (Statham, Harvard Aparatos GMBH, Germany) (Figure 
19). The cuff was inflated to 150 mmHg and 15 to 25 pressure inflate-deflate cycles were 
performed and data were automatically registered (PowerLab system-ADInstruments). 
The first 5 cycles were considered “acclimatization” cycles and were not used in the 
analysis. This procedure was obtained during 3 consecutive days for the rats to become 
accustomed. The measurements of SBP recorded on days 2 and 3 were averaged for 
statistical analysis.  
 



















III. SAMPLE COLLECTION 
 
The animals were first weighted and then anesthetized in a CO2 chamber, and a blood 
sample was obtained by cardiac puncture using a syringe, and placed into EDTA-
containing tubes. Thereafter, the blood was centrifuged (3000 rpm, 15 min, 4ºC) and 
the supernatant plasma was stored at -80ºC until used. 
After the animals were euthanized by exsanguination the mesenteric bed and tail 
arteries were collected in cold Krebs–Henseleit solution (KHS) with the following 
composition (in mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, NaH2PO4 1.2, NaHCO3 25, 
glucose 11, ascorbic acid 0.3 and disodium EDTA 0.03 (pH 7.4). Thereafter, the 
mesenteric artery and vein, and tail artery were dissected. For functional studies, these 
three vessels were used immediately. For histological studies, a small part of mesenteric 
artery from each rat was placed in paraformaldehyde 4% in phosphate buffer solution 
(PBS; in g/L: NaCl 8.0, Na2HPO4.2H2O 0.77, KCl 0.20, KH2PO4 0.19; pH 7.2) during 50 min 
for immunohistochemical procedures or, for other procedures, until used. For RT-PCR 
the mesenteric arteries were frozen with liquid nitrogen and stored at -80ºC until used.  
 
IV. VASCULAR HISTOLOGY 
 
i. CHEMICALS 
For this study the following staining were used: hematoxylin-eosin (Merck cat. no. 
1.09249.2500 and 1.15935.0025 Darmstadt, Germany), Masson's trichrome (Merck cat. 
no. 1.16316.0050 Darmstadt, Germany) to assess connective tissue components 
(collagen and muscle cells), and orcein (Merck cat. no. 1.07100 Darmstadt, Germany) to 
detect elastic fibres. Entellan (Merck cat. no. 1.07961.0500 Darmstadt, Germany) was 



















ii. EXPERIMENTAL HISTOLOGICAL PROCEDURE  
Briefly, the mesenteric artery placed in paraformaldehyde 4% PBS was dehydrated in a 
growing alcohol battery and rinsed in xylene. Thereafter, it was included in a paraffin 
block, and serial sections of 2 µm thickness were made using a microtome. The sections 
were dewaxed in xylene, then they were hydrated in alcohols of decreasing 
concentrations and stained with haematoxylin-eosin, Masson's trichrome and orcein. 
Each tissue was cut in five levels along the length of the vessel to ensure data represents 
the putative mesenteric artery heterogeneity rather than only a specific location of the 
artery. Each batch represents histochemical staining for one type of dye and include 
sections from all five levels of mesenteric artery from each animal. This procedure was 
repeated three times (3 batches). In total, for each treatment, 150 sections were 
obtained. Sections were stained for each dye and divided according to animal source. 
Within each of these groups, a random selection of the sections was carried out. 
 
iii. IMAGE ACQUISITION AND QUANTIFICATION 
Stained sections were visualized using a high-resolution Zeiss Axiocam 105 color digital 
camera mounted on a Zeiss Primo Star microscope, using an X10 objective, to analyse 
the arterial lumen, media, and adventitia layer. Morphometry was performed with 
Image J software [221], and data of lumen diameter, cross sectional area of the media 








FIGURE 20| Example of morphometry analysis using ImageJ. Section of a mesenteric artery: in yellow it is 

















V. PRESYNAPTIC FUNCTION 
 
i. BACKGROUND 
To study the vascular presynaptic function, [3H]-NA was used, possible to trace, and 
electric field stimulation that simulates physiological conditions of an action potential. 
Indeed, electrically evoked tritium overflow from tissue preparations incubated with 
radioactive NA has been shown to reflect action potential-evoked neuronal NA release 
and drug-induced changes in evoked tritium overflow have been assumed to reflect 
changes in neuronal NA release, as observed in previous studies [26, 222, 223]. In this 
way, it is possible to study the receptors implicated in presynaptic function with specific 
drugs (agonists and/or antagonists). Additionally, it is possible to estimate the amount 
of NA that has been incorporated into the nerve terminal (Figure 21).  
 
FIGURE 21| Schematic representation of NA release (1) and uptake (2) in the synaptic cleft.  
 
ii. CHEMICALS 
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline, specific activity 44.8 
Ci/mmol (DuPont NEN, I.L.C., Lisboa, Portugal), losartan (Merck Portuguesa, Lisbon, 
Portugal), angiotensin II (Sigma-Aldrich, St. Louis, USA) and desipramine hydrochloride 

















pure water and diluted in superfusion medium immediately before use. The scintillation 
mixture used was from OptiPhase ‘Hisafe’ 3, PerkinElmer, I.L.C., Lisboa, Portugal.  
 
iii. EXPERIMENTAL PROCEDURE 
[3H]-NA release experiments were carried out as previously described [26, 224, 225]. 
Vessels were preincubated in 2 mL KHS containing 0.1 µmol/L [3H]-NA (for 60 min at 
37°C) and transferred into superfusion chambers, superfused with [3H]-NA free medium 
of KHS (1 mL/min; constant rate) with desipramine 400 nmol/L to inhibit NA’s neuronal 
uptake. Three identical periods of electrical stimulation were applied (Hugo Sachs 
Elektronik, March-Hugstetten, Germany; constant current mode, rectangular pulses; 1 
ms, with current strength 50 mA; 5 Hz, 100 pulses). The first, starting at t=30 min (S0) 
was not used for determination of tritium outflow. The subsequent periods (S1 and S2) 
were applied at t=90 min and t=120 min, respectively. The superfusate was collected 
each 5 min period, starting from minute 85 of superfusion onwards.  
Implication of presynaptic AT1 receptors was addressed using an agonist for these 
receptors, Ang II (30 nmol/L), and an antagonist, Losartan (100 nmol/L): Ang II was 
added 5 min before S2 and kept until the end of the stimulation period; losartan was 
added immediately after S1 and kept until the end of the experimental procedure (Figure 
22). 
At the end of experiments (t=130 min), tritium was measured in the collected 
superfusate samples and in the vessels (previously solubilized: sonicated 1 h with 2.5 
mL, 0.2 mol/L perchloric acid). For this, 6 mL of a scintillation mixture was added to each 
sample and, thereafter, analysed by liquid scintillation spectrometry (LS 6500, Beckman 




















FIGURE 22| Superfusion chambers (A) and schematic representation of [3H]-NA release experiments (B). 
Tissue preparations were pre-incubated with [3H]-NA for 60 min. After that, tissues were superfused with 
[3H]-NA free medium containing desipramine and were stimulated three times at 30-min intervals (S0, S1 
and S2). The superfusate was collected each 5 min period from minute 85 of superfusion onwards. 
Antagonists (yellow line) added immediately after S1 and kept until the end of the experimental 
procedure; agonists (red line) added 5 min before S2 and kept until the end of the stimulation period. 
 
iv. QUANTIFICATION 
Tissue labelling with [3H]-NA and evaluation of electrically-evoked tritium overflow 
changes was performed as previously described [26, 224, 225]. Effects of drugs added 
after S1 on electrically-evoked tritium overflow were evaluated as the ratio of the 
overflow elicited by S2 and the overflow elicited by S1 (S2/S1). S2/S1 ratios obtained in 
individual experiments in which a drug was added after S1 were calculated as a 
percentage of the respective mean ratio in the appropriate control group (solvent 
instead of the respective drug).   
Values of [3H]-NA uptake were estimated using the following approach. At the end of 
each [3H]-NA release experiment, the tissue tritium content was obtained. This content 
was sum to values of [3H]-NA previously collected in the 5-min superfusate samples 
(from t = 85 min to t = 130 min, control preparations). The sum final value was 
considered to be the total amount of incorporated [3H]-NA in individual mesenteric 


















VI. REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) 
 
i. BACKGROUND 
RT-PCR is a technology by which RNA molecules are converted into their complementary 
DNA (cDNA) sequences by reverse transcriptases, followed by the amplification of the 
newly synthesized cDNA by standard PCR procedures [226]. The cDNA is then used as 
the template for the quantitative PCR reaction (Figure 23). In this work, this technique 
was used to quantify RAS receptors (AT1, AT2, Mas and MrgD) and enzymes (renin, ACE 
and ACE 2). 
 
FIGURE 23| Basic principles of reverse transcriptase polymerase chain reaction. Adapted from “Beginner’s 
Guide to Real-Time PCR”, Primerdesign, UK.  
 
ii. CHEMICALS 
Specifically, for the extraction procedure RNAlater®-ICE (Thermo Fisher, US) and TRIzol 
(Invitrogen, ThermoFisher Scientific, USA) were used. The Kit used for cDNA synthesis 
was Xpert cDNA Synthesis Mastermix Kit (GRiSP, Porto, Portugal) and the fluorophore 
for RT-PCR was 1X SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, Milan, Italy). 

















TABLE 1| Reference and target genes: primer specifications  
 
Primers selected for renin-angiotensin study, including the main enzymes (renin, 
ACE, ACE2) and receptors (AT1, AT2, Mas and MrgD). The 3 housekeeping genes used 
were: Hprt-1, Hmbs and Papbn-1. F, forward primer sequence (5’-3’); R, reverse 
primer sequence (5’-3’). 
 
iii. RNA  EXTRACTION AND REVERSE TRANSCRIPTION 
For RNA extraction, mesenteric arteries were dissected ensuring maximum protection 
of the RNA; they were stored in sterile tubes and frozen at -80ºC, until their use. To 
defrost the arteries, RNAlater®-ICE was used to process the samples by common 
homogenization methodology to extract high quality RNA. Soaking frozen tissue samples 
overnight in RNAlater®-ICE at –20°C eliminates the need to pulverize frozen tissue 
samples, because soaking in RNAlater®-ICE changes the physical state of the tissue from 
brittle to pliable at –20°C, minimizing RNA degradation. After that, samples were placed 
in TRIzol, homogenized in Precelys (Bertin Technologies, France) and RNA was extracted 
by following the manufacturer’s instructions. Briefly, after homogenate the samples, 
chloroform was added and the tube was mixed. After centrifugation for 15 min at 12000 

















a colourless upper aqueous phase, which contains the RNA.  This aqueous phase was 
transferred to a new tube to which isopropanol was added, incubate for 10 min and then 
centrifuged for 10 min at 12000 × g at 4°C. Total RNA precipitate formed a white gel-like 
pellet at the bottom of the tube. After discarding the supernatant, the pellet were 
resuspended in 75% ethanol, mixed and centrifuged for 5 min at 7500 × g at 4°C. Finally 
the supernatant was discarded and the pellet was air dried for 10 min. 
The pellet was resuspended in RNase-free water and incubated in a heat block set at 
60°C for 15 min. The integrity of total RNA was detected by electrophoresis of samples 
on 1% agarose gel and total RNA purity and concentration were evaluated 
spectrophotometrically (Synergy HT MultiMode Microplate Reader, Biotek, VT, USA). 
The absorbance was measure at 260 nm and 280 nm and RNA concentration was 
calculated using the formula A260  × dilution  × 40 = µg RNA/mL. The RNA purity was 
calculated by the A260/A280 ratio which is consider pure around 2.  
The RNA samples were stored at −80◦C. A quantity of 1 μg of total RNA obtained from 
each sample was reverse transcribed with Xpert cDNA Synthesis Mastermix Kit 
according to the manufacturer’s instructions. 
 
iv. QUANTITATIVE RT-PCR  ANALYSIS OF GENE EXPRESSION  
Real-Time PCR reactions were carried out in a 96-well CFX RT-PCR System (Bio-Rad, 
Milan, Italy). Each reaction was performed 10 μl reaction mixture, including 2 ng of 
template cDNA, 0.4 μM of each primer and 1X SsoAdvanced Universal SYBR Green 
Supermix. Gene amplification protocol started with 95◦C for 30 s, followed by 39 cycles 
at 95◦C for 15 s and 60◦C for 30 s. Each assay was performed in triplicates, with negative 
control. The combination of GeNorm and qBase software technology, following recent 
guidelines, was used to choose 3 housekeeping genes: HPRT-1: hypoxanthine 
phosphoribosyltransferase I; Hmbs: Hydroxymethylbilane synthase; Papbn-1: 
Polyadenylate-binding protein 1 [227]. The average Ct values obtained from each 
triplicate was converted to a relative quantity and analysed with CFX Manager 
algorithm. Gene stability is expressed by the M value, which is calculated as the average 

















housekeeping genes chosen were considered stable for having the M value < 0.5. A 
standard curve for each target and housekeeping gene was evaluated to assess 
amplification efficiency and linearity. 
 
VII. FLUORESCENCE CONFOCAL MICROSCOPY STUDY  
 
i. BACKGROUND 
To study simultaneously the location of RAS receptors on specific nerve structures, 
fluorescence confocal microscopy was used. Confocal microscopy allows to study thick 
tissues, due to the presence of a pinhole which discards the fluorescence coming from 
planes below and above the focal plane and permits the study of small structures with 
detail [13]. Other advantages over conventional optical microscopy, are the ability to 




The following antibodies were used: rabbit polyclonal anti-AT1 receptor (Santa Cruz 
Biotechnology, Inc., CA, USA); rabbit polyclonal anti-AT2 receptor (Santa Cruz 
Biotechnology, Inc., CA, USA); rabbit polyclonal anti-Mas (Alomone labs, Jerusalem, 
Israel), rabbit polyclonal anti-MrgD (Alomone labs, Jerusalem, Israel); goat polyclonal 
anti-p22phox (Santa Cruz Biotechnology, Inc., CA, USA);  mouse monoclonal anti-
tyrosine hydroxilase (ab129991, Abcam, UK) and mouse monoclonal anti-glial fribrilary 
acidic protein (GFAP, G6171, Sigma-Aldrich, Inc., USA). 
The following fluorescent probes were used: Alexa Fluor® 488 goat anti-mouse IgG (H+L) 
antibody, highly cross-adsorbed, Alexa Fluor® 594 anti-goat IgG (H+L) antibody, highly 
cross-adsorbed and Alexa Fluor® 647 goat anti-rabbit IgG (H+L) antibody, highly cross-

















Technologies, SA, Madrid, Spain); vectashield mounting medium with DAPI (Vector 
Laboratories, UK). 
 
iii. STAINING PROTOCOL 
Immunohistochemistry procedures were previously described [222]. Briefly, the artery 
was immediately placed in cold PBS and was cut in 4 segments. Each artery segment was 
fixed (paraformaldehyde 4% PBS; 50 min; room temperature). After two 15 min PBS 
washing cycles, artery segments were incubated with the following primary antibodies: 
 rabbit polyclonal antibodies against angiotensin receptors subtypes anti-AT1 
anti-AT2, anti-Mas and anti-MrgD (1:100 dilution, overnight, 4ºC) 
 goat polyclonal anti-p22phox (1:200 dilution, overnight, 4ºC) to stain NADPH 
oxidase. 
 mouse monoclonal anti-tyrosine hydroxylase (TH, 1:100 dilution, overnight, 4ºC) 
to stain noradrenergic nerve terminals. 
 mouse monoclonal anti-glial fibrillary acidic protein (GFAP, 1:200 dilution, 
overnight, 4ºC) to stain glial cells such as Schwann cells.  
Thereafter, tissues were incubated with Alexa 647 anti-rabbit and Alexa 488 anti-mouse 
fluorescent secondary antibodies (1:1000 dilution, 1 h, room temperature). Negative 
controls were incubated on adjacent sections using 10% normal horse serum or blocking 
solution instead of the primary antibody. After three PBS washing cycles, the arteries 
were mounted intact with antifading agent (vectashield mounting medium with DAPI, 
Vector Laboratories, UK). A representative scheme of the protocol using a 96-well plate 


























FIGURE 24| Representative scheme of immunohistochemistry experiments. 
 
iv. LASER SCANNING CONFOCAL MICROSCOPY (LSCM)  
Preparations were visualized with a Leica SP2 LSCM system (Leica Microsystems, 
Wetzlar, Germany) fitted with an inverted microscope (× 63 oil immersion lens) (Figure 
25). Stacks of 1-µm-thick serial optical images were captured from 5 randomly chosen 
regions along the adventitial layer of the mesenteric artery, which was identified by the 
shape and orientation of the nuclei stained with DAPI [228].  
 
FIGURE 25| Confocal microscopy - Leica SP2 LSCM system of UAM. 
 
From each region, three stacks of images were sequentially obtained at different 
wavelengths. The first stack was taken with the Ex 405 nm and Em 412-470 nm 
wavelength to visualize cell nuclei (DAPI staining). The second was taken with the Ex 488 

















noradrenergic terminals or glial cells) and the third with the Ex 633 nm and Em 640-720 
nm wavelength, to detect RAS receptors distribution stained with the secondary 
antibody Alexa Fluor 647 (different subtypes depending on primary antibody). Image 
acquisition was performed always under the same laser power, brightness, and contrast 
conditions. The resulting images were reconstructed separately for each wavelength for 
later quantification.  
 
v. IMAGE QUANTIFICATION 
Quantitative analysis of confocal z-stacks images was performed using image analysis 
software (PAQI, CEMUP, Porto, Portugal), as previously described [229]. Briefly, a 
sequential routine was designed and developed to analyse each fluorescent signal used. 
PAQI software measured the surface area and strength of the fluorescence signal 
marking the postganglionic nerves, the surface area and strength of the attachment 
signal marking the receptors and determined the surface area of interception of the 
receptors on the nerves as well as the intensity of fluorescence of the receptors on 






























TABLE 2| Description of the algorithm steps for the quantification of AT1 receptors, sympathetic 





Adapted from JB Sousa et al.,  Microscopy: advances in scientific research and education, 2014. 
 
VIII. PLASMA ANGIOTENSIN II 
 
i. BACKGROUND 
Enzyme-linked immunosorbent assay (ELISA) is a plate-based assay technique designed 
for detecting and quantifying substances such as peptides, proteins, antibodies and 
hormones. In this technique the antigen must be immobilized on a solid surface and 
then complexed with an antibody linked to an enzyme. The detection is accomplished 
by assessing the conjugated enzyme activity via incubation with a substrate to produce 
a measureable product (Figure 26). A key element of the detection strategy is a highly 
specific antibody-antigen interaction. 


















FIGURE 26| Basic principle of ELISA. A capture antibody on a multi-well plate will immobilize the antigen 
of interest. This antigen will be recognized and bound by a detection antibody conjugated to biotin and 
streptavidin-HRP.  
 
ii. EXPERIMENTAL PROCEDURE 
Ang II was first extracted from plasma samples by solid phase extraction (Discovery® 
DSC-Ph SPE tube, Sigma-Aldrich) (Figure 27). Briefly, the columns were activated with a 
sequence of 5 ml of the following solvents in this order: methanol, tetrahydrofuran, 
hexane, methanol and ultrapure water. Thereafter, 1 ml of plasma samples were placed 
in the columns and the extraction was made with another sequence of 5 ml of the 
following solvents in this order: ultrapure water, acetic acid 4% and finally a mixture 
consisting in ethanol:acetic acid:water (90:4:6). The last 5 ml with the mixture were 




























Ang II levels were quantified by ELISA using a commercial kit (Peninsula Laboratories 
International) according to the manufacturer’s instructions. Briefly, in a 96-well plate, 
each sample and standard were loaded in duplicate and, after reaction, absorbance was 
read at 450 nm on a plate reader (Synergy HT MultiMode Microplate Reader, Biotek, VT, 
USA), within 10 min after the end of the protocol. The concentration of Ang II in the 
sample is inversely proportional to the measured optical density. For the calculation of 
results, the mean absorbance values of each duplicate of the sample were obtained and 
the concentration was determined from the standard curve.  
  
IX. STATISTICAL ANALYSIS 
 
Statistical analyses were performed with Graph-Pad Prism (version 8.3). 
Sample size was calculated assuming a probability error of alpha type of 5% (p<0.05) and 
potency of 80%.   
The normality of the variables was evaluated with Kolmogorov-Smirnov test. Since the 
variables followed a normal distribution, parametric tests were used. Results were 
expressed as mean±s.e.m. Differences of means were compared using one- or two-way 
ANOVA, followed by post-hoc Holm-Sidak's multicomparison t test or Student’s t test. A 


















I. HEMODYNAMIC PARAMETERS 
 
At the age of 6 months, body weight was not significantly different between MUN and 
CONTROL male rats (MUN=460,18±8,1 g; CONTROL= 486,6±18,6g; n= 6; p=0,21). 
Statistical differences were not detect between body weight of SHR and WKY rats at the 
age of 6 months (SHR=377,4±8,9 g; WKY= 367,0±11,9 g; n=6, p=0,52).  
Hemodynamic parameters were measure in rats under anaesthesia and in awake rats. 
In anaesthetized rats, MUN rats exhibited significantly larger SPB, DBP but not HR 
compared to their respective controls (Figure 28A and 29).  SHR exhibited significantly 
larger SBP, DBP and HR compared to controls (Figure 28B and 29).  MUN rats exhibited 
lower SBP and DBP levels compared to SHR rats.  
 
FIGURE 28| Systolic (SBP) and diastolic (DBP) blood pressure of the 4 animal groups in study. MUN, 
offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from mothers fed 
ad libitum during pregnancy; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto rat.  Values are 
mean±s.e.m. from 6 rats of each group. Significant differences from the respective control rat: *p<0.05. 
 
FIGURE 29| Heart rate of the 4 animal groups in study. MUN, offspring exposed to maternal undernutrition 
during pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy; SHR, 
spontaneously hypertensive rat; WKY, Wistar Kyoto rat. Values are mean±s.e.m. from 6 rats of each group. 







In awake MUN rats, it was confirmed that, at the age of 6 months, significantly higher 
SBP values (164.40±3.61 mmHg; n=6) were observed, compared to CONTROL animals 
(134.13±3.35 mmHg; n=6; p=0.003).   
 
II. INFLUENCE OF FETAL UNDERNUTRITION ON VASCULAR MORPHOLOGY  
 
Both morphology and collagen content were analysed in both models of hypertension. 
Histological sections of the mesenteric artery showed a reduced lumen diameter in MUN 
and SHR when compared to their respective control group (Figure 30A).  
The quantitative analysis of the images demonstrated that:  
i. The lumen area of MUN and SHR is significantly reduced when compared to their 
control (CONTROL and WKY, respectively) (Figure 30B).  
ii. The media layer of MUN and SHR is significantly thicker when compared to their 
control (CONTROL and WKY, respectively) (Figure 30C).  
iii. The adventitia layer of MUN is significantly thicker when compared to CONTROL 
(Figure 30D – left panel). The raise observed in SHR was not statistically different 
(Figure 30D – right panel). 
iv. The ratio media/lumen and adventitia/lumen was significantly increased in MUN 
and SHR when compared to their control (CONTROL and WKY, respectively) 
(Figure 31). 
v. A significant increase in collagen content is observed both in MUN and SHR when 








FIGURE 30| Representative images (A) and histomorphometric analysis (B, C and D) of mesenteric 
arteries from CONTROL and MUN (right panel) and WKY and SHR rats (left panel). Images were obtained 
from orcein stained arteries (scale bar = 500 µm). The graphics show the lumen area (B); cross sectional 
area of tunica media (C) and tunica adventitia (D). MUN, offspring exposed to maternal undernutrition 
during pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy; SHR, 
spontaneously hypertensive rat; WKY, Wistar Kyoto rat. Values are mean±s.e.m. from 6 rats of each group. 










FIGURE 31| Histomorphometric analysis and representative images of mesenteric arteries from 
CONTROL and MUN (A) and WKY and SHR rats (B). The graphics show the ratio media/lumen (left) and 
the ratio adventitia/lumen (right). Images were obtained from hematoxylin-eosin stained arteries (scare 
bar = 300 µm). MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring 
from mothers fed ad libitum during pregnancy; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto 
rat. Values are mean±s.e.m. from 6 rats of each group. Significant differences from the respective control 
rat: *p<0.05. 
 
FIGURE 32| Perivascular collagen content and representative images of mesenteric arteries from 
CONTROL and MUN (A) and WKY and SHR rats (B). The graphics show the collagen content; results are 
expressed as percentage of the total artery area. Images were obtained from Masson’s trichrome stained 
arteries (scare bar = 300 µm). MUN, offspring exposed to maternal undernutrition during pregnancy; 
CONTROL, offspring from mothers fed ad libitum during pregnancy; SHR, spontaneously hypertensive rat; 
WKY, Wistar Kyoto rat.  Values are mean±s.e.m. from 6 rats of each group. Significant differences from 







III. INFLUENCE OF FETAL UNDERNUTRITION ON PERIVASCULAR SYMPATHETIC 
INNERVATION  
 
i. SYMPATHETIC INNERVATION 
Confocal microscopy studies were then carried out to evaluate the immunoreactivity for 
the sympathetic neuronal marker, TH. These studies were performed in the adventitial 
layer of mesenteric arteries which was identified from LSCM images by the shape and 
orientation of the nuclei and exhibiting scattered elastic fibres [228]. No significant 
immunoreactivity was observed when the primary antibodies were omitted (negative 
controls).  Immunoreactivity for the sympathetic neuronal marker TH was evident in 
mesenteric arteries from all experimental groups (Figure 33, green marker). However, 
the pattern of TH immunoreactivity in MUN and in SHR was significantly larger than in 
CONTROL and WKY arteries, respectively (Figure 33).  
FIGURE 33| Quantitative analysis of LSCM images and representative images of the adventitia from 
mesenteric arteries from CONTROL and MUN (A) and WKY and SHR rats (B). Images shows the 
immunofluorescence reactivity to TH (green) with DAPI-stained nuclei (blue) (scare bar = 25 µm). MUN, 
offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from mothers fed 
ad libitum during pregnancy; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto rat. In the graphics 








ii. SYMPATHETIC NEUROTRANSMISSION  
Electrical field stimulation (5 Hz, 1 ms, 100 pulses, 50 mA) significantly increased tritium 
outflow from all vessels studied of both MUN and CONTROL rats (Figure 34). The 
fractional rate of basal tritium outflow (b1), electrically-evoked tritium overflow (S1) of 
mesenteric arteries and veins and of caudal arteries are shown in Table 3. Basal outflow 
and electrically-evoked tritium overflow remained constant throughout the CONTROL 
experiments, with bn/b1 and Sn/S1 values close to unity. Electrically-evoked tritium 
overflow (S1) was higher in MUN compared to CONTROL vessels (Table 3).  
 
TABLE 3| Basal and electrically evoked tritium overflow from MUN and CONTROL vessels.  
 
Tissues were stimulated twice at 30-min intervals (S1-S2; 100 pulses, 5 Hz, 1 ms, 50 mA): b1 refers to the 
5-min period immediately before S1. The electrically-evoked tritium overflow is expressed as a percentage 
of the tissue tritium content at the onset of stimulation. MUN, offspring exposed to maternal 
undernutrition during pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy. 
Values are mean±s.e.m. and n denotes the number of tissue preparations used from 5 MUN and 5 









FIGURE 34| Representative examples of time course tritium outflow from mesenteric artery (A), 
mesenteric vein (B) and tail artery (C). Tritium outflow is expressed as a percentage of the total 
radioactivity present in the tissue at the beginning of the collection period. Each line represents the 
outflow of tritium from a single superfusion chamber. MUN (triangles), offspring exposed to maternal 









Since results obtained were similar between the vessels in study, the mesenteric artery 
was used to make a comparison with SHR.  A significant increase in NA released in the 
stimulation period was observed in SHR mesenteric arteries compared to WKY rats 
(Table 4 and Figure 35). 
 
TABLE 4| Results of NA release experiments. 
 
 
Tissues were stimulated twice at 30-min intervals (S1-S2; 100 pulses, 5 Hz, 1 ms, 50 mA): b1 
refers to the 5-min period immediately before S1. The electrically-evoked tritium overflow is 
expressed as a percentage of the tissue tritium content at the onset of stimulation. Basal tritium 
outflow (b1), electrically evoked tritium overflow (S1) and S2/S1 ratios from the four animal 
groups in study. MUN, offspring exposed to maternal undernutrition during pregnancy; 
CONTROL, offspring from mothers fed ad libitum during pregnancy; SHR, spontaneously 
hypertensive rat; WKY, Wistar Kyoto rat. Values are mean±s.e.m., from 6 rats of each group. 







FIGURE 35 | Representative examples of time course tritium outflow from mesenteric artery of the 4 
groups in study. On the right panel are the CONTROL (circles) and MUN (triangles) and on the left panel 
are the WKY (circles) and SHR (triangles). Each line represents the outflow of tritium from a single 
superfusion chamber. MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, 
offspring from mothers fed ad libitum during pregnancy; SHR, spontaneously hypertensive rat; WKY, 
Wistar Kyoto rat. 
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iii. [3H]-NA UPTAKE 
Since similar results were obtained between the vessels studied, the mesenteric artery 
was used to study the uptake of [3H]-NA. In our experimental conditions, total tissue 
tritium content (per mg of tissue), after incubation with [3H]-NA, was significantly higher 
in MUN than in CONTROL arteries (Figure 36). 
[3H]-NA uptake was significantly larger in MUN and SHR mesenteric arteries when 
compared to CONTROL and WKY, respectively (Figure 36).  
Tissue content of NA was larger in CONTROL and MUN rats, compared to WKY and SHR.  
 
FIGURE 36| [3H]-NA uptake in mesenteric artery of CONTROL and MUN (A) and WKY and SHR rats (B). 
MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from mothers 
fed ad libitum during pregnancy; SHR, spontaneously hypertensive rat; WKY, Wistar Kyoto rat. Values are 








IV.  INFLUENCE OF FETAL UNDERNUTRITION ON RENIN-ANGIOTENSIN SYSTEM 
 
i. ROLE OF ANG II IN VASCULAR SYMPATHETIC NEUROTRANSMISSION 
Ang II (30 nmol/L; a non-selective agonist of angiotensin receptors) facilitated 
electrically-evoked tritium overflow in all the vessels studied (mesenteric artery, 
mesenteric vein and tail artery) from both experimental groups, as shown by the ratio 
(S2/S1) in the absence of the drug. No statistical differences were observed between 
different vessels or between different experimental groups (Figure 37). 
Endogenous Ang II-mediated effects on vascular sympathetic neurotransmission were 
evaluated by blocking the AT1 receptor with Losartan, a selective AT1 receptor 
antagonist. In the presence of Losartan (100 nmol/L), an inhibition of electrically-evoked 
tritium overflow was observed in all the MUN vessels studied (Figure 37). Losartan was 








FIGURE 37| Effects of Ang II and Losartan on the electrically-evoked tritium overflow in mesenteric artery 
(A), mesenteric vein (B) and tail artery (C) from CONTROL and MUN rats. Ordinates: S2/S1 values obtained 
in individual tissue preparations, expressed as a percentage of the appropriate S2/S1 control value. MUN, 
offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from mothers fed 
ad libitum during pregnancy. Values are mean±s.e.m. from 5 to 16 tissue preparations from 6 rats of each 







ii. PLASMATIC ANGIOTENSIN II 




FIGURE 38| Plasmatic concentration of Ang II in CONTROL and MUN rats. MUN, offspring exposed to 
maternal undernutrition during pregnancy; CONTROL, offspring from mothers fed ad libitum during 
pregnancy. Values are mean±s.e.m., from 8 rats of each group. Significant differences from CONTROL rats: 
*p<0.05. 
 
iii. EXPRESSION OF RAS ENZYMES IN THE MESENTERIC ARTERY 
a. Renin 
Statistical differences were not detect in renin expression in the mesenteric artery 
























FIGURE 39| Expression of renin in mesenteric arteries from MUN and CONTROL rats. RT-PCR analysis of 
transcripts for renin.  MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, 
offspring from mothers fed ad libitum during pregnancy. Data are normalized to the 28s gene and fold 
changes between MUN and CONTROL are expressed as mean±s.e.m., from 6 rats of each group. 







b. Angiotensin Converting Enzyme 
Concerning ACE, the enzyme that converts Ang I into Ang II, it was found a significant 
higher expression in mesenteric artery from MUN rats when compared to CONTROL rats 








FIGURE 40| Expression of ACE in mesenteric arteries from MUN and CONTROL. RT-PCR analysis of 
transcripts for ACE. MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, 
offspring from mothers fed ad libitum during pregnancy. Data are normalized to the 28s gene and fold 
changes between MUN and CONTROL are expressed as mean ± s.e.m., from 6 rats of each group. 
Significant differences from CONTROL rats: *p<0.05. 
 
c. Angiotensin Converting Enzyme 2 
Regarding ACE 2, the enzyme that converts Ang II in Ang 1-7, it was found a significant 








FIGURE 41| Expression of ACE 2 receptor in mesenteric arteries from MUN and CONTROL. RT-PCR analysis 
of transcripts for ACE2. MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, 
offspring from mothers fed ad libitum during pregnancy. Data are normalized to the 28s gene and fold 
changes between MUN and CONTROL are expressed as mean±s.e.m, from 6 rats of each group. Significant 































iv. EXPRESSION OF ANGIOTENSIN RECEPTORS IN THE MESENTERIC ARTERY 
a. AT1 Receptors 
RT-PCR data revealed a higher expression of AT1 receptor in the mesenteric artery of 

























FIGURE 42| Expression of AT1 receptor in mesenteric arteries from MUN and CONTROL rats. RT-PCR 
analysis of transcripts for AT1 receptor. MUN, offspring exposed to maternal undernutrition during 
pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy. Data are normalized to 
the 28s gene and fold changes between MUN and CONTROL are expressed as mean±s.e.m from 6 rats of 
each group. Significant differences from CONTROL rats: *p<0.05. 
 
In addition, LSCM revealed the presence of AT1 receptor immunoreactivity in both 
CONTROL and MUN mesenteric arteries (Figure 43A, red images). However, in MUN 
arteries the quantitative analysis evidenced that the relative amount of AT1 receptor 
immunoreactivity was much higher (up to 80% higher) than that exhibited by CONTROL 
mesenteric arteries (Figure 43B). 
The localization pattern of AT1 receptors in sympathetic nerves, stained with TH, were 
analysed. The immunoreactivity for AT1 receptors showed substantial overlay with TH 
marker suggesting that these receptors might be localized on the same structure, the 
postganglionic sympathetic nerves (Figure 43A, overlay images). Nonetheless, 
immunoreactivity for AT1 receptors in non-neuronal cells could also be observed. 
Quantitative analysis of LSCM images revealed considerable differences in the relative 







groups: values obtained from MUN animals almost doubled comparatively to CONTROL 
rats (Figure 43B).  
Relative mean ratio of AT1 receptor and TH overlay, with respect to the total TH 
immunoreactivity, was slightly higher in MUN comparatively to CONTROL mesenteric 
arteries: 25% of sympathetic neurons exhibit AT1 receptor immunoreactivity in 
CONTROL versus 35% observed in MUN vessels (Figure 43C). Also, the relative mean 
ratio of AT1 receptor and TH overlay, regarding the total AT1 immunoreactivity revealed 
the presence of AT1 receptors in other cells than sympathetic neurons: 70% in CONTROL 









FIGURE 43| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries (A) exhibiting TH (green), AT1 receptor (red), and overlay of AT1 receptor-TH 
immunoreactivities, nuclei (blue); Relative means of TH, AT1 and AT1-TH overlay expressed as 
percentage of CONTROL values (B); Mean percentage of overlay ratio with TH (C) and mean percentage 
of overlay ratio with AT1 receptors (D). Images are reconstructions from 9–28 serial optical sections 
analysed using PAQI software. MUN, offspring exposed to maternal undernutrition during pregnancy; 
CONTROL, offspring from mothers fed ad libitum during pregnancy. Values are mean±s.e.m. from 6 rats 









b. AT2 Receptors 
RT-PCR data revealed a lower expression of AT2 receptors in the mesenteric artery of 

























FIGURE 44| Expression of AT2 receptor in mesenteric arteries from MUN and CONTROL rats. RT-PCR 
analysis of transcripts for AT2 receptor. MUN, offspring exposed to maternal undernutrition during 
pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy.  Data are normalized to 
the 28s gene and fold changes between MUN and CONTROL are expressed as mean±s.e.m from 6 rats of 
each group. Significant differences from CONTROL rats: *p<0.05. 
 
LSCM also revealed the presence of AT2 immunoreactivity in both CONTROL and MUN 
mesenteric arteries (Figure 45, red images). Quantitative analysis evidenced that the 
relative amount of AT2 immunoreactivity present in MUN arteries was reduced (up to 
40% lesser) than that exhibited by CONTROL vessels (Figure 45B). 









FIGURE 45| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries (A) exhibiting TH (green), AT2 receptor (red), and overlay of AT2-TH immunoreactivities, nuclei 
(blue) and quantitative analysis of LSCM images from mesenteric arteries (CONTROL and MUN) staining 
with AT2 antibodies (B).  MUN, offspring exposed to maternal undernutrition during pregnancy; 
CONTROL, offspring from mothers fed ad libitum during pregnancy. Values are mean±s.e.m. from 6 rats 











c. Mas Receptors 
RT-PCR data revealed a lower expression of Mas receptors in the mesenteric artery of 

























FIGURE 46| Expression of Mas receptor in mesenteric arteries from MUN and CONTROL rats. RT-PCR 
analysis of transcripts for Mas receptor. MUN, offspring exposed to maternal undernutrition during 
pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy. Data are normalized to 
the 28s gene and fold changes between MUN and CONTROL are expressed as mean±s.e.m from 6 rats of 
each group. Significant differences from CONTROL rats: *p<0.05. 
 
This quantification was in line with our confocal study for this type of receptor, a 
significant lower immunoreactivity for Mas receptors was found in MUN rats when 








FIGURE 47| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries exhibiting Mas receptors (red) and nuclei (blue) (A) and quantitative analysis of LSCM images 
(B). MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from 
mothers fed ad libitum during pregnancy. Values are expressed as mean±s.e.m. from 6 rats of each group. 









d. MrgD Receptors 
RT-PCR data revealed a significant lower expression of MrgD receptors in the mesenteric 

























FIGURE 48| Expression of MrgD receptor in mesenteric arteries from MUN and CONTROL rats. RT-PCR 
analysis of transcripts for MrgD receptor. MUN, offspring exposed to maternal undernutrition during 
pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy. Data are normalized to 
the 28s gene and fold changes between MUN and CONTROL are expressed as mean±s.e.m from 6 rats of 
each group. Significant differences from CONTROL rats:*p<0.05. 
 
A lower expression of MgD receptor in MUN rats was also confirmed by the confocal 








FIGURE 49| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries exhibiting MrgD receptors (red) and nuclei (blue) (A) and quantitative analysis of LSCM images 
(B). MUN, offspring exposed to maternal undernutrition during pregnancy; CONTROL, offspring from 
mothers fed ad libitum during pregnancy. Values are mean±s.e.m from 6 rats of each group. Significant 









v. LOCALIZATION OF RAS RECEPTORS 
During confocal study of RAS receptors, it was noticed the presence of receptors in other 
cells besides sympathetic neurons. The presence of AT1 receptors on Schwann cells was 
investigated. To localize Schwann cells, anti-GFAP-immunoreactivity was used.  
Data from LSCM images evidenced AT1 receptors and GFAP overlaid immunoreactivities 
(Figure 50), confirming the presence AT1 receptors on Schwann cells. In addition, other 













FIGURE 50| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries exhibiting GFAP (green), AT1 receptors (red), and overlay of AT1 receptors-GFAP 
immunoreactivities, nuclei (blue). MUN, offspring exposed to maternal undernutrition during pregnancy; 
CONTROL, offspring from mothers fed ad libitum during pregnancy.  
 
The possible location of RAS receptors within the nucleus was also investigated. It was 
found that AT1 and AT2 receptors, Mas and MrgD exhibited immunofluorescence inside 










FIGURE 51| Laser scanning confocal microscopy representative images of MUN and CONTROL mesenteric 
arteries exhibiting RAS receptors (red) and nuclei (blue). MUN, offspring exposed to maternal 








V. IMPACT OF FETAL UNDERNUTRITION IN •O2- PRODUCTION 
 
A higher immunoreactivity for p22phox, a subunit of NADPH oxidase, was observed in 
MUN rats, when compared to CONTROL (Figure 52A). This observation was in line with 
the quantitative analysis of the images collected, where a significant higher p22phox 
immunoreactivity was found in MUN rats (Figure 52B).  
 
FIGURE 52| Laser scanning confocal microscopy representative images of CONTROL and MUN mesenteric 
arteries (A) exhibiting TH (green), p22phox (red), and overlay of p22phox-TH immunoreactivities, nuclei 
(blue); and quantitative analysis of LSCM images (B). MUN, offspring exposed to maternal undernutrition 
during pregnancy; CONTROL, offspring from mothers fed ad libitum during pregnancy. Values are 



































At present, CVDs continue to be the leading cause of death and disability in the world, 
responsible for almost one third of global deaths, being essential hypertension one of 
the most important risk factors. Epidemiological studies have consistently found an 
association between exposure to fetal stress, LBW and increased risk in adulthood to 
develop hypertension and CVDs, a phenomenon known as fetal programming. 
Additionally, experimental and clinical studies have demonstrated that sustained 
maternal nutrient restriction, a well-known fetal stress factor, activate adaptive cardiac 
and vascular changes that might explain this association. However, the mechanisms 
underlying the observed cardiovascular alterations are not fully understood, and more 
research is needed to identify strategies to prevent and/or treat FPH, aiming to reduce 
the socioeconomic impact of CVDs.  
Over the past years, some studies have addressed the activation of SNS and RAS as 
possible mechanisms implicated in FPH. Increasing clinical evidence indicates a key role 
for sympatho-activation in the development of CVDs, highlighting the need gain insight 
on how the SNS interfaces with the cardiovascular system and how this interaction may 
result in increased morbidity or mortality.  The RAS is also an important system 
implicated in hypertension, and a target in the current treatment mainly directed to the 
renin/ACE/Ang II/AT1 receptor axis. Moreover, the ACE2/Ang 1-7/Mas and MrgD axis is 
a possible future therapeutic target.  This work aimed to develop new knowledge about 
the role of SNS and RAS in FPH and to study the possible interplay between these two 
systems. Another aim of this work was to compare the alterations induced by fetal stress 
(undernutrition) and those found in SHR, a well-known model of essential hypertension, 
to determine if hypertension of fetal origin shares similitudes with essential 
hypertension. 
To address this, an animal model of FPH based on maternal undernutrition during 
pregnancy (MUN) was used, which is known to produce offspring with LBW that, later 
in life, develop hypertension [184, 220, 230]. This model was chosen, instead of the one 
based on maternal low protein diet, since it better resembles suboptimal nutrition to 
the fetus in humans, induced either by maternal malnutrition or by placental 
insufficiency. In both situations, there is a global reduction of nutrient access to the 













In order to facilitate the discussion, at the beginning of each section a scheme that 
summarizes the most relevant results is included. 
 
i. HEMODYNAMIC ALTERATIONS INDUCED BY FETAL UNDERNUTRITION. 
COMPARISON WITH SHR  MODEL. 
 
FIGURE 53| Hemodynamic parameters alterations in MUN (blue) and SHR (orange). 
 
BP was assessed by two methods, direct measurement in anesthetized rats through the 
femoral artery, and in awake animals with plethysmography. It was demonstrated that 
at the age of 6 months MUN male rats had reached a hypertensive state, since they 
presented a significant higher SBP and DBP than CONTROL rats. These findings confirm 
previous results with the same model of fetal stress induced by global nutrient 
restriction during intrauterine life [108, 204, 230-232].  
SHR also exhibited higher values of SBP and DBP than the control WKY, as shown in many 
studies with this rat strain [233-235]. Comparing both animal models of hypertension, 
the increase in SBP and DBP was higher in SHR, than in MUN rats. 
No differences were found in HR of anesthetized MUN and CONTROL rats, similar to the 
findings in other studies using maternal low protein [182, 236], or low micronutrients -
such as zinc [237]- or vitamin B12 [238] diets during pregnancy. However, in SHR, HR 
was elevated. This tachycardia may reflect an alteration in baroreceptors regulation, 
which has been demonstrated to be defective in SHR rats [239]. It is possible that in SHR 














To anesthetize the rats, medetomidine was used, a drug which has an agonist effect on 
α2-adrenoceptors. This anaesthetic has been reported to reduce NA outflow within the 
central nervous system, dampening the central sympathetic tone and resulting in 
bradycardia [240, 241]. Therefore, to test the possible influence of anaesthesia on BP, 
measurement with the tail-cuff method, in awake rats, was performed.  Similar results 






ii. VASCULAR REMODELLING INDUCED BY FETAL UNDERNUTRITION. 
COMPARISON WITH SHR  MODEL. 
FIGURE 54| Vascular morphological alterations in MUN (blue) and SHR (orange). 
 
In a healthy artery, sustained changes in the extravascular environment, local signaling 
molecules, or hemodynamic modifications, initiate structural adaptations within the 
different cell types and layers of the vessel wall. Once the initial stimulus is restored, the 
vascular wall returns to the original state. Nevertheless, in disease states, these changes 
do not return to baseline levels, but instead initiate pathological vascular alterations 
observed in CVDs, in a process defined as “vascular remodelling” [242].  
Fetal undernutrition induces in male rat offspring high BP, with no 
alterations in HR, in adulthood.  
 
Fetal undernutrition induces a milder form of hypertension than in a 













Vascular remodelling is a heterogeneous process and differs depending on the vessel 
type and specific disease state or progression. In the majority of studies of hypertensive 
remodelling, resistance vessels have been used, since they contribute to peripheral 
resistance and are usually affected in hypertension [30, 243]. In this study the superior 
mesenteric artery was chosen, since it is an important vessel which contributes to BP 
maintenance [211, 244].  
The mesenteric artery of MUN rats exhibit a lower lumen area and an increased media 
and adventitia layers compared to the CONTROL. These geometrical changes are 
classified as inward hypertrophic vascular remodelling. This type of remodelling is 
characteristic of hypertension, and can contribute to an increased total peripheral 
vascular resistance [30]. In mesenteric resistance arteries from rats exposed to 
undernutrition in utero, the same type of remodelling has also been found [245], while 
the aorta, a conduit artery, presented outward hypertrophic remodelling [232, 245]. 
These data indicate that different vessels exposed to the same stress factor undergo 
different types of structural adaptations.  
The hypertrophy observed in the media layer in MUN rats may be due to cellular 
hypertrophy caused by VSMC proliferation or growth. Previous studies demonstrated 
that offspring exposed to maternal undernutrition have reduced angiogenesis and 
consequently, a decreased number of mesenteric microvessels at birth, which may 
induce a flow stress and elicit a compensatory increase in VSMC [246]. This has also been 
observed in the aorta from this rat model of undernutrition, which exhibit hypotrophy 
at birth followed by hypertrophy in the perinatal period which is maintained in adult age 
[232]. Excess GC may also be implicated in the abnormal growth and differentiation of 
VSMC, since they have been shown to be elevated in the maternal circulation of food-
restricted rats [245]. Besides these factors, Ang II and NA are well known trophic factors 
and an elevation can also favour the hypertrophy of VSMC [243, 247]. Sympathetic 
hyper-innervation was shown to be related to media hypertrophy in jejunal arteries of 
SHR, since an increase in the number of nerve fibres was present before the 
development of hypertension, or increase in thickness of the arterial media [248]. This 
suggests that increased SNA possible plays a causal role in the development of 













It has been demonstrated that increased VSMC could influence the expression of 
vascular extracellular matrix components, such as collagen. In animal models of FPH 
increased collagen has been observed in the aorta [246]. Similarly, in the mesenteric 
artery of MUN rats collagen content was also increased. This is an important finding in 
MUN rats since collagen is the extracellular component that may alter the passive 
pressure/diameter relation of arteries at higher pressures and thus, induce a progressive 
stiffening of the vascular wall [15] 
In addition to VSMC, collagen can be also generated by fibroblasts in the adventitial 
layer; it has been proposed that phenotypic changes of these cells into myofibroblasts, 
play a major role in arterial remodelling and matrix deposition [249]. The adventitia has 
not been well explored in the context of FPH, and to our best knowledge, this is the first 
study demonstrating that mesenteric arteries of MUN rats have significantly increased 
adventitia area and collagen content. Furthermore, the presence of an increased 
media/lumen ratio and adventitia/lumen ratio in MUN rats was also demonstrated. 
Since wall/lumen is associated with higher risk of adverse cardiovascular events [28, 29], 
the remodelling process in MUN rats does not seem to be adaptive and is likely to 
contribute to cardiovascular damage.  
The alterations in vascular morphology of mesenteric arteries of MUN and CONTROL 
rats were compared with the results obtained for SHR, a well-known model of 
hypertension with structural alterations in both conduit [250] and resistance vessels 
[251-253].  This study demonstrate that in the mesenteric artery of SHR an inward 
hypertrophic vascular remodelling was observed. In mesenteric resistance vessels from 
SHR inward eutrophic remodelling occurs while in models of secondary hypertension 
hypertrophy has been observed [31]. However, fibrosis and excessive extracellular 
matrix deposition seems to be a common denominator in different types of 
hypertension [18, 19].  Our study demonstrates that the remodelling process is relatively 
similar in MUN and SHR rats (inward hypertrophic), with a larger contribution of the 




















iii. ALTERATIONS IN SYMPATHETIC NEUROTRANSMISSION INDUCED BY 
FETAL UNDERNUTRITION. COMPARISON WITH SHR. 
FIGURE 55| Vascular sympathetic neurotransmission alterations in MUN (blue) and SHR (orange). 
 
The hypothesis that essential hypertension may include, in its multifactorial etiology, an 
abnormality in the autonomic modulation of BP homeostasis has been investigated for 
a long time. This process involves a sympathetic activation coupled with a 
parasympathetic inhibition, called “neurogenic hypothesis of hypertension” [71]. 
Indeed, the SNS activity can elevate BP by: augmenting the force and/or rate of cardiac 
contraction; decreasing the diameter of resistance arteries; and reducing sodium and 
water excretion by the kidneys [254].  
In the present work, confocal microscopy was used to analyse sympathetic innervation 
with an antibody against TH. This is a technique that allow studying the entire adventitial 
layer without the need to dissect it. LSCM data revealed the presence of nerve fibres 
positive for TH both in CONTROL and MUN. We observed that sympathetic nerves 
spread through the adventitia reaching the medial layer. There was, however, a larger 
thickness of sympathetic nerve fibres in MUN mesenteric arteries. The higher 
immunoreactivity for TH observed in MUN rats indicates a sympathetic hyper-
Fetal undernutrition induces inward hypertrophic remodelling in the 
mesenteric artery, with the contribution of both the media and the 
adventitia layers, and the presence of vascular fibrosis. 
 
Fetal undernutrition and essential hypertension share similar 













innervation induced by exposure to undernutrition during fetal life.  This is in accordance 
with the findings in other FPH animal model, such as induced by prenatal hypoxia, which 
demonstrated a sympathetic hyper-innervation in tibial arteries [173].  
In SHR mesenteric arteries a larger innervation was also observed in accordance with 
previous studies in the same vessel [223, 255]. When comparing FPH model to essential 
hypertension it is visible that innervation is larger in MUN and CONTROL rats. It is 
important to notice that, at the age of 6 months, MUN rats did not differ in weight 
relative to CONTROL rats and the same was observed between SHR and WKY. However, 
at the same age, the SHR are smaller than MUN rats. This is likely related to the fact that 
they originate from different strains (WKY and Sprague Dawley, respectively) and 
Sprague Dawley rats are larger [256]. As so, it is expected that MUN rats presented larger 
vessels and, therefore, denser sympathetic innervation. This fact is also compatible with 
the larger adventitial layer, probably due to the trophic effects of NA. 
In order to confirm that a larger innervation was associated with higher NA release, 
functional studies were conducted using radioactive NA. In sympathetic terminals, [3H]-
NA can be taken up by a specific NA transporter into vesicles [257, 258]. Therefore, total 
tissue tritium content (per mg of tissue) can be considered an indicator of the 
sympathetic innervation density [233]. The total tissue content of the mesenteric 
arteries of MUN was significantly higher than in CONTROL, indicating that the nervous 
terminals of MUN can incorporate more NA. Also, this is compatible with an increased 
bioavailability of NA in the synaptic cleft of MUN rats. Similar data was found in SHR as 
in previous studies with the mesenteric [233] and tail artery [259] and also mesenteric 
resistance arteries [260]. 
To evaluate possible differences between blood vessels, the mesenteric vein and the tail 
artery were also studied. These vessels have been extensively used as models for the 
study of neuromodulation exerted by substances in the vasculature [222, 233, 261]. This 
work evidence that hyperactivation of SNS is a generalized phenomenon in MUN vessels, 
as shown by the significant increased NA release upon electrical stimulation. It was also 
observed that the increase in basal and electrically induced NA release in MUN vessels 
was more noticeable in arteries than in veins. This data also suggests that the vascular 













activates postsynaptic α1-adrenoceptors in VSMC leading to vasoconstriction in arteries 
and in veins, as noticed on splanchnic circulation in animal models of hypertension [262, 
263]. As so, our data is in agreement with studies demonstrating that SNS activation 
seem to be increased in other models of FPH [173, 178, 183, 264-266]. Indeed, there is 
evidence of an increased circulating levels of NA in animal models of FPH [174, 180, 267] 
and also in LBW humans [181]. Therefore, and in accordance with those reported data, 
our findings indicate that the sympathetic hyperactivity observed in MUN vascular 
tissues can be explained by the larger amount of sympathetic innervation, as 
demonstrated by TH staining. An increased sympathetic neurotransmission can 
contribute to increased vascular tone and to the observed remodelling, which, in turn, 
can be one of the mechanisms behind hypertension development in MUN.  
When comparing to SHR, the increased NA release observed was analogous to MUN 
rats, although SHR presented a smaller basal outflow. This data is in accordance with 
studies previously performed in SHR, where a sympathetic hyperactivity was also 
described in cerebral artery [268], tail artery [26] and mesenteric bed [222].  
The elevated sympathetic neurotransmission in MUN and SHR support that SNS play a 
role in the development of hypertension in both fetal programming and essential 





Fetal undernutrition is associated with a sympathetic 
hyperinnervation in the adventitia layer of mesenteric artery.  
 
Fetal undernutrition is associated with a sympathetic 
hyperactivation and enhanced sympathetic neurotransmission in 
several vascular beds. 
 
FPH and essential hypertension exhibit similar alterations in 













iv. RAS ALTERATIONS IN FETAL PROGRAMMING OF HYPERTENSION 
FIGURE 56| RAS alterations in MUN rats. 
 
A presynaptic functional alteration of the perivascular sympathetic neurotransmission 
was found in the rat model of FPH, which could contribute to the development or 
maintenance of hypertension. Sympathetic activity is regulated at the presynaptic level 
through auto-receptors, and it is also influenced by several other factors locally 
released, including adenosine, prostaglandins and Ang II [269-271]. Ang II may play a key 
role in the observed alterations in sympathetic neurotransmission, since functional 
cross-talk between AT1 receptors and other vascular signalling pathways is believed to 
contribute to hypertension and remodelling [47, 247].   
The RAS has been found to be altered in several animal models of fetal programming. 
Thus, it has been shown that inappropriate activation of the RAS may occur in response 
to prenatal exposure to GC, which up-regulates expression of the renal RAS [272]. In 
addition, central expression of the AT1 receptors is increased in offspring exposed to 
maternal protein restriction [190, 236] and nicotine [193]. However, the relationship 
between RAS and SNS has not been addressed, particularly in the adventitia. Therefore, 
the possible influence of RAS on sympathetic neurotransmission was evaluated. For this 
part of the study, only the FPH model was used.  
The present work demonstrates that release of NA from sympathetic nerve terminals is 













both in arteries and veins from CONTROL and MUN rats, confirming the interplay 
between RAS and vascular sympathetic neurotransmission, through facilitatory RAS 
presynaptic receptors. The facilitation of NA release induced by exogenous Ang II in 
CONTROL rats was more pronounced in the arterial territories than in the veins.  An 
increased facilitatory role of Ang II on NA release has been previously demonstrated in 
rat models of hypertension, including in SHR [273-275].  
Ang II deleterious effects on the cardiovascular system are known to be mediated 
through AT1 receptors [47, 247]. Therefore, we explored the role of this type of receptor 
on sympathetic activity. When AT1 receptors were blockade (in the presence of Losartan, 
an AT1 receptor antagonist), NA overflow was similar to that obtained in the absence of 
this drug in CONTROL rats. However, in MUN rats a reduction of NA overflow was 
observed in the presence of Losartan, indicating a blockade of tonic facilitation. This 
result suggest that local Ang II is being released acting as paracrine factor on presynaptic 
AT1 receptors, facilitating sympathetic neurotransmission. As so, this data suggests the 
occurrence of higher levels of endogenous Ang II in the sympathetic cleft of MUN rats. 
Curiously, the tonic effect, mediate by endogenous Ang II on presynaptic AT1 receptors 
was similar in all the MUN vessels studied, discarding the possibility that this vascular 
sympathetic alteration occurs only locally or in specific territories, but rather indicating 
a widespread effect both in resistance and capacitance vessels.  
The measurement of Ang II in the synaptic cleft was not possible, due to methodological 
limitations. Nevertheless, plasmatic Ang II was addressed and no significant difference 
was detect between MUN and CONTROL. Yu et al. reported reduced plasma levels of 
Ang II in male adult offspring of GC-treated pregnant rats [276]. However, in a maternal 
GC-exposed sheep model, circulating levels of Ang II in 6 months old offspring were not 
significantly changed [277]. As described in the literature, plasmatic Ang II levels do not 
always reflect local Ang II levels, which may have more relevant effects on specific 
organs. To assess local Ang II production, it has been proposed that local ACE gene 
expression or activity should be used [278, 279]. In fact, previous data provide evidence 
that increased vascular ACE lead to increased local Ang II formation [278, 280]. 
Therefore, the presence of RAS enzymes in the vascular wall was investigated in MUN 













vascular neurotransmission, the mesenteric artery was chosen as a representative 
vessel for this study.  
Renin expression was not different in MUN vessels. It is known that vascular angiotensin 
generation depends on the uptake of circulating renin and/or its precursor prorenin 
[281]. This uptake into the vascular wall may be an important mechanism to enhance 
Ang II-dependent vascular tone or growth [280].  However, both ACE and ACE2 exhibited 
a higher expression in the mesenteric arteries from MUN rats. Usually, lower levels of 
ACE2 expression are found in VSMC and in the adventitia of large blood vessels [282].  
This was also observed in mesenteric arteries from CONTROL rats.  It has been proposed 
that the increase in tissue levels of ACE2 in pathological conditions may reflect a 
compensatory response, which may contribute to alter the balance of Ang II and Ang 1–
7 pathways within a particular tissue or cell type [283]. This is also evidenced by the fact 
that the circulating levels of ACE2, which are typically low or even undetectable in 
physiological conditions, are also increased in experimental conditions of diabetic 
hypertension [284]. Therefore, the fact that both ACE and ACE2 expression are increased 
in MUN mesenteric arteries, suggests a potential compensatory mechanism, which 
would increase Ang II degradation into Ang 1-7.   
Based on the above results, it seems plausible that the higher inhibition of sympathetic 
neurotransmission by AT1 receptors blockage with Losartan in MUN rats is related to 
larger AT1 receptor content. Therefore, their expression in the mesenteric artery and 
their distribution, specifically in the adventitia layer of the artery, were evaluated. In 
fact, a higher expression of AT1 receptors was demonstrated in MUN mesenteric arteries 
when compared to CONTROL rats. This was corroborated by LSCM images which show 
higher immunoreactivity for AT1 receptors and localization of these receptors within 
sympathetic nerves. This fact can explain, at least in part, the facilitatory tone regulating 
NA release from MUN mesenteric arteries stimulated with exogenous or endogenous 
Ang II. Together with functional data, these results reveal and support that enhanced 
sympathetic neurotransmission is related to alterations in AT1 receptors in MUN rats. 
These results are in line with previous works that identify an upregulation of AT1 
expression in the kidneys from maternal undernutrition rat offspring [169], and in the 













development. Similarly, increased pulmonary AT1 receptor expression was found in 
lungs of mice exposed to hypoxia [110] and in the kidney of near-term ovine fetuses 
exposed to high altitude [285]. Our data add support to the implication of alterations in 
AT1 receptors in FPH.  
Besides, lower expression of AT2 receptor was found in the mesenteric artery of MUN 
rats. Downregulation of  AT2 receptors has also been demonstrated in the kidney of 
offspring exposed to maternal undernutrition and low protein diet [171, 286], hypoxia 
[285] and GC [114].  
Regarding the ACE2/Ang 1-7/Mas and MrgD axis, a lower expression and 
immunoreactivity for Mas and MrgD receptors were also observed in mesenteric 
arteries from MUN rats. Similar results are found in Mas receptor protein expression, 
being also significantly lower in the brain of a 6-month sheep exposed to maternal GC 
[287]. The same group demonstrated that the reduced expression of the Mas receptor 
and increased metabolism of Ang 1–7 in brain may contribute to the loss of Ang 1–7 
tone, as well as the enhanced responsiveness of the Ang II-AT1 receptor pathway in GC-
dependent programming.  The present data support similar findings in the vascular wall 
from MUN rats. The potential increase in Ang 1-7 by the enhanced ACE2 expression 
would be blunted by the reduction in receptor expression. 
Considering the actions of Mas, MrgD and AT2 receptors activation, favouring the 
vasodilation and natriuresis and the opposite effects of AT1 receptor activation [42, 47, 
51, 283], our results support that mesenteric artery from MUN rats is more prone to 
vasoconstriction, inflammation, and oxidative stress. Ang II has been shown to induce 
fibrosis and hypertrophy through AT1 receptor activation [47, 247]. Therefore, the 
present data suggest that, in addition to an altered sympathetic neurotransmission, RAS 
alterations may also contribute to the observed remodelling in mesenteric arteries. In 
this study, the postsynaptic function was not assessed. However, it is likely that 
vasoconstriction may be also enhanced. This is also supported by the fact that we 
observed inward remodelling and it has been suggested that this may be induced by 
sustained vasoconstriction [288-290] or reduced blood flow [30, 291]. Altogether, the 
observed alterations in RAS and SNS can contribute to the development of hypertension 













The present data reveal for the first time the presence of RAS receptors not only in 
sympathetic nerves but also in other adventitia cells. Some of these cells seem to be 
Schwann cells. This possibility was confirmed by data showing that AT1 receptors were 
present in GFAP positive cells, a marker for glial cells such as Schwann cells. In fact, the 
presence in Schwann cells of other receptors or enzymes with a role on NA 
neurotransmission was previously demonstrated by our group [26, 223], supporting a 
trophic role of these cells and of its close association with neurons. These data suggest 
that Ang II may be exerting trophic actions through AT1 receptors, contributing to the 
hypertrophy of sympathetic innervation, observed in MUN rats.  In addition to the 
location of these receptors on Schwann cells, confocal images also show that these 
receptors are present in other adventitia cells, possibly macrophages, mesenchymal 
cells or fibroblasts. Activation of fibroblasts may be responsible for proliferation and the 
increased collagen deposition in MUN mesenteric arteries. Indeed, the adventitia has 
been identified as an important source of ROS that may function as paracrine molecules 
modulating neighbouring cells and, thus, contributing to vasoconstriction and vascular 
remodelling [23]. Adventitial fibroblasts have been shown to produce substantial 
amounts of NADPH oxidase-derived ROS in response to vascular injury or vasoactive 
substances, and play an active role in collagen deposition and vascular remodelling 
[292]. Among them, Ang II is recognized as one of the key humoral factor implicated in 
NADPH oxidase activation in the vascular wall [90, 293, 294]. The present data also 
support this mechanism in MUN rat mesenteric arteries by showing a higher 
immunoreactivity to p22-phox, the stabilizing subunit of NADPH oxidase, which is the 
main enzymatic system responsible for superoxide anion in the vasculature [85, 293].  
An increased level of ROS, if not counteracted by enough antioxidants, may led to 
oxidative damage. In fact, in the MUN model of FPH, our group has previously 
demonstrated that at the age of 6 months MUN rats exhibit lower levels of plasmatic 
antioxidants [204]. Higher expression of NADPH oxidase and Xanthine oxidase have also 
been reported in the heart of these animals [220]. The presence of higher  NADPH 
oxidase  in the vasculature of this model of FPH adds evidence of the importance of 
oxidative stress in FPH [168]. An increased ROS production in the vascular wall, can 













described, and also by promoting endothelial dysfunction. In this regard, previous data 
suggested that superoxide anion release from the adventitia might reduce endothelial 
NO bioavailability [27, 295], which would also enhance vasoconstriction and increase 
resistance. Besides, excess ROS may be also implicated in the observed increase in 
sympathetic neurotransmission in MUN mesenteric arteries. Interestingly, it has been 
demonstrated that an increased ROS is a primary mechanism whereby Ang II causes an 
increased SNS activity, in a complex mechanism involving the contribution of the 
adaptive immune response [296].  
Taking together, the present data indicate that increased Ang II/AT1 receptor axis in the 
adventitia may be implicated in the development of vascular remodelling, fibrosis and 
enhanced sympathetic neurotransmission in MUN rats, being ROS possible mediators. 
Ang II is a hydrophilic substance and has been mainly regarded as a humoral factor with 
activity on membrane receptors. However, the present work demonstrated, by confocal 
microscopy, the presence of nuclear location of RAS receptors.  The presence of RAS 
receptors in cellular nucleus has been previously described in the literature. Robertson 
and Khairallah reported  over 40 years ago the localization of Ang II binding sites on the 
chromatin fraction of VSMC and cardiomyocytes suggesting an intracellular site of action 
for Ang II [297]. Several studies subsequently identified Ang II receptors using classical 
receptor binding techniques on nuclei isolated. In rat models it was reported the 
existence of nuclear AT1 and AT2 receptors in the kidney, liver and brain [298]. A nuclear 
localization of Mas receptor was also find in VSMC from the kidneys of young adult 
sheep [299]. The present study, demonstrating nuclear RAS receptors clearly support an 
emerging view for the localization of various GPRCs to the nucleus [298, 300, 301]. 
Further studies are needed to clarify the impact of nuclear GPCRs in pathological 


































The present work points out the tunica adventitia has an important layer in the 
development of FPH. The physiologic function of the adventitia was believed to be 
limited to providing structural support to the blood vessel wall, transporting oxygen and 
nutrients to the adventitia and outer media of large vessels, and maintaining 
sympathetic innervation of the vessel wall. These were generally considered 
physiological static functions and were not believed to play a dynamic role in vascular 
development and vascular injury and repair [24]. However, the tunica adventitia is the 
most complex layer of the vessel wall and is comprised of a variety of cells including 
fibroblasts, immunomodulatory cells (dendritic and macrophages), progenitor cells, 
Fetal undernutrition involves a tonic facilitation mediated by Ang 
II, trough AT1 receptors, leading to an increased vascular 
sympathetic activity. 
 
Fetal undernutrition may enhance the production of Ang II and 
Ang 1‐7 in the mesenteric artery inducing ACE and ACE2 
expression. 
 
 Fetal undernutrition also alters the expression of RAS receptors, 
favouring the vasoconstrictor, inflammatory, fibrotic and 
oxidative role of Ang II in AT1 receptors, thus contributing to an 
elevation of BP. 
 
The presence of nuclear RAS receptors clearly support an 
emerging view for the localization and signaling pathways of 
GPCRs in the nucleus. 
 
Fetal undernutrition is associated with an oxidative damage in 
the adventitia of mesenteric artery possible through an increase 
in ROS production together with a decreased antioxidant 
capacity. ROS production through Ang II actions may participate 














vasa vasorum, endothelial cells, adrenergic nerves and perivascular adipose tissue. As a 
result, this layer plays important roles in the vascular development and remodelling. In 
response to vascular stress or injury, adventitial cells are often the first to be activated 
and re-programmed to then influence tone and structure of the vessel wall, to initiate 
and perpetuate chronic vascular inflammation, and to act to stimulate expansion of the 
vasa vasorum, which can act as a conduit for continued inflammatory and progenitor 
cell delivery to the vessel wall [23]. Under conditions of elevated BP, the adventitia 
becomes the predominant wall component due to the profound influence on intima and 
media function in disease [22, 23]. As so, our work corroborates others suggesting that 
the adventitia exerts a modulatory role on vascular function [27]. Thus, a comprehensive 
investigation of the constituents of the adventitia, both in normal physiology and in 
disease, is needed to understand how they interact and cross-talk to promote and inhibit 
vascular disease [24]. 
In summary, this study supports the existence of vascular remodelling in MUN 
mesenteric arteries that contribute to increased vascular resistance and subsequent 
increase in BP. Our data also supports the occurrence of a sympathetic hyperactivation, 
involving a tonic facilitation, by endogenous Ang II, through presynaptic AT1 receptors. 
Moreover, the alterations in the expression of vascular RAS receptors and enzymes 
demonstrated in this work can justify, at least in part, the occurrence of hypertension in 
these animals. In particular, for the first time in an adult murine model, it is 
demonstrated that an increased vascular sympathetic activity secondary to an 
inappropriate RAS activation, may play an important role on hypertension development 
subsequent to fetal undernutrition (Figure 57). Future studies will establish the role of 
















































i. Fetal undernutrition leads to high BP in adult males rats without alterations in HR. 
ii. Hypertension induced by fetal undernutrition is milder compared to the essential 
hypertension model SHR, possibly related to the absence of tachycardia.   
iii. Fetal undernutrition induces inward hypertrophic remodelling in the mesenteric 
artery, with the contribution of both the media and the adventitia layers, and the 
presence of vascular fibrosis.  
iv. Hypertension programmed by fetal undernutrition and essential hypertension share 
similar characteristics of vascular remodelling in the mesenteric artery.   
v. Fetal undernutrition is associated with hypertrophy of the sympathetic innervation 
in the mesenteric artery and enhanced sympathetic neurotransmission in several 
vascular beds. 
vi. FPH and essential hypertension exhibit similar alterations in vascular sympathetic 
neurotransmission.   
vii. Increased vascular SNA in rats exposed to fetal undernutrition may be, at least in part, 
mediated by tonic facilitation by Ang II, trough AT1 receptors.  
viii. Local Ang II and Ang 1-7 production in the mesenteric artery may be enhanced in rats 
exposed to fetal undernutrition, show by the higher ACE and ACE2 expression.  
ix. Fetal undernutrition is associated with RAS receptors disbalance, with a higher AT1 
and lower AT2, Mas and MrgD receptors, favouring the vasoconstrictor, 
inflammatory, fibrotic and oxidative role of Ang II. 
x. FPH is associated with increased NADPH oxidase on adventitial cells, possibly related 
to Ang II through AT1 receptors on these cells.  
xi. Adventitial ROS production through Ang II actions may participate in vascular 
hypertrophy and fibrosis observed in rats exposed to fetal undernutrition.  
General conclusion: In rats exposed to fetal undernutrition increased vascular 
sympathetic neurotransmission contributes to hypertension development, through 
enhanced NA spill-over and vascular remodelling, alterations in common with essential 
hypertension. In fetal programming, enhanced sympathetic activity is caused, at least in 















i. La desnutrición fetal conduce a hipertensión en ratas macho adultas sin alteraciones 
en la frecuencia cardíaca. 
ii. La hipertensión inducida por la desnutrición fetal es más leve en comparación con el 
modelo de hipertensión esencial, rata SHR, posiblemente relacionado con la ausencia 
de taquicardia en el modelo de programación fetal. 
iii. La desnutrición fetal induce remodelado hipertrófico de tipo “inward” en la arteria 
mesentérica, con la contribución de las capas de media y adventicia, y la presencia 
de fibrosis vascular. 
iv. La hipertensión programada por la desnutrición fetal y la hipertensión esencial 
comparten características similares de remodelado vascular en la arteria 
mesentérica. 
v. La desnutrición fetal se asocia con hipertrofia de la inervación simpática en la arteria 
mesentérica y neurotransmisión simpática elevada en varios lechos vasculares. 
vi. La hipertensión programada por la desnutrición fetal y la hipertensión esencial 
muestran alteraciones similares en la neurotransmisión simpática vascular. 
vii. El aumento de la actividad simpática vascular en ratas expuestas a la desnutrición 
fetal puede estar, al menos en parte, mediado por la facilitación tónica por Ang II, a 
través de los receptores AT1. 
viii. En ratas expuestas a desnutrición fetal la producción local  vascular de Ang II y Ang 1-
7 puede estar aumentada en la arteria mesentérica, como sugiere la mayor expresión 
de ACE1 y ACE2. 
ix. La desnutrición fetal se asocia con el desequilibrio de los receptores del SRA, con 
mayor expresión de AT1  y menor de AT2, Mas y MrgD, lo que favorece la actividad 
vasoconstrictora, inflamatoria, fibrótica y oxidativa de la Ang II. 
x. La hipertensión programada por la desnutrición fetal está asociada con un aumento 
de la NADPH oxidasa en las células de la adventicia, posiblemente mediada por Ang 
II a través de receptores AT1 localizados en estas células. 
xi. En ratas expuestas a desnutrición fetal, el aumento en la producción de ROS en la 
adventicia puede participar en el desarrollo de hipertrofia y fibrosis vascular, a través 














Conclusión general: en las ratas expuestas a la desnutrición fetal, el aumento de la 
neurotransmisión simpática vascular contribuye al desarrollo de la hipertensión, a 
través del aumento de la liberación de noradrenalina y el remodelado vascular, 
alteraciones en común con las observadas en el modelo de hipertensión esencial. En la 
programación fetal, la actividad simpática aumentada es causada, al menos en parte, 
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The interaction between sympathetic nervous system and G-protein coupled receptors 
is a key factor to discover new pharmacologic interventions to prevent/treat fetal 
programming of hypertension. 
ABSTRACT 
Cardiovascular diseases (CVDs) are the first cause of death owing to non-communicable 
diseases worldwide. In addition to the classical CVDs risk factors related to 
lifestyle/genetic background, exposure to adverse intrauterine environment 
compromises fetal development leading to low birth weight and increasing offspring 
susceptibility to develop CVDs later in life, particularly hypertension, a process known as 
fetal programming of hypertension (FPH). In FPH animal models, permanent alterations 
were detected in gene expression, in the structure and function of heart/blood vessels, 
compromising cardiovascular physiology and favoring hypertension development. This 
review focuses on the role of sympathetic nervous system and its interplay with G-protein 
coupled receptors, emphasizing strategies that envisage the prevention/treatment of 
FPH through interventions in early life.  
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Cardiovascular diseases (CVDs) are the main cause of mortality/morbidity due to non-
communicable diseases worldwide, and more than 75% of deaths occur in low/middle-
income countries [1]. Together with the already known CVDs risk factors related to 
lifestyle (sedentary, unhealthy diet, tobacco) and genetic background, it is well 
recognized the importance of fetal life [2-4]. The fetus can adapt to adverse intrauterine 
conditions, as malnutrition, oxygen deprivation, placental insufficiency, exposure to 
excess glucocorticoids (GC) or toxic substances, to ensure survival [5-7]. However, 
these conditions induce alterations in fetal development, which result, later in life, in an 
increased susceptibility to develop CVDs, a phenomenon named Developmental Origins 
of Health and Disease (DOHaD) or fetal programming. 
David Barker was the first to advocate the hypothesis that adaptive responses of the 
fetus to maternal undernutrition (MUN) resulted in low birth weight (LBW) and, in adult 
life, in the development of coronary heart disease and hypertension [2, 8]. Over the past 
years, several epidemiological studies in populations exposed to starvation/intrauterine 
stress have validated Barker´s hypothesis, demonstrating an association between LBW 
and increased blood pressure (BP) in adult life, a process known as fetal programming 
of hypertension (FPH) [6, 9-11].  
MUN seems to be the major cause of LBW in underdeveloped or developing countries, 
while in high-income societies LBW is mostly related with prematurity or obstetric 
complications associated with delayed pregnancy. For example, placental insufficiency, 
causing placental hypoxia and fetal oxygen delivery privation [12, 13], and pre-
eclampsia, are conditions related with the increased maternal age [14, 15], associate 
with offspring hypertension in adult life [15]. Excess fetal exposure to GC may also 
contribute to LBW [16], which is clinically relevant, since women with risk of preterm 
delivery are treated with CG to improve fetal pulmonary function and reduce mortality. 
Besides, maternal psychological stress may abnormally elevate cortisol levels [17]. 
Cortisol access to the fetus is limited to the placental barrier owing its conversion by 11-
β hydroxysteroid dehydrogenase 2 into cortisone. However, this enzyme can be reduced 
in adverse fetal conditions [18], favoring cortisol access to the fetus. Other stress factors, 
such as exposure to toxic substances (alcohol, tobacco) or environmental pollutants, can 
also affect fetal development, contributing to FPH [19-21].  
Despite the efforts carried out so far, the mechanisms underlying the predisposition to 
FPH are not completely understood. Nevertheless, increasing evidence has shown the 
implication of oxidative stress [22, 23], renin-angiotensin system (RAS) [24-26] and 
sympathetic nervous system (SNS) [27-29], as well as alterations in the GC axis [6, 30-
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32]. Some of these alterations seem to be mediated by epigenetic modulation of genes 
implicated in cardiovascular control [33-36]. Altoghether, these aspects may contribute 
to the FPH development (Figure 1). 
Experimental data gathered in animal studies have been very valuable to understand the 
relationship between adverse intrauterine environment and increased susceptibility to 
hypertension. Among others, the most common animal models mimicking the different 
fetal stress factors are maternal nutritional restriction during pregnancy or lactation 
(protein, global nutrients, vitamins, etc), exposure to hypoxia, placental insufficiency or 
treatment with GC [37, 38].  
In these animal studies, high BP is associated with changes in blood vessels 
(remodeling, stiffening and endothelial dysfunction), heart (cardiomyocyte hypertrophy 
or intramyocardial fibrosis), and kidneys (low nephron number, alterations in sodium 
handling, etc.) [6, 39-42]. These studies have also evidenced the important influence of 
sex in FPH. As so, male offspring from all the above-mentioned experimental models 
develop hypertension by adult age, while females remain normotensive or develop milder 
forms of hypertension [43]. This sexual dimorphism has been proposed to be related to 
the protective effects of estrogens on the cardiovascular system [44, 45]. In addition, the 
concept of sex of the placenta has also been put forward, and it has been suggested that 
the placenta nourishing female fetus could adapt better to adverse intrauterine 
environments, thus, contributing to the lower impact of FPH in females [46, 47]. Despite 
the fact that in animal models of FPH the role of sex has been well documented, in 
humans, this is not so evident. This discrepancy is likely related to differences in the age 
of the populations under study, and the confounding factor of menopause [44, 48].  
 
Sympathetic Nervous System and Fetal Programming of Hypertension 
SNS has an integral role in the regulation of heart rate and contractility, vascular tone 
and fluid volume. Excessive sympathetic nerve activity (SNA) has deleterious effects 
namely increased cardiac output, peripheral resistance, retention of salt and water, thus, 
contributing to the development and/or maintenance of hypertension [49-53]. In vessels, 
increased SNA is responsible for vascular remodeling related to smooth-muscle 
hypertrophy and fibrosis [54].  
Data from humans and experimental animal models of hypertension support the 
neurogenic hypothesis of hypertension, which considers SNA as the primary factor 
underlying the elevation of BP [55-58]. Although the main causes of increased SNA 
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remain undefined, alterations of reflexes and/or metabolic factors have been proposed 
as candidates [58]. 
In several animal models of FPH, altered SNS control is evident. In offspring of maternal 
low-protein-diet (MLPD) rats, hypertension was associated with increased 
cardiovascular sympathetic tone [59], while no baroreflex dysfunction was found [60]. 
Offspring from rats exposed to intermittent hypoxia at the end of pregnancy exhibit 
increased BP related to an altered sympatho-vagal balance [61]. Also, in MLPD rat 
offspring, increased SNA was reported in response to physical stress induced by 
activation of exercise pressor reflex [62], most probably due to an exaggerated increase 
in renal SNA [63]. Other FPH rat model (induced by hypoxia in utero), showed an 
increased muscle SNA and an hyper-sympathetic innervation in skeletal muscle arteries 
[28].  
Another alteration corroborating an abnormal SNS control in FPH rats is the elevation of 
catecholamines in the cardiovascular system, due to increased release or biosynthesis. 
In FPH rats induced by placental insufficiency or MLPD, circulating catecholamines were 
raised both in the fetus and in adult offspring, possibly because of increased SNA [29, 
64, 65]. In this sense, an increased electrically-evoked noradrenaline output has been 
reported in mesenteric arteries from MUN rat offspring [66]. Besides, there is evidence 
of elevated catecholamine biosynthesis due to increased expression of adrenal 
phenylethanolamine N-methyltransferase (PNMT), in dexamethasone exposure during 
gestation rat offspring [67]. Elevated PNMT mRNA expression was also detected in 
spontaneously hypertensive rat (SHR) brain [68]. 
In addition to alterations at the peripheral level, data also indicates changes in central 
SNA. An elevated basal and stimulated dopamine output has been described in rat 
offspring exposed to prenatal stress [69]. Significant SNA alterations were also found in 
nucleus tractus solitarius [62], hippocampus and hypothalamic paraventricular nucleus 
from MUN rat offspring, with a marked activation of hypothalamo-pituitary adrenal axis 
[30]. Changes in central SNA could be related to alterations in redox balance. Oxidative 
stress is known to contribute to FPH, though many mechanisms (for details, see review 
[23]), but the relevance of SNA in redox status and vice versa has been recently 
highlighted. For example, in SHR, oxidative stress contribute to an increased SNA [70], 
and MUN rat offspring exhibit changes in brainstem redox status accompanied by an 
increase in SNA [71].  
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Excess cortisol levels may also contribute to FPH through the SNS. For example, in 
sheep fetuses, it has been shown that adrenal GC contribute to cardiovascular regulation 
by modulation of SNA and arterial baroreflex [72]. 
In LBW humans, there is also evidence of altered SNA [73, 74]. Children with LBW, due 
to prematurity or small for gestational age, excrete high catecholamines levels [75], 
which has been associated with longer periods of tachycardia during stress exposure 
[76]. LBW is also associated with exaggerated BP responses to psychological stressors, 
related to alterations in baroreflex control [77], and greater SNA response [76]. Young 
men and women born with LBW also exhibit raised muscle SNA [73] and exaggerated 
sympathetic discharge in response to muscle metaboreflex [78]. Abnormalities in heart 
rate and baroreflexes are also observed in premature infants, related to the immaturity 
of their autonomic nervous system [79], which may contribute to increased 
cardiovascular risk in this population [80].  
Taken together, data are consistent with a pathophysiological role of the SNS in FPH, 
with evidence indicating the occurrence of an increased SNA.   
 
G-Protein-Coupled Receptors and FPH 
G Protein-Coupled Receptors (GPCRs) are a large family of seven-transmembrane 
domain proteins activated by several peptides or proteins, such as neurotransmitters and 
hormones [81]. GPCRs trigger intracellular signal transduction pathways and influence 
several physiological functions, including cardiovascular control [82]. Indeed, some 
GPCRs are involved in the modulation and regulation of vasodilator and vasoconstrictor 
responses, thus, influencing vascular responsiveness and BP control.  
Dysregulation of GPCRs-mediated mechanisms during fetal life may be implicated in 
FPH. Among possible mechanisms, we can include changes in the receptor itself, or in 
the intracellular mechanisms or even in the concentration of receptor ligands. All these 
changes can lead to an up or down regulation of GPCRs, which may modify endocrine 
and nervous responses involved in BP control.  
Below we discuss evidence of alterations of key GPCRs, namely adrenoceptors, 





Noradrenaline released from sympathetic nerves can activate  or adrenoceptors 
modulating postsynaptic nerve or vascular responses with both types described as being 
involved in FPH. Indeed, studies in rats provide evidence of the implication of 
adrenoceptors localized in central SNS in FPH: the natriuretic effect induced by central 
noradrenaline injection was abolished by α1-adrenoceptor antagonist (prazosin) in MLPD 
rat offspring [83]; administration of α2-adrenoceptor antagonist (yohimbine) normalized 
urinary sodium excretion and reduced BP in FPH offspring [83]. Conversely, -
adrenoceptors may also contribute to FPH: in 2-week-old MUN rat offspring, the 
myocardial mRNA expression of 2-adrenoceptors was increased, which might explain 
the increased susceptibility to ischemia-reperfusion injury [84]. 
In humans, recently, the involvement of adrenoceptors in FPH has been suggested since 
α-adrenoceptors blockade attenuated the development of hypertension in preeclampsia 
[85].  
Taken together, information is in agreement with a relevant role of adrenoceptors in FPH.  
 
Angiotensin Receptors  
Contribution of angiotensin receptors (ATR) to FPH has been demonstrated in animals 
exposed to nutritional insults such as low-protein, high-fat or sugar diets [86-88], toxics, 
such as nicotine [89, 90], or to CG [91]. 
Accumulating evidence in rats indicates that AT1R and AT2R expression is altered in 
response to several fetal stressors. An upregulation of AT1R expression was found in 
the kidneys [24] and mesenteric vasculature [66] from MUN rat offspring and in the brain 
of adult rats exposed to MLPD [92] or to nicotine [90] during fetal development. Similarly, 
increased pulmonary AT1R expression was found in lungs of mice exposed to hypoxia 
[93] and in the kidney of near-term ovine fetuses exposed to high altitude [94]. Regarding 
AT2R expression, a downregulation was shown in the kidney of offspring of MUN, MLPD 
[26, 95], hypoxia [94] and fetal exposure to GC [96]. 
Epigenetic and gene expression changes are responsible for many alterations in FPH 
[36], some of them associated with RAS. MLPD led to an increased AT1R gene 
expression and subsequent upregulation of AT1R in adrenal glands from adult rat 
offspring, ultimately contributing to the development of hypertension [35]. Maternal GC 
in early pregnancy may induce changes in methylation and expression of the AT1R gene. 
In addition, in prenatal high sucrose exposure aged offspring, mRNA and protein 
expressions of AT1R gene were significantly increased in large/small blood vessels, 
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which should be closely associated with the changes of epigenetic mechanisms such as 
histone modifications [97]. In brain MLPD mice offspring, an upregulation of mRNA 
expression of angiotensinogen and angiotensin-converting enzyme (ACE) and a 
downregulation of mRNA levels of AT2R were reported [98]. 
ACE is other RAS player modified in FPH. Both pulmonary and plasma ACE activities 
seem to be increased in MUN adult rat offspring [99].  
In experimental FPH, hypertension was controlled after treatment with ACE inhibitors or 
ATR antagonists [25, 99, 101] similarly to what occur in essential hypertension.  
The above studies evidence the role of the classical ACE-Angiotensin II (Ang II)-
AT1R/AT2R axis in FPH. Recently, the non-classical ACE2-Ang-(1–7)-Mas receptor axis 
was also suggested to be implicated [102], as shown by the altered Ang-(1–7) system 
within the brain and in the kidney in rats exposed GC in fetal life, proving their contribution 
to cardiovascular dysfunction.  
In humans exposed to adverse intrauterine conditions, information is still scarce 
regarding ATRs or other RAS players. Nevertheless, children born from preeclamptic 
pregnancies have increased circulating levels of aldosterone [103]. Also, boys with LBW 
exhibited a significant increase in ACE activity and circulating Ang II, which were 
associated with increased systolic BP [104]. However, this association was not found in 
girls, supporting the existence of sex differences in FPH also in humans. Indeed, RAS 
alterations associated with FPH seem to be age and sex-specific [37, 91]. 
Overall, experimental data are consistent and support the idea that RAS might be a 
common mechanism that underlies hypertension of developmental origins. 
 
Adenosine Receptors 
Considerable evidence supports the involvement of adenosine and its receptors (A1R, 
A2AR, A2BR and A3R) in hypertension [105, 106]. Adenosine is a key signalling molecule 
that coordinate a rapid multi-cellular physiological response to hypoxia or tissue damage. 
Indeed, chronic systemic hypoxia in utero affects cardiovascular responses in adult rat 
offspring through an A1R-mediated mechanism [107]. These rats have functional A1R in 
the heart and vasculature but show attenuated adenosine release and endothelium-
dependent vasodilation [107]. 
In humans, adenosine is determinant in pregnancy diseases associated with altered 
umbilical blood flow, namely preeclampsia [108, 109]. Alterations in enzymes involved in 
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adenosine bioavailability, such as increased placental 5’-nucleotidase and reduced 
placental adenosine deaminase, favour high placental adenosine levels, which coupled 
with an enhanced A2BR receptor signalling, may contribute to preeclampsia 
pathogenesis [110]. Furthermore, in women with preeclampsia, it has been proposed 
that reduced angiogenesis mediated by adenosine might be associated with the 
development of hypertension in the offspring [111]. 




Endothelin 1 (ET-1), mainly released from endothelium, is a peptide that can activate 
endothelin receptors type A (ETAR) and type B (ETBR). These receptors exert opposite 
cardiac and vascular effects: ETAR mediates vasoconstriction while ETBR mediates 
vasodilation [112]. In the context of FPH, few works establish a role for ET-1 and/or its 
receptors. 
Hypoxia [114] and MUN [39] rat offspring present an enhanced vasoconstriction to ET-
1. In rat offspring exposed to fetal hypoxia, treatment with tezosentan, an ETA/BR 
antagonist, caused a significant reduction in BP [114]. The selective ETAR antagonist 
ABT-627 reduced BP in FPH rats, accompanied by a disruption in ET-1 expression [115]. 
These studies encourage further clarification regarding the usefulness of endothelin 
receptors as targets to treat/prevent FPH. Despite of this, recent efforts on endothelin 
receptor antagonists envisage their putative use for the treatment of resistant 
hypertension  [116]. 
Nevertheless, more studies are required to completely understand the implication of 
GPCRs in the development and maintenance of hypertension of fetal origins. 
 
Interplay between the Sympathetic Nervous System and GPCRS in FPH 
SNA can be influenced by different GPCRs, since these receptors can modify 
noradrenaline bioavailability in the synapsis and/or interact with signaling cascades. 
Furthermore, altered SNA can also influence GPCRs activation by modifying their 
expression or conditioning its own signaling events. In FPH, increased SNA has been 
associated with hyper-sympathetic innervation and/or with alterations in specific GPCRs 
expression or function. These changes condition vascular responsiveness or renal 
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function and may contribute to increase BP (Figure 3). The association between FPH 
animal models and the experimental results related to SNS and GPCRs are depicted in 
Table 1.  
 
Interventions to counteract FPH 
Understanding the causative mechanisms of FPH opens new opportunities and 
challenges for prevention through early life interventions. Firstly, pharmacological 
treatments or lifestyle changes during pregnancy may help to reduce programming. 
Secondly, early interventions in the offspring during key developmental windows, such 
as lactation, may also help to reduce the impact of CVDs in the future generations. 
Pharmacological or nutritional interventions with antioxidants are a plausible strategy 
since oxidative stress is one of the underlying mechanisms in FPH, common to different 
fetal stressors, namely malnutrition [117], exposure to toxic substance [118, 119] or GC 
[120]. Studies in animal models have provided proof of the effectiveness of antioxidant 
treatments, in pregnancy, against FPH. In hypoxic pregnancies, treatment with vitamin 
C improved transplacental oxygenation [124]. In addition, melatonin and N-acetylcisteine 
administration during the entire pregnancy and lactation have demonstrated 
effectiveness against the development of hypertension in FPH rat model induced by NG-
nitro-L-arginine-methyl ester during gestation [125]. Resveratrol has also promising 
effects for the treatment of feto-placental flow alterations in preeclampsia, due to its anti-
inflammatory/antioxidant properties in vitro [126]. In MLPD rat offspring, resveratrol 
administration during pregnancy partially prevents oxidative stress and metabolic 
dysfunction [127]. In the same animal model, prenatal treatment with lazaroid, a lipid 
peroxidation inhibitor, abolished the increased Ang II-mediated contractile response and 
prevented the increase in BP [128]. Also, tempol avoid the BP increase in adult mice of 
FPH induced by GC exposure [129]. 
In humans, pregnancy alterations such as preeclampsia, which program the offspring, 
are also related to oxidative unbalance. In low and middle income-countries, 
micronutrient dietary deficiencies can contribute to fetal programming through oxidative 
stress [14]. In these settings, nutritional interventions with vitamins or minerals during 
pregnancy have been demonstrated to be an effective approach to reduce the risk of 
prematurity and LBW [121] and to improve offspring cardiometabolic health [122]. In 
high-income societies, the main problem are the obstetric complications that alter 
placental function leading to LBW and premature births (and subsequent need of GC 
treatment). We have previous evidenced the association between a low antioxidant 
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status in early pregnancy and the later development of obstetric complications [14]. 
Therefore, antioxidant treatment can be a useful strategy to reduce preeclampsia and 
other placental disorders once antioxidant deficiency in pregnancy increase oxidative 
damage and compromise feto-placental flow through NO inactivation by reactive oxygen 
species. In fact, several antioxidants, namely N-acetylcisteine, Vitamin C, or melatonin, 
as well as NO donors, like L-Arginine, have been used in women with pregnancy 
complications with variable results, but most of them have shown benefits and safety 
[123].  
The above mentioned data suggest that antioxidant therapy, either through nutritional or 
pharmacological interventions, may be a strategy to counteract or reduce FPH.  
A second possible developmental window to counteract the effects of FPH is the lactation 
period. In this regard, drugs used to treat hypertension have been studied in 
experimental animal FPH offspring concerning their putative usefulness to modulate the 
development of hypertension postnatally. Administration of nifedipine (calcium channel 
blocker) in FPH offspring with 4 to 12 weeks did not modify BP [101], discarding the use 
of this pharmacological group for this purpose. However, in MLPD rat offspring and in 
rats exposed to placenta insufficiency, with 2-4 weeks old, captopril and enalapril (ACE 
inhibitors) treatment (initiated after weaning), prevented the development of 
hypertension, with animals remaining normotensive at least for 12 weeks after treatment 
suppression [25, 99, 101, 130]. This is corroborated also in MUN rat offspring, since 
treatment with aliskiren, or losartan, an AT1R antagonist, administered between 2-4 
weeks of postnatal life, prevented the development of hypertension until 12-weeks old 
[131]. Treatment with AT1R antagonists such as losartan [101] or candesartan [132], 
were also effective in preventing the development of hypertension in MUN adult rat 
offspring. Candesartan not only lowered BP, but also protected against cardiac 
enlargement and coronary perivascular fibrosis [132]. However, this therapeutic strategy 
could only be implemented after birth, owing to the teratogenic effects ascribed to this 
group of drugs during pregnancy and their impact avoiding adequate nephrogenesis.  
After birth, vitamin C and E treatments reverse the increased vasoconstrictor responses 
in FPH rats [133], and allopurinol, a xanthine oxidase inhibitor, had analogous effects 
[134]. Coenzyme Q decreased oxidative stress and DNA damage in aorta from FPH 
offspring [135] and resveratrol improved insulin sensitivity, vascular function and 
prevented cardiac dysfunction and hypertrophy [136] [137]. Therefore, antioxidant 
therapy should be considered, per se, or in association with other drugs in FPH.  
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In humans, breast milk is an important source of antioxidants and other bioactive 
compounds, thus, breast-feeding may help to counteract the negative effects of oxidative 
stress in newborns, particularly in preterm infants, which exhibit deficiency of antioxidant 
systems, and are at higher risk of FPH [138]. 
Regarding pharmacological intervention, research is needed to analyze the reverting 
effect of treatments on FPH with drugs binding to GPCRs. Currently, several drugs are 
in the forefront to be used in FPH but no ongoing clinical trials are being performed, so 
far, with this particular purpose. 
Concluding remarks  
Data collected so far suggest that FPH is related with the exposure to stress factors 
during pregnancy and subsequent LBW, and will likely continue to contribute to the 
burden of CVDs in the next decades. In this context, determining the main mechanisms 
implicated is imperative, namely those related with sex differences. Thus, therapeutic 
approaches targetted properly to these sex differences may offer the best opportunity to 
mitigate the progression of cardiovascular disease in both women and men.  In addition, 
increasing evidence supports the implication of increased SNA eventually linked to some 
GPCRs, which modify the bioavailability of noradrenaline in the synapsis and/or interact 
with signaling cascades, ultimately, conditioning renal, cardiac and vascular responses.  
This knowledge will open the door to risk stratification for the development and definition 
of new preventive/therapeutic strategies. 
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Figure 1: The developmental programming of cardiovascular diseases hypothesis. 
(Figure made with graphic components obtained from the website 
https://smart.servier.com) 
Figure 2: Schematic representation of the involvement of adrenoceptors, angiotensin II, 
adenosine and endothelin receptors in FPH. (Figure made with graphic components 
obtained from the website https://smart.servier.com) 
Figure 3: Role of SNS and its interplay with GPCRs in FPH. (Figure made with graphic 
components obtained from the website https://smart.servier.com) 
 
Table 1: FPH-mediated mechanisms associated with respective GPCR and mediator 
levels dysregulation in experimental FPH models. 
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A B S T R A C T
Fetal stress increases the susceptibility to cardiovascular diseases in adult age, including hypertension, a process
known as fetal programming of hypertension (FPH). This study intends to investigate the interplay between
vascular sympathetic nervous system (SNS) and RAS, namely the neuromodulatory role exerted by Angiotensin
II (Ang II) receptor-1 (AT1) in FPH, and respective contribution for hypertension.
Methods: 6-month old Sprague-Dawley offspring from mothers fed ad-libitum (CONTROL) or with 50% intake
during the second half of gestation (maternal undernutrition, MUN) were used. Sympathetic neurotransmission
was studied in mesenteric/tail arteries and mesenteric veins by electrically-evoked [3H]-noradrenaline release
experiments using RAS drugs. AT1 receptors in sympathetic nerves of mesenteric arteries were investigated by
immunohistochemistry and Laser Scanning Confocal Microscopy.
Results: Ang II facilitated noradrenaline release in the vessels studied from MUN and CONTROL rats. Losartan
induced a tonic facilitation only in MUN vessels. Sympathetic innervation was larger in MUN versus CONTROL
vessels. AT1 receptors on sympathetic nerves were present in higher amounts in MUN versus CONTROL vessels.
Conclusions: Findings support that FPH is associated with a vascular hyper-sympathetic activation, involving a
tonic facilitation of prejunctional AT1 receptors by endogenous Ang II, which can justify, at least in part, the
development of hypertension.
1. Introduction
Along with genetic and lifestyle factors it is now established that
some stress factors during fetal life, particularly undernutrition, con-
tribute to the development, in adult age, of cardiovascular diseases,
particularly hypertension [1–8]. This is known as Fetal Programming of
Hypertension (FPH). In western countries, although the probability of
maternal malnutrition is low, fetal undernutrition may result from
placental insufficiency and intrauterine growth retardation, which are
increasing due to pregnancy delay.
Several mechanisms have been proposed to explain the relationship
between poor fetal growth and later hypertension development. One of
the proposed mechanisms is an alteration of the renin angiotensin
system (RAS). Thus, in infants with intrauterine growth retardation,
renin activity is elevated in umbilical cord and, in animal models of
FPH, the pressure response to angiotensin II (Ang II) is elevated
[6,9–13]. Indeed, Ang II play a crucial role in blood pressure regulation
through pleiotropic actions such as vasoconstriction and vascular/car-
diac hypertrophy [14]. These actions of Ang II are mediated via inter-
action with metabotropic cell membrane bound G-protein coupled re-
ceptors. Four types of RAS receptors are known (AT1, AT2, Mas and
MrgD), of which the AT1 and AT2 receptors are the most studied. These
two receptors share a similar high affinity to Ang II but the con-
sequences of their binding are opposite. AT1 receptor is highly ex-
pressed in adults and mediates Ang II-induced vasoconstriction [15],
proliferation [16], inflammation [17], and extracellular matrix re-
modeling [18]. On the other hand, AT2 receptor activation produces
opposite effects, providing a cardiovascular protective action [19].
Ang II-induced hypertension is associated with a decrease in cardiac
output and a marked increase in total peripheral resistance. Moreover,
Ang II has been described to cause increased sympathetic nervous ac-
tivity in rats consuming a high-salt diet [20]. However, the association
between Ang II and sympathetic dysfunction in FPH based on maternal
undernutrition is still to be addressed. We postulate that the effects
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mediated by Ang II are altered in FPH individuals leading to an in-
creased vascular sympathetic activity, and consequently, to an increase
in vascular responsiveness and hypertension. To check on this possi-
bility, the interplay between SNS and RAS was studied, namely the
vascular neuromodulatory role of AT1 receptor in FPH, using an animal
model of FPH. We also evaluated the regional distribution/localization
and relative amount of AT1 receptors and sympathetic nerves in FPH
mesenteric arteries.
2. Materials and methods
2.1. Animals
2.1.1. Animal ethical considerations
Sprague–Dawley (SD) rats from the colony maintained at the animal
house facility of the Universidad Autonoma de Madrid were used. All
experimental procedures were approved by the Ethics Review Board of
Universidad Autonoma de Madrid (CEI63–1112-A097) and conformed
to the Guidelines for the Care and Use of Laboratory Animals (National
Institutes of Health publication no. 85–23, revised in 1996), the Spanish
legislation (RD 1201/2005) and the Directive 2010/63/EU on the
protection of animals used for scientific purposes. The rats were housed
in buckets 36.5/21.5/18.5 cm (length/width/height) on aspen wood
bedding, under controlled conditions of 22 °C, 40% relative humidity
and 12/12 light/dark photoperiod. The animal health monitoring in-
dicated that they were free from pathogens that may interact with any
of the parameters studied. The rats were fed with breeding diet (SAFE
A03) containing 51.7% carbohydrates, 21.4% protein, 5.1% lipids,
3.9% fiber, 5.7% minerals and 12.2% humidity (Safe Augy, France).
Drinking water was provided ad libitum in all cases.
2.1.2. Experimental animal model of FPH
FPH model based on global maternal nutrient restriction was in-
duced as previously described [21]. The litters were divided in two
groups, one from mothers receiving ad libitum diet (CONTROL)
throughout pregnancy and the other group from mothers with ad li-
bitum diet during the first 10 days of gestation and 50% of the daily
intake from day 11 to the end of gestation (Maternal Undernutrition,
MUN). The maximum daily intake of rat chow was previously de-
termined in a group of pregnant rats as 24 g/day. Therefore, during the
second half of gestation, the second group received 12 g of rat chow per
day. After delivery the litters were culled to 12 rats and the respective
mothers received food ad libitum during the suckling period. 6month
old male offspring from MUN (n= 6) and CONTROL (n=6) were used.
The animals were euthanized using a guillotine, the method reported as
the sacrificial advisable in studies involving the nervous system. The
mesenteric and tail arteries and the mesenteric vein were collected and
immediately used. Four segments were obtained from each vessel for
different experimental procedures.
2.2. Chemicals
The following drugs were used: levo-[ring-2,5,6-3H]-noradrenaline,
specific activity 44.8 Ci/mmol (DuPont NEN, I.L.C., Lisboa, Portugal),
losartan (Merck Portuguesa, Lisbon, Portugal), angiotensin II (Sigma-
Aldrich, St. Louis, USA) and desipramine hydrochloride purchased from
Sigma-Aldrich (Sintra, Portugal). The following antibodies were used:
rabbit polyclonal anti-AT1 were purchased from Santa Cruz
Biotechnology, Inc., CA, USA and mouse monoclonal anti-tyrosine hy-
droxilase antibody (TH, ab129991,Abcam, UK) and mouse monoclonal
anti-glial fribrilary acidic protein (GFAP, G6171, Sigma-Aldrich, Inc.,
USA). The following fluorescent probes were used: Alexa Fluor 488 goat
anti-mouse IgG (H+ L) antibody, highly cross-adsorbed and Alexa
Fluor 647 goat anti-rabbit IgG (H+L) antibody, highly cross-adsorbed
(Molecular Probes) secondary fluorescent antibodies (Invitrogen, Life
Technologies, SA, Madrid, Spain); vectashield mounting medium with
DAPI (Vector Laboratories, UK). Stock solutions were made up in ul-
trapure water and diluted in superfusion medium immediately before
use.
2.3. Hemodynamic parameters measurement
Systolic blood pressure (SBP) was measured using the tail-cuff
method with a NIPREM 645 noninvasive blood pressure acquisition
system for rats (CIBERTEC, Madrid, Spain). The experiments were
conducted in a quiet area at 22 ± 2 °C. Firstly, the rats were placed in a
chamber at 37 °C for 10–15min to induce vasodilatation. Thereafter,
they were placed inside a soft support in the darkness to prevent ex-
cessive movement. A pulse sensor and a pressure cuff were place around
the tail for SBP recordings. Sessions of recorded measurements were all
made by a single investigator. The cuff was inflated to 150mmHg and
15 to 25 pressure inflate-deflate cycles were performed and data were
automatically registered. The first 5 cycles were considered “acclima-
tization” cycles and were not used in the analysis. This procedure was
obtained during 3 consecutive days for the rats to become accustomed.
The measurements recorded on days 2 and 3 were similar and averaged
for statistical analysis.
2.4. [3H]-Noradrenaline release experiments
[3H]-noradrenaline release experiments were carried out as pre-
viously described [27–29]. Vessels were preincubated in 2mL Krebs-
Henseleit solution (KHS) containing 0.1 μmol/L [3H]-noradrenaline (for
60min at 37 °C) and transferred into superfusion chambers, superfused
with [3H]-noradrenaline-free KHS (1mL/min; constant rate) with de-
sipramine 400 nmol/L to inhibit noradrenaline's neuronal uptake. After
30min of stabilization, two periods of electrical stimulation (5 Hz, 100
pulses, 1 ms, 50mA; Hugo Sachs Elektronik, March-Hugstetten, Ger-
many) were applied, S1 and S2, with 30min intervals (t=90min and
t=120min, respectively). The superfusate was collected each 5min
period from 85min of superfusion onwards.
To address the implication of presynaptic AT1 receptors, the agonist
for AT1 receptors, Ang II (30 nmol/L), and the antagonist, losartan
(100 nmol/L), were used: Ang II was added 5min before S2 and was
present until the end of the stimulation period; losartan was added
immediately after S1 and kept until the end of the experiment.
At the end of the experiments (t=130min), the tritium was mea-
sured in the collected superfusate samples and in the vessels (previously
solubilized: sonicated 1 h with 2.5 mL, 0.2mol/L perchloric acid). For
this, 6 mL of a scintillation mixture (OptiPhase ‘Hisafe’ 3, PerkinElmer,
I.L.C., Lisboa, Portugal) was added to each sample and analyzed by
liquid scintillation spectrometry (LS 6500, Beckman Instruments,
Fullerton, USA).
2.4.1. Measurement of drug effects on electrically-evoked tritium overflow
Tissue labelling with [3H]-noradrenaline and evaluation of elec-
trically-evoked tritium overflow changes was performed as previously
described [22,23]. Effects of drugs added after S1 on electrically-evoked
tritium overflow were evaluated as ratios of the overflow elicited by S2
and the overflow elicited by S1 (S2/S1). S2/S1 ratios obtained in in-
dividual experiments in which a drug was added after S1 were calcu-
lated as a percentage of the respective mean ratio in the appropriate
control group (solvent instead of the respective drug).
2.5. Laser scanning confocal microscopy (LSCM) experiments
Immunohistochemistry procedures were previously described [26].
Briefly, the artery was immediately placed in cold phosphate buffer
solution (PBS; in g/L): NaCl 8.0, Na2HPO4.2H2O 0.77, KCl 0.20,
KH2PO4 0.19 (pH 7.2), and was cut in 4 segments. Each artery segment
was longitudinally opened and fixed (paraformaldehyde 4% PBS;
50min; room temperature). After two 15min PBS washing cycles,
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artery segments were incubated with primary antibodies raised against
rabbit polyclonal angiotensin receptor subtype anti-AT1 (AT1, 1:100
dilution, overnight, 4 °C) and mouse monoclonal anti-tyrosine hydro-
xylase (TH, 1:100 dilution, overnight, 4 °C) to stain noradrenergic nerve
terminals or mouse monoclonal anti-glial fibrillary acidic protein
(GFAP, 1:200 dilution, overnight, 4 °C) to stain glial cells such as
Schwann cells. Thereafter, tissues were incubated with Alexa 647 anti-
rabbit and Alexa 488 anti-mouse fluorescent secondary antibodies
(1:1000 dilution, 1 h, room temperature). Negative controls were in-
cubated on adjacent sections using 10% normal horse serum or
blocking solution instead of the primary antibody. After two PBS
washing cycles, tissue preparations were mounted with antifading
agent (vectashield mounting medium with DAPI, Vector Laboratories,
UK), with the adventitial side facing up. Preparations were visualized
with a Leica SP5 LSCM system (Leica Microsystems, Wetzlar, Germany)
fitted with an inverted microscope (× 63 oil immersion lens). Stacks of
1-μm-thick serial optical images were captured from the entire ad-
ventitial layer, which was identified by the shape and orientation of the
nuclei stained with DAPI [30].
From each preparation, three stacks of images were sequentially
obtained from the same region, the first with the Ex 405 nm and Em
412–470 nm wavelength to visualize cell nuclei. The second was taken
with the Ex 488 nm and Em 490–570 nm wavelength to visualize the
TH or GFAP staining (location of noradrenergic terminals or glial cells)
and the third with the Ex 633 nm and Em 640–720 nm wavelength, to
detect the AT1 receptor distribution stained with the secondary anti-
body Alexa Fluor 647 (different subtypes depending on primary anti-
body). Image acquisition was performed always under the same laser
power, brightness, and contrast conditions. Adventitia was scanned
along each mesenteric artery segment and the resulting images were
reconstructed separately for each wavelength.
2.5.1. Specificity of primary antibodies
The specificity of the primary AT1 antibody used has been estab-
lished in previous studies: AT1 sc-31,181 [24,25]. In addition, pre-ad-
sorption with the corresponding synthetic peptide antigen was carried
out in our experimental conditions for all the primary antibodies used.
Western-blot was also performed using arteries extracts as protein
source to immunoblot with antibodies and/or with peptides.
2.5.2. Laser scanning confocal microscopy images quantification
Quantitative analysis of confocal z-stacks images was performed
using image analysis software (PAQI, CEMUP, Porto, Portugal), as
previously described [22,26]. Briefly, a sequential routine was designed
and developed to analyze each fluorescent signal used. PAQI software
measured the surface area and strength of the fluorescence signal
marking the postganglionic nerves, the surface area and strength of the
fluorescence signal marking the receptors and determined the surface
area of attachment of the receptors on the nerves as well as the intensity
of fluorescence of the receptors on nerves (corrected for background).
2.6. Data analysis
Results are expressed as mean ± s.e.m. and n denotes the number
of animals used. Quantitative analysis of confocal images is presented
as staining fractional area, expressed as a percentage of the tissue total
area. Differences of means were compared for significance using one- or
two-way ANOVA, followed by post-hoc Holm-Sidak's multicomparison
t-test or Student's t-test. A P value lower than 0.05 was considered to
denote statistically significant differences.
3. Results
3.1. Blood pressure measurements
Blood pressure was evaluated in MUN and CONTROL animals: a
significantly larger SBP values were observed in MUN
(164.40 ± 3.61mmHg; n= 6) comparatively to values from
CONTROL animals (134.13 ± 3.35mmHg, respectively; n= 6;
p= .003).
3.2. Noradrenaline release from sympathetic nerve terminals
Electrically-evoked tritium overflow from tissue preparations in-
cubated with [3H]-noradrenaline has been shown to reflect action po-
tential-evoked neuronal noradrenaline release and drug-induced
Fig. 1. Representative examples of time course tritium outflow from: mesen-
teric artery, mesenteric vein and tail artery from CONTROL (circles) and MUN
(triangles) from typical experiments. After pre-incubation with [3H]-nora-
drenaline, tissues were superfused with [3H]-noradrenaline free medium con-
taining desipramine (400 nM). Tritium outflow (ordinates) is expressed as a
percentage of the total radioactivity present in the tissue at the beginning of the
collection period and was measured in samples collected every 5min. Artery
segments were stimulated twice by 100 pulses/5 Hz, (S1, S2). Each line re-
presents the outflow of tritium from a single superfusion chamber.
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changes in evoked tritium overflow can be assumed to reflect changes
in neuronal noradrenaline release, as observed in previous studies
[22,26,27].
Electrical field stimulation (100 pulses/5 Hz) significantly increased
tritium outflow from all vessels studied of both CONTROL and MUN
rats (Fig. 1). The fractional rate of basal tritium outflow (b1), elec-
trically-evoked tritium overflow (S1) of mesenteric arteries and veins
and of tail arteries are shown in Table 1. Basal outflow and electrically-
evoked tritium overflow remained constant throughout the CONTROL
experiments, with bn/b1 and Sn/S1 values close to unity. Electrically-
evoked tritium overflow (S1) was higher in MUN compared to CON-
TROL vessels (Table 1).
Tissue preparations of mesenteric and caudal arteries and mesen-
teric vein were pre-incubated with [3H]-noradrenaline for 40min. After
pre-incubation with [3H]-noradrenaline, tissues were superfused with
[3H]-noradrenaline free medium containing desipramine (400 nM).
Tissues were stimulated twice at 30-min intervals (S1-S2; 100 pulses,
5 Hz, 1ms, 50mA): b1 refers to the 5-min period immediately before S1.
The electrically-evoked tritium overflow was calculated by subtracting
the estimated basal outflow from total outflow observed during and in
the 25-min period subsequent to S1 and expressed as a percentage of the
tissue tritium content at the onset of stimulation. Values presented are
means± SEM and n denotes the number of tissue preparations.
Significant differences of S1 values from SD-C vessels: *P < 0.05.
3.3. Role of Ang II in vascular sympathetic neurotransmission
Ang II (30 nmol/L; a non-selective agonist of angiotensin receptors)
facilitated electrically-evoked tritium overflow in all the vessels studied
from both experimental groups, as shown by the ratio (S2/S1) in the
absence of the drug. No statistical differences were observed between
different vessels or between different experimental groups (Fig. 2), in-
dicating that exogenous activation of angiotensin receptors is equiva-
lent in arteries and veins and was not modified by maternal under-
nutrition.
Endogenous Ang II-mediated effects in vascular sympathetic neu-
rotransmission were evaluated by blocking the AT1 receptor with a
selective antagonist. In the presence of the AT1 receptor antagonist
losartan (100 nmol/L), an inhibition of electrically-evoked tritium
overflow was observed in all the MUN vessels studied (Fig. 2). Losartan
was unable to modify tritium overflow in vessels from CONTROL rats.
This finding is consistent with the occurrence of a tonic facilitation
mediated by endogenous Ang II via AT1 receptor activation in MUN
rats.
3.4. Localization of AT1 receptors adventitia mesenteric arteries
Adventitial layer of mesenteric arteries was identified from LSCM
Table 1
Basal tritium outflow (b1), electrically evoked tritium overflow (S1) and S2/S1
ratios from SD-C and SD-MUN vessels.
Basal outflow (b1) Evoked overflow (S1) S2/S1 n
(fractional rate of
outflow; min−1)
(% of tissue tritium
content)
Mesenteric artery
SD-C 0.097 ± 0.009 0.221 ± 0.039 1.085 ± 0.091 7
SD-MUN 0.093 ± 0.007 0.348 ± 0.029* 1.076 ± 0.009 5
Mesentery vein
SD-C 0.088 ± 0.006 0.265 ± 0.021 0.992 ± 0.057 7
SD-MUN 0.073 ± 0.006 0.381 ± 0.032* 1.078 ± 0.068 5
Tail artery
SD-C 0.072 ± 0.007 0.163 ± 0.045 1.001 ± 0.098 7
SD-MUN 0.082 ± 0.009 0.268 ± 0.003* 1.086 ± 0.089 5
Fig. 2. Effects of Ang II (30 nM) or of losartan (100 nM) on the electrically-
evoked tritium overflow from CONTROL and MUN vessels. Ang II was added
10min before S2 and was present until the end of the stimulation period.
Losartan was added immediately after S1 and kept until the end of the ex-
periment. Ordinates: S2/S1 values obtained in individual tissue preparations,
expressed as a percentage of the appropriate S2/S1 CONTROL value. Values are
mean ± s.e.m. from 5 to 16 tissue preparations. Significant differences from
the appropriate CONTROL: ∗P <0.05; from the CONTROL vessels: #P < 0.05.
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images by the shape and orientation of the nuclei [28]. No significant
immunoreactivity was observed when the primary antibodies were
omitted (negative controls; Supplementary material). Immunoreactivity
for the sympathetic neuronal marker TH was evident in mesenteric
arteries from both experimental groups (Fig. 3, green images). MUN
vessels exhibited a larger immunoreactivity compared to CONTROL
arteries.
LSCM also revealed the presence of AT1 immunoreactivity in both
CONTROL and MUN mesenteric arteries (Fig. 3, red images). Quanti-
tative analysis evidenced that the relative amount of AT1 im-
munoreactivity present in MUN arteries was much higher (up to 80%
higher) than that exhibited by CONTROL vessels (Fig. 4A). These results
together with functional data (Fig. 2) reveal and support differences in
the sympathetic dynamic induced by AT1 receptors in MUN animals. It
is relevant to notice the absence of a pattern compatible with a co-
localization of TH with AT1 receptors immunoreactivities. This is in
line with previous reports using this sympathetic neuronal marker and
other membrane receptors [22,23] and, it is explained by the fact that
AT1 receptors is present at the cytoplasmatic membrane while the en-
zyme tyrosine hydroxylase is storage inside vesicles in the sympathetic
axoplasm [29]. Immunoreactivity for AT1 receptors show substantial
overlay with TH marker suggesting that these receptors might be lo-
calized on the same structure, the postganglionic sympathetic nerves.
Nonetheless, immunoreactivity for AT1 receptors in non-neuronal cells
could also be observed.
Quantitative analysis of LSCM images revealed considerable differ-
ences in the relative mean of TH, AT1 and AT1-TH overlay between the
two experimental animal groups (Fig. 4A): values obtained from MUN
animals almost doubled comparatively to CONTROL.
Relative mean ratio of AT1 receptor and TH overlay, with respect to
the total TH immunoreactivity, was slightly higher in MUN compara-
tively to CONTROL mesenteric arteries: 25% of sympathetic neurons
exhibit AT1 receptor immunoreactivity in CONTROL versus 35% ob-
served in MUN vessels (Fig. 4B). Also, the relative mean ratio of AT1
receptor and TH overlaid, regarding the total AT1 immunoreactivity
revealed the presence of AT1 receptors in other cells than sympathetic
neurons: 70% in CONTROL and 60% in MUN mesenteric arteries
(Figs. 3 and 4C).
We have previously demonstrated that sympathetic nerves are sur-
rounded by Schwann cells (anti-GFAP-immunoreactivity) [30]. The
putative presence of AT1 receptors in Schwann cells was evaluated
staining vessels with GFAP. Data from LSCM images evidenced the
occurrence of AT1 and GFAP overlaid immunoreactivities (Fig. 5),
confirming the presence AT1 receptors in adventitia cells other than the
postganglionic sympathetic neurons.
4. Discussion
There is a gap in the knowledge regarding the complex interplay
between vascular sympathetic neurotransmission and Ang II in FPH.
This study points out that an increase vascular sympathetic activity
might play an important role on hypertension development subsequent
to fetal undernutrition. This is a relevant finding since sympathetic
nervous system is a key contributor to vascular tone. Therefore, an
increase in sympathetic neurotransmission would, likely, lead to an
elevation in vascular resistance and subsequent elevation of blood
pressure.
In MUN male rats a significant elevation in SBP was observed. This
data in conscious rats is similar to that previously reported in male
offspring from this rat model under anesthesia [31].
An increase in sympathetic neurotransmission was observed in our
model of FPH both in arterial and venous territories. This data is in
accordance with studies previously performed in a spontaneously hy-
pertensive rat model, the SHR, where a hyper-sympathetic activity was
also described in several arterial territories such as cerebral [32,33], tail
[26] and mesenteric [26,27] and also in mesenteric vein [27]. More-
over, data is also in agreement with studies demonstrating that sym-
pathetic nervous system activation seem to be increased in other
models of FPH [34,35]. Some of these studies reported an increased
circulating levels of noradrenaline: a model of intrauterine growth re-
striction induced by maternal protein restriction in the rat [36] and
another model of placental insufficiency in both rat [37] and sheep
[38,39]. In addition, chronic prenatal hypoxia is associated with hy-
perinnervation and an increase in adrenal medullary noradrenaline
content and TH activity [40–42]. Therefore, and in accordance with
those reported data, our findings indicate that the hyper-sympathetic
activity observed in MUN vascular tissues can be explained by the
larger amount of sympathetic innervation, as demonstrated by TH
staining.
In MUN vessels, the observed increase in basal and electrically-in-
duced noradrenaline release seems to be more evident in arteries than
in veins. This data also suggests that the baseline tone is higher in ar-
teries from MUN than in CONTROL. In fact, noradrenaline once re-
leased can activate α1-adrenoceptors in vascular smooth muscle cells
leading to vasoconstriction in arteries [43,44] and in veins [45,46] as
noticed on splanchnic circulation and other vascular territories in an-
imal models of hypertension.
We also observed that release of noradrenaline from sympathetic
Fig. 3. Laser scanning confocal microscopy re-
presentative images of CONTROL and MUN mesen-
teric arteries exhibiting TH (green), AT1 receptor
(red), and overlay of AT1 receptor-TH im-
munoreactivities; nuclei are shown in blue. Scale
bar = 20 μm. (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
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nerve terminals was under the influence of Ang II through AT1 re-
ceptors. Thus, exogenous Ang II caused an increase in noradrenaline
release both in arteries and veins from CONTROL and MUN groups,
confirming the interplay between RAS and vascular neurotransmission.
The facilitatory role of Ang II on noradrenaline release has been pre-
viously demonstrated in rat models of hypertension [47–50] other than
FPH. In this study, the facilitation of noradrenaline release induced by
exogenous Ang II was more pronounced in the arterial territories than
in the veins from CONTROL animals. In addition, exogenous Ang II
caused a similar increase in noradrenaline release in CONTROL and
MUN but only in the arterial tissues. In the mesenteric veins, the fa-
cilitation of noradrenaline release was more marked in MUN than in
CONTROL veins. These findings are in line with results obtained in
other studies made in mesenteric veins of SHR animals [51].
It has been shown that inappropriate activation of the RAS may
occur in response to a development insult: prenatal exposure to glu-
cocorticoids up-regulates expression of the renal RAS [52]; central ex-
pression of the AT1 receptors is increased in offspring exposed to ma-
ternal protein restriction [53] and nicotine exposure [54]. However, in
a maternal undernutrition animal model, these alterations had not been
studied.
In our study, the treatment with AT1 receptor antagonist losartan
was unable to modify tritium overflow in vessels from CONTROL rats.
However, this procedure caused a facilitation in MUN vessels. This
finding is consistent with the occurrence of a tonic facilitation mediated
by endogenous Ang II via AT1 receptor activation. This effect was ob-
served in all the MUN vessels studied.
Data support the possible occurrence of higher levels of endogenous
Ang II in the sympathetic cleft of MUN rats. Curiously, the tonic effect,
mediate by endogenous Ang II in prejuctional AT1 receptors was similar
in all the MUN vessels studied, discarding the possibility that this
vascular sympathetic alteration occurs only locally or in specific terri-
tories, but rather indicating a widespread effect both in resistance and
capacitance vessels.
Taken together data revealed that local RAS is more effective in
vascular sympathetic neurotransmission modulation in arterial terri-
tories than in veins. Furthermore, it also reinforces their relevance as a
potential mechanism in FPH.
Since all the vessels studied showed a similar functional profile in
vascular neurotransmission we chose the mesenteric artery as a re-
presentative vessel for the morphological study. LSCM data revealed the
presence of nerve fibers (TH positive) both in CONTROL and MUN. We
observed that sympathetic nerves spread through the adventitia
reaching the medial layer. There was, however, a larger thickness of
sympathetic nerve fibers in MUN mesenteric arteries accompanied by a
parallel AT1 receptors overlaying these neurons. These higher amounts
of AT1 receptors can explain, at least in part, the facilitatory tone
regulating noradrenaline release from MUN mesenteric arteries stimu-
lated with exogenous or endogenous Ang II. Data also show for the first
time that AT1 are located in two main locations: one expressed in nerve
fibers and another, in other adventitia cells. Some of these cells seem to
be Schwann cells. This possibility was confirmed by data showing that
AT1 receptors are overlaying GFAP, a marker for glial cells such as
Schwann cells. In fact, the presence in Schwann cells, of other receptors
or enzymes with a role on noradrenaline neurotransmission, was pre-
viously demonstrated [22,26] supporting a trophic role of these cells
and of its close association with neurons. Images also show that these
receptors are present in other type of adventitia cells like macrophages
or mesenchymal cells. Altogether these data correlates well with the
functional results obtained, showing an increase in the neuromodula-
tory role ascribed to Ang II in several vascular beds.
In summary, this study supports the occurrence of a hyper-sympa-
thetic activation, involving a tonic facilitation, by endogenous Ang II, of
prejunctional AT1 receptors, which can justify, at least in part, the
occurrence of hypertension in these animals. These alterations also
supports the possibility of vascular remodeling in MUN mesenteric ar-
teries, as previously described in aorta [55]. A vascular structural al-
teration could also contribute to increase vascular resistance and the
development of hypertension in this model of FPH.
Fig. 4. Quantitative analysis of LSCM images from mesenteric arteries
(CONTROL and MUN) staining with TH and AT1 antibodies. (A) Relative means
of TH, AT1 and TH-AT1 overlay expressed as percentage of CONTROL values;
(B) Mean percentage of overlay ratio with TH (C) and mean percentage of
overlay ratio with AT1 are depicted. Images are reconstructions from 9 to 28
serial optical sections analyzed using PAQI software. Values are mean ±
s.e.m., and n= 3–4 animals. Significant differences from SD-CONTROL:
*P < 0.05.
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Cell surface G-protein-coupled receptors (GPCRs) are targets for  30% of drugs currently on the market,
and are the largest group of gene products targeted by drugs. Until recently, signaling mediated by
GPCRs was thought to emanate exclusively from the cell membrane as a response to extracellular
stimuli. However, recent research has revealed the existence of nuclear (n)GPCRs with the ability to
trigger identical and/or distinct signaling pathways to their respective counterparts on the cell surface.
Understanding of the GPCR signaling platform on the nuclear membranes and its involvement in
physiology and/or pathophysiology will be important to develop selective pharmacological and
pharmaceutical approaches. In this review, we summarize our current understanding of nGPCRs, with
emphasis on their potential as novel pharmacological targets.
Introduction
GPCRs belong to a diverse superfamily with  800 members with
heptahelical transmembrane domains [1]. According to the
IUPHAR Guide to Pharmacology, GPCRs can be divided into six
classes (A–F) based on their sequence homology: A (rhodopsin-
like); B (secretin receptor family); C (metabotropic glutamate);
D (fungal mating pheromone receptors); E (cyclic AMP receptors);
and F (frizzled), with classes D and E not found in vertebrates [1].
Conventionally, GPCRs are cell surface receptors (mGPCRs) that
respond to a variety of external stimuli through ligands including
peptides or proteins, ions, lipids, odorants and light. GPCRs signal
commonly through the heterotrimeric guanine (G) nucleotide-
binding proteins (a, b, and g subunits), mediating and dictating
their downstream signaling and ultimate effects [2]. Over the
past few decades, an increasing body of evidence has highlighted
the existence of active GPCR signaling systems in intracellular
compartments, including endosomes, endoplasmic reticulum
(ER), mitochondria, and nucleus [3]. Some have been intensively
studied, revealing attractive physiological functions and/or plau-
sible roles in pathological conditions. Therefore, the occurrence of
GPCRs other than mGPCRs requires a reassessment of, and devel-
opment of new, models for pharmacological interventions. This is
particularly important given that GPCRs are targets for approxi-
mately one-third of drugs used in clinical practice, acting on 108
GPCRs [4]. In this review, we provide a summary of the current
knowledge regarding nGPCRs and discuss their potential as phar-
macological targets for new and of already used drugs.
Nuclear GPCRs: from origin to function
In 1971, a pioneering study demonstrated that injection of angio-
tensin II (Ang II) in a nuclear zone induced ultrastructural cellular
changes [5], an effect later attributed to the triggering of a GPCR
located in the nucleus. Since then, evidence supporting the nuclear
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radioligand binding assays, electron and confocal microscopy
techniques [immunolabeling, fluorescent ligands or receptors fused
with fluorescent tag(s)], and western blots [6], using isolated nuclei
and/or intact cells, and functional assays with caged and/or photo-
lyzed ligands [7] or cytosolic microinjections [6].
More than 40 functional nGPCRs from several classes have been
identified in the nuclear membrane of distinct cell types, as
summarized in Table 1. Despite extensive research efforts, further
clarification is required for some aspects of nGPCRs, including
their exact nuclear location, relevant receptor and ligand origins,
signaling cascades and ultimate effects. Nevertheless, nGPCRs
appear to be evolutionarily conserved, given that their presence
has been confirmed in a range of organisms, including nematodes
(Caenorhabditis elegans), insects (Drosophila), and mammals, as also
summarized in Table 1.
Origin of nuclear GPCRs
The appearance of GPCRs in the nucleus has been suggested to
have occurred in at least four different ways (Fig. 1). nGPCRs could
appear in the nucleus following mGPCR internalization and their
subsequent translocation into the nuclear membrane [8]. Multiple
mechanisms for mGPCR nuclear translocation (from cell mem-
brane to nucleus) have been reported [8], via a process that can be
either agonist dependent or independent. Agonist-dependent
translocation of GPCRs occurs as a consequence of prolonged
and/or repetitive exposure to agonists. In some cases, the receptor
can be internalized along with the concomitant activation of
signal pathways, such as the mitogen-activated protein kinase
(MAPK) and protein kinase B (Akt) and/or phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) pathways [9,10], which elicit
genomic delay responses [11]. Once internalized, GPCRs can be
recycled back to the cell membrane or transported to organelles
such as lysosomes, ER, Golgi body [12–14], and mitochondria [3]
or, ultimately, translocated into nucleus [3,11,15]. The GPCRs
translocated from the cell membrane to the nucleus can (but
not always) trigger a late response (e.g., gene transcription) which
can complement (or oppose) the initial response triggered by
mGPCR, without retaining the information obtained from the
extracellular space.
Other stimuli or events can promote mGPCR nuclear import
from the cell membrane via an agonist-independent process. Such
GPCR activation challenges traditional GPCR pharmacology and
introduces the environment as an important, and in some cases,
decisive factor determining certain signal events and effects. For
example, the neurokinin 3 (NK3) receptor is activated, internal-
ized, and transported to the nucleus following osmotic changes
[16]. Other examples include the presence of parathyroid hor-
mone 1 (PTH1) receptors in nuclear membranes of osteoblast-like
cells only during certain stages of the cell cycle, when the DNA is
exposed to transcriptional activity [17], and the presence of the
vasoactive intestinal peptide 1 (VPAC1) receptor, the translocation
of which is induced by palmitoylation [18].
Agonist-dependent or -independent nuclear translocation
appears to be cell type specific and depends on cellular conditions,
such as concomitant activation with other receptors, metabolic
state, or pathologies. The oxytocin (OT) receptor (OT [19]) and
Ang II receptor type 1 (AT1 [20,21]) have demonstrated both
agonist-dependent and -independent nuclear localizing capabilities
according to the cell type. Any alteration of any of the environmen-
tal conditions would lead to a modified response triggered
by nGPCRs.
The translocation of GPCR to the nucleus has a specific finger-
print: in the C terminus or an intracellular loop of nGPCRs, short
peptide sequences comprising basic amino acid residues (usually
lysine/glycine-arginine repeats) have been found and are consid-
ered classical nuclear localization sequences (NLS) [22]. These NLS
appear to direct GPCRs to the nucleus via small GTPases and/or
importin mechanisms, as demonstrated for platelet-activating
factor (PAF) [23], OT [11], protease-activated 2 (PAR2) [24], and
PTH1 receptors [25].
The translocation of receptors might be independent on the
presence of the NLS motive, as observed for the translocation of
the bradykinin B2 receptor, which, despite the NLS being present,
is dependent on heterodimerization of the receptor with lamin C
[26]. Furthermore, other peptide sequences that do not resemble
classic NLS might also promote the nuclear import of receptors
[27]. For example, the M9 sequence, a 38-amino acid-long
fragment from heterogeneous nuclear ribonucleoproteins A1
and A2 proteins, is recognized by transportin, which mediates
both nuclear import and export [28].
In addition to the cell membrane origin of nGPCRs, recent
findings have suggested that resident nGPCRs are synthesized in
ER (in an identical process to that described for mGPCRs) and
traffic directly to the nucleus by lateral diffusion, as appears to
occur with the endothelin subtype B (ETB) receptor [29]. Other
recent findings also suggest that GPCRs also appear in the nucleus
through a fourth pathway: the direct synthesis of nGPCRs within
the nucleus [30], a possibility supported by the occurrence of
protein translation inside the nuclei of mammalian cells, support-
ing this as a possible direct source of nGPCRs [8,31].
Location and function of nuclear GPCRs
nGPCRs have been found in the nuclear envelope at the inner and/
or outer nuclear membranes (INM and ONM, respectively) where
they can be anchored securely (as demonstrated for the metabo-
tropic glutamate 5 (mGlu5) receptor, which is firmly retained in
the INM via its interactions with chromatin [32]) and oriented in
such a way that exposes the effector-binding domain to either the
nucleus or the cytosol (Fig. 2). nGPCRs have also been suggested to
be present in the nucleoplasm in the network of invaginations of
both nuclear membranes [33] or through transport within
micelles, maintaining membrane-embedded GPCR [34]. However,
the nuclear location of GPCRs does not suggest that nuclear
signaling is limited to the nucleus. Evidence suggests the presence
of receptors in the INM with the effector-binding domain directed
towards the interior of nucleus, but with ultimate effects in the
cytosol because of the translocation of effector proteins to the
cytosol, as observed for the a1A-adrenoceptor [35].
Key components of signaling pathways and the machinery
typically associated with mGPCRs (G proteins, downstream effec-
tor molecules, second messengers, ion channels, and regulators)
are found in the nucleus of several cell types [3,6]. These data
reinforce the idea that the nucleus is an autonomous signaling
organelle retaining functional nGPCRs. nGPCRs mainly regulate
nuclear calcium [Ca2+]n, nitric oxide levels or cAMP production,
although other second messengers, such as IP3, cGMP, and DAG,
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TABLE 1
Nuclear GPCR subtypes in different cells and/or tissues and their respective functions
Family name Subtype(s) Cell/Tissue Signalling/Function Refs
Class A
Adrenoceptors a1 Mouse cardiac myocytes Gaq–PLCb1–ERK activation [36]
a1A Mouse cardiac myocytes a1A–Gaq/11–PKCd–"cTnI contractility" [35]
a1, b1 Rat ventricular myocytes [6]
b Rat cardiomyocytes Gai–PI3K–Akt–ERK1/2–# NF-kB transcription; "
Ripk2 + # NF-kB, ATF-2, IL1r1 and Tnfrsf1b
transcription
[22]
b3 Rat cardiomyocytes Gai–NOS–GC–PKG transcription [22]





Rat hypothalamus, thalamus, septum, and
midbrain
[56]
Rat VECs, SMCs, and cardiomyocytes [5]
Rat liver and spleen [57]
Rat liver " Renin + angiotensinogen transcription [6]
Rat and hamster myocytes "[Ca2+]n [6]
AT1 Rat liver [6]
Rat and human VSMCs " [Ca2+]n [6]
Human VSMCs " [Ca2+]n [6]
Rat VSMC line A10 " p-CREB; " proliferation [6]
Transfected HEK293 cells, mouse cardiac
myocytes
" COX2 gene transcription (PTGS-2) [21]
mRen(2).Lewis rat kidneys # Nuclear AT1 [51]
Rat kidneys PKC–NADPH oxidase (NOX4) activation; " ROS [70]
AT1, AT2 Rat and mouse substantia nigra pars compacta
(dopaminergic neurons), transfected MES 23.5
dopaminergic neuron cell line
AT1–IP3–" [Ca2+]n–" AT2 + angiotensin + PGC-
1a + IGF-1 transcription ! protective effect;
AT1–NOX4–" superoxide/H2O2; AT2–NOS–" NO
[71]
Rat liver " Renin, angiotensinogen, c-myc, PDGF
transcription
[6]
Rat cardiomyocytes AT1/AT2–" NF-kB expression; AT1–"IP3–"
[Ca2+]n transcription"
[22]
Sheep kidney AT2–" NO [72]
Sheep kidney of a fetal programming model " ROS, NO [73]
Canine cardiac fibroblasts AT1–"IP3–" [Ca2+]n"; AT2–"  NO"; AT1+AT2
regulate fibroblast proliferation, collagen gene
expression, and collagen secretion
[7]
Apelin receptor Human cerebellum and hypothalamus,




B2 Rat hepatocytes "[Ca2+]n–"Akt acetylation of histone H3–iNOS
gene induction"
[22]
B2 Transfected HEK cells Heterodimer with lamin C [26]
B2 Rat olfactory bulb, cerebral cortex,
hippocampus, basal forebrain, basal ganglia,
thalamus, hypothalamus, cerebellum, and
brainstem
[58]
B2 Human placenta [74]
B2 HEK-293T cells [34]
B1, B2 Rat hippocampus [59]
Chemokine
receptors
CCR2 Transfected HEK cells [15]
CXCR4 Human non-small cell lung cancer [52]
Human hepatoma cancer cells [6]
Human prostate cancer cell lines Gai–" [Ca2+]n [22]
HeLa cells [6]




Human endocardial endothelial cells and aortic
VSMCs
"[Ca2+]n–" ROS [22]
Rat heart "NO–# transcription [76]
ETB Human heart and VSMCs "[Ca2+]n [6]
ETB Rat cardiomyocytes IP3–" [Ca2+]n [29]
ETA, ETB Rat cardiac ventricular myocytes "[Ca2+]n [42]
Formylpeptide
receptors
FPR2 Human cancer cells Gai–ERK2, c-Jun, and c-Myc phosphorylation [22]
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GnRH1 HEK 293 and HTR-8/Svneo cell lines Histone H3 acetylation and phosphorylation [22]
Ce-GnRHR Caenorhabditis elegans [6]
Leukotriene
receptors
CysLT1 Human colon epithelial cells and colon cancer
cells
Proliferative ERK1/2 signaling [22]
Human VSMCs " [Ca2+]n–PAI-2 transcription [22]
CysLT1, CysLT2 Mouse B16, human HaCaT prekeratinocytes NOX4 nuclear translocation, ROS




LPA1 Porcine cerebral microvascular endothelial
cells
COX-2 and iNOS transcription [22]
Transfected HTC4 rat hepatoma cells [6]
Rat liver Gai/o–PI3K–Akt–" [Ca2+]n/" iNOS expression [6]
LPA1 Porcine cerebral endothelial cells GC–eNOS/cGMP phosphorylation–" [Ca2+]n +
p42 MAPK activation, NF-kB binding to DNA
+ iNOS expression
[6]
LPA1 HBEC, PC12, and CHO cells Regulates protein phosphorylation [6]
S1P1 C57BL/6 mouse splenic CD4 T cells Gai/o–# p-Erk + p-c-Jun [46]
S1P1 Human umbilical vein endothelial cells Cyr61 and CTGF expression [79]
Melanocortin
receptors
MC2 H295R cell Interaction with Nup50 [6]
Melatonin
receptors




Rabbit cornea and endothelial cells " cGMP, # cAMP [6]
Chinese hamster ovary cells " DNA and RNA polymerase II activity [6]
Neuropeptide Y
receptors
Rat pituitary gland [6]
Y1 Human endocardial endothelial cells " [Ca2+]n [6]
Neurotensin
receptor
NTS1 Rat substantia nigra, transfected Chinese




Opioid receptors d NG 108-I 5 neurohybrid cells [6]
m Human mesothelial cell line and human
abdominal adhesions
[82]
k Mouse undifferentiated GTR1 cells PKC–GATA-4 + Nkx-2.5 gene transcription [83]
k Pluripotent embryonic P19 cell line GATA-4 + Nkx-2.5 gene expression [6]
k Hamster ventricular myocardial cells PKC–opioid peptide gene transcription [22]
Oxytocin
receptors
OT Mouse osteoblasts Expression of osteoblast differentiation genes
(Sp7, Atf4, Ibsp, and Bglap)
[11]
Human osteosarcoma (U2OS, MG63, OS15, and
SaOS2), breast cancer (MCF7), and primary
human fibroblastic cells (HFF)
[19]
Human epithelial glandular cells of






PAF Rat liver Phospholipase C–DAG [6]
Porcine cerebral microvascular endothelial
cells and neurons
Gai/o–# cAMP; "[Ca2+]n; ERK1/2 + NF-kB
binding–iNOS + COX-2 transcription
[22]
HEK293T and CHO-K1 cells and rat retinas " Growth factors (e.g., VEGF) ! angiogenesis [23]
Prostanoid
receptors
EP1 Porcine cerebral microvascular endothelial
cells
[6]
Transfected HEK 293 cells
Murine fibroblast Swiss 3T3 cells
(overexpressing EP1)
" [Ca2+]n–c-fos transcription
Pig myometrium " [Ca2+]n–c-fos transcription
EP1, EP3 Rat cerebral cortex endothelial cells and
neurons
EP3 Piglet brain endothelial cells Gai/o–KCa2+ Channels–" [Ca2+]n–PI3K/Akt
+ Erk1/2 + NF-kB–" eNOS expression
[22]
EP1, EP2, EP3, EP4 Neonatal porcine brain [22]
Rat liver EP3–Gi/o–" [Ca2+]n
Porcine cerebral microvascular endothelial
cells
" iNOS expression
TP Rat oligodendrocytes Gas -"cAMP–p-CREB + myelin basic protein
transcription + " survival
[39]













have also been described. These messengers influence several
processes, including the redox status, transcription, cell prolifera-
tion, and tumorigenesis, as summarized in Table 1. However,
whether nGPCR transduction mechanisms are similar to those
described for mGPCRs needs to be clarified. nGPCRs have been
studied with in situ microinjections or using isolated nuclei,
allowing the identification of discriminative effects concerning
the activation and signaling events triggered by nGPCRs versus
mGPCRs. However, most of the methodologies used to study
nGPCRs were developed for mGPCR studies (e.g., cell-permeable
fluorescent dyes or appropriately targeted biosensors), resulting in
limitations to targeting nGPCRs owing to their permeability and
ability to discriminate between mGPCR and nGPCRs. Therefore,
improved methodologies are required to obtain more discrimina-
tive information about the transduction mechanisms associated
with nGPCRs.
nGPCRs can be constitutively active or activated by endogenous
ligands. Extracellular ligands might reach nGPCRs through cellu-
lar uptake via selective transporters (e.g., noradrenaline [36]),
through membrane exchangers (e.g., glutamate [37]), or via en-
docytosis through caveolin-coated pits (e.g., urotensin-II [38]).
nGPCR exposure to ligands might differ from that observed for
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NK1 Rat dorsal root ganglia [6]
NK3 Rat ventral tegmental area [6]
NK3 Rat hypothalamus [16]
Urotensin
receptor
(UT) Rat brain " Total transcription rate [44]
Monkey brain, human glioblastoma-
astrocytoma U87-MG and human
neuroblastoma SH-SY5Y cell lines





PTH1 Red deer osteoclasts [6]
PTH1 Mouse osteoblast-like cell line (MC3T3-E1) [20]
PTH1 Osteoblast-like cells (mouse MC3T3-E1, rat ROS
17/2.8 and UMR106, and human SaOS-2)
In MC3T3-E1 cells, receptors are involved in
DNA synthesis and mitosis
[86]
PTH1 Rat liver, kidney, uterus, gut, and ovary [6]
VIP and PACAP
receptors
VPAC Human colonic adenocarcinoma cell line
(HT29)
[6]
VPAC1 Human breast carcinoma cell lines (T47D and
MDAMB-468)
Gas –" cAMP [22]
VPAC1 Chinese hamster ovary cells Antiapoptotic activity [18]





mGlu1 Rat cortex, olfactory bulb, thalamus, and
cerebellum, transfected HEK293 cells
" [Ca2+]n; control of brain development [6]
mGlu5 Heterologous cells, mouse midbrain and
cortical neurons, transfected HEK293 cells
" [Ca2+]n [22]
Rat striatal neurons " [Ca2+]n + p-CREB [22]
Rat and monkey substantia nigra [87]
Rat striatal neurons, HEK293 cells Gaq/11–PLC–IP3/ryanodine receptor –" [Ca2+]n [6]
Neonatal rat and mouse striatal cells JNK, CaMK, CREB, ERK1/2 and Elk-1
phosphorylation; p-Elk-1–" c-fos + egr1
[6]
Rat and mouse striatal neurons [Ca2+]n + ERK1/2 + CaMK–" cytoskeletal-
associated proteins (Arc/Arg3.1)
[45]
Rat hippocampus " [Ca2+]n [37]
Rat spinal dorsal horn neurons " [Ca2+]n; p-ERK1/2, Arc/Arg3.1 and c-fos !
neuropathic pain
[50]
Orphans GPR158 Human trabecular meshwork cell line Cell proliferation [22]
Class Frizzled




Abbreviations: Akt, protein kinase B; ATF-2, activating transcription factor 2; [Ca2+]n, nuclear calcium; CaMK, Ca2+/calmodulin-dependent protein kinase; COS-7, monkey kidney
fibroblasts cell line; cTnI, cardiac troponin I; ERK, extracellular signal-regulated kinases; HEK, human embryonic kidney cells; HEK293, human embryonic kidney cells; IL1r1, interleukin 1
receptor, type I; IP3, inositol trisphosphate; NF-kB, factor nuclear kappa B; NOS, nitric oxide synthase; p-, phosphorylated; PDGF, platelet-derived growth factor; PI3K, phosphoinositide
3-kinase; PKC, protein kinase C; PKG, cGMP-dependent protein kinase; Ripk2, receptor-interacting serine/threonine-protein kinase 2; SMCs, smooth muscle cells; Tnfrsf1b, tumor necrosis










mGPCRs because of the differential permeability of the extracel-
lular ligands and of preferentially exposure to intracellular ligands
that normally do not reach and influence mGPCRs. Indeed,
nGPCRs might be preferentially activated by endogenous ligands
that can be synthetized within the cell by enzymes located in the
vicinity of the respective nGPCR, ensuring ligand bioavailability in
the microenvironment of nuclear receptors. This type of process
occurs for various ligands, including lipid mediators, such as
prostanoids [39], platelet-activating factor, and lysophosphatidic
acid [31], as well as peptides, namely apelin, bradykinin, Ang II
[40], or endothelin [41]. All these attributes open new possibilities
for determining pharmacological responses among these receptor
subpopulations in future studies.
Nuclear GPCRs versus cell membrane GPCRs
The nuclear location of nGPCRs appears to be both cell type and
tissue specific. Furthermore, the GPCR subtype has also been
suggested as a feature contributing to differential nuclear versus
cell membrane location. Different receptor densities have been
observed at the cell and nuclear membranes, favoring one or
other of the locations [34,42]: the nuclear membrane appears to
be the preferential location for some GPCRs (e.g., ETB [29])
whereas, for others, an alternative destination has been observed
(e.g., AT1 receptor [21]).
nGPCRs and mGPCRs usually present identical structures with a
heptahelical chain sequence. However, there are exceptions,
where only a small functional portion of the heptahelical chain
might be translocated into the nuclear membrane, as reported for
the Frizzled-2 (FZD2) receptor, the C terminus of which is cleaved
and then translocated into the nuclear membrane [43]. In some
cases, GPCRs might undergo differential post-translational mod-
ifications between the cell and nuclear membranes [44]. For
instance, the cell surface ETB receptor undergoes N-glycosylation
but this is absent in its nuclear counterpart [29].
Activation of nGPCRs can trigger responses aligned with those
elicited by their respective cell surface counterparts. In this regard,
similar signaling events have been described concerning the
nuclear and cell surface mGlu5 receptors. Nuclear mGlu5 receptors
have similar roles (i.e., induction of oscillatory Ca2+ responses) to
those attributed to the cell surface mGlu5 receptors, with identical
impacts on synaptic plasticity and the growth and/or differentia-
tion of striatal neurons [45].
Interestingly, differential signaling between nGPCRs and
mGPCRs has also been observed, such as in the case of sphingosine
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FIGURE 1
Schematic representation of conceivable origins for nuclear full-length G-protein-coupled receptors (GPCRs). Nuclear membranes might be an alternative
destination for plasma membrane GPCRs that undergo nuclear translocation via an agonist-dependent (1) and/or -independent (2) pathway. Resident nuclear
membranes GPCRs might be synthesized in the endoplasmic reticulum (ER) (3) or within the nucleus (4). (1) Receptor translocation from the cell membrane to
the cell nucleus could occur as part of an agonist-mediated internalization event. Binding of an agonist to a receptor induces a first signaling phase at the cell
membrane, which, after a long exposure, results in the desensitization and internalization of the receptors, culminating in nuclear translocation (frequently via
small GTPases/importins mechanisms). (2) Other events and/or stimuli might also induce receptor internalization and nuclear translocation independently of
agonist binding, such as palmitoylation or osmotic changes. (3) Nuclear import of newly rough ER-synthesized receptors can occur via lateral diffusion (given
that the outer nuclear membrane is continuous with the ER) or from vesicular transport after ER and/or trans-Golgi network post-translational modifications. (4)













1-phosphate (S1P) subtype 1 (S1P1) receptors. In unstimulated
T cells, these receptors were not detected in the nucleus, whereas
they were found to be involved in cell migration when located in the
cell membrane. However, in stimulated T cells, nuclearization of
most of the cell surface S1P1 receptors appears to be induced and
triggers a decrease in cell proliferation [46]. Another example of
discriminated signaling events triggered by nGPCRs and cell surface
counterparts is the PAR2 receptor: activation of the cell surface PAR2
receptor leads to expression of genes related to vessel maturation
[47], whereas nuclear PAR2 receptor activation stimulates the
recruitment of transcription factors that promote angiogenesis [47].
Nuclear GPCRs in pathological conditions
An increasing body of evidence has revealed that nGPCRs are
involved in numerous key physiological and/or pathophysiologi-
cal conditions, predominantly in the cardiovascular and nervous
systems, but also in the reproductive system, liver, and kidney
(Table 1). The density of nGPCRs also appears to be modified in
pathological conditions. For example, nGPCR upregulation has
been observed in cancer, pain and heart failure, whereas their
downregulation was reported in hypertension. For instance, a
higher density of nuclear VPAC1 receptors in high-grade gliomas
was reported, possibly constituting a mechanism of tumor resis-
tance [48]; cysteinyl leukotriene 1 (CysLT1) receptors are present in
the ONM, after internalization induced by prolonged exposure to
leukotriene D4, and are upregulated in cancer [49]; in spinal dorsal
horn neurons,~80% of mGLU5 receptors are intracellularly locat-
ed, mainly within nucleus (~ 60%), where they are functional
active, and have recently been associated with persistent pain
[50]; an increased density of AT1 receptors was described in a heart
failure model, associated with collagen gene expression and secre-
tion and with the regulation of fibroblast proliferation [7]; the
nuclear location of PTH1 receptors appears to be favored upon
metabolic deprivation, whereas, under standard metabolic condi-
tions, the cell surface and nuclear receptors are both present in
similar amounts [25]. By contrast, in hypertension, the expression
of nuclear AT1 appears to be reduced in the kidney, probably as a
compensatory mechanism because of increased levels of Ang II
[51]. Nevertheless, further studies are needed to clarify the impact
of nGPCRs in pathological conditions to evaluate their relevance
as putative therapeutic targets.
Interestingly, the expression of nuclear C-X-C chemokine type 4
(CXCR4) receptors has been associated with significantly better
outcomes in early-stage non-small cell lung cancer [52], suggesting
that some nGPCRs could be used as predictors of disease outcome.
It is also conceivable that, after the improvement and validation of
methodologies that allow refined discrimination between effects
ascribed to different GPCRs populations, nGPCRs could be used to
monitor the evolution of disease.
Are nuclear GPCRs pharmacologically targetable?
The existence of GPCRs in the nucleus opens new opportunities
and challenges for pharmacological intervention using these
targets. GPCRs are targets of approximately one-third of drugs
currently used in the clinic, acting on >100 types of receptors, and
94% of them are class A GPCRs [4]. More than 80% of these drugs
target GPCRs such as aminergic receptors (adrenoceptors, musca-
rinic acetylcholine, histamine, dopamine, and 5-hydroxytrypta-
mine receptors) and opioid receptors (gpcrdb.org) signaling
mostly via the Gai/o (~ 38%), Gaq/11 (~ 29%), and Gas (~ 24%)
subunits [53]. Therefore, it is plausible that some of the effects
of these drugs result from actions on nGPCRs. For example,
activation of a1A-adrenoceptors promotes cell cycle arrest, hyper-
trophy, and the differentiation of rat-1 fibroblasts into smooth
muscle cells as well as the expression of negative cell cycle
regulators by a mechanism independent of the cAMP/PKA signal-
ing pathway [54]. Although not addressed, the involvement of
nuclear adrenoceptors might explain these effects. Thus, the
possibility that nuclear a1A-adrenoceptors contribute to the clini-
cal effects of a1A-adrenoceptor antagonists used in the treatment
of benign prostatic hyperplasia cannot be discarded. The same
rationale can be applied to CysLT1-selective antagonists, such as
montelukast, used in the treatment of asthma, or to AT1 receptor
antagonists, such as losartan, used in hypertension and heart
failure, where the reported presence of the respective receptors
in the nuclear membranes might partially contribute to their
clinical efficacy.
In addition to drugs that interact directly with receptors, several
others might influence the intracellular availability of ligands
indirectly and, possibly, the ligand concentration in the microen-
vironment of nuclear receptors. The most obvious example is
zileuton (a 50-lipoxygenase inhibitor used in the treatment of
asthma; 50-lipoxygenase is an enzyme involved in the initial events
of leukotriene synthesis, which occurs at the nuclear membrane
[55]): when 50-lipoxygenase is inhibited by zileuton, it impacts the
concentration of leukotrienes available for nuclear leukotriene
receptors. Other examples of drugs the therapeutic effects of which
might have a contribution from nuclear GPCRs include captopril
and other inhibitors of angiotensin-converting enzymes. These
drugs interfere simultaneously with two endogenous ligands
(a decrease in Ang II and the accumulation of bradykinin), the
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FIGURE 2
Schematic representation of the predicted topology of G-protein-coupled
receptors (GPCRs) in the nucleus. Nuclear GPCRs were reported to be located
at either nuclear envelope membranes (inner or outer) probably positioned
in such a way that signals would be directed to the cytosol or nucleus. In
some cases, nuclear GPCRs have been found within the nucleoplasm,










receptors of which (AT1 and AT2 receptors [6,7,22,56,57] and
bradykinin B1 and B2 receptors [58,59], respectively) were reported
to have a nuclear location. In terms of adrenoceptors, several drugs
are envisaged to have the potential to interfere with the concen-
tration of their endogenous ligands (noradrenaline and adrena-
line), namely monoaminoxidase (MAO) inhibitors, reserpine, and
amphetamines. MAO inhibitors have been used in the treatment
of depression and Parkinsons disease, and their effects have been
explained by sparing monoamines (such as noradrenaline, adren-
aline, dopamine, histamine, and serotonin) from metabolism and,
consequently, favoring their cytosolic accumulation in the synap-
tic vesicles. However, such accumulation can also impact the
ability of these monoamines to reach other intracellular targets,
namely nGPCRs. Therefore, the involvement of nGPCRs could
explain the alterations in gene expression caused by MAO inhi-
bitors [60,61]. nGPCRs might also have a role in the effects
mediated by reserpine. Reserpine, an antipsychotic drug (also used
in hypertension), inhibits the vesicular ATP/Mg2+ pump, leading
to a cytosolic increase in monoamines that might target nuclear
adrenoceptors. This could explain the increase in gene transcrip-
tion observed after reserpine administration [62,63]. The involve-
ment of nGPCR-mediated effects is also a possibility in the case of
recreational drugs with a high risk of addiction, such as amphe-
tamines: the stimulatory effects of amphetamines result from the
transient facilitation of neurotransmission, which is caused by
monoamine transport from the cell, instead of the usual transport
into cell [64]. However, addiction to these drugs is coupled with
long-lasting transcriptional alterations that require alternative
explanations [65,66]. The possibility that they result from a reduc-
tion in the number of messengers available intracellularly to
activate nGPCRs is a tempting hypothesis.
The development of new drugs with higher affinity toward
nGPCRs than to their cell surface counterparts is a challenging
field of research. Therefore, an improved understanding of the
different signaling events triggered by nGPCRs and their cell
surface counterparts will be relevant to enable the development
of drugs targeting solely nGPCRs. Drugs with preferable activity on
nGPCR membrane receptors should be designed using techniques
such as molecule modification through the addition of a ‘caging’
moiety, a removable functional group that increases cell perme-
ability and decreases affinity for the cell surface receptor [67]. This
type of approach could be sufficient to ensure the activation of
nGPCRs, although without discriminative properties that could
rule out the activation of mGPCRs on the cell surface. Other
approaches could be the use of nanoparticles [68] or cell-penetrat-
ing peptides [69] that enter cells usually by endocytosis and/or can
be coupled with a NLS peptide, taking advantage of the natural
active transport system of the cell into the nucleus. The use of
‘Trojan Horses’ (i.e., drugs inside a carrier that is sensitive to
intracellular enzymes) could be a strategy to circumvent the
activation of cell membrane receptors and to deliver drugs prefer-
entially into the intracellular environment, providing more
possibilities to be translated into clinical practice.
Concluding remarks
GPCRs were thought to solely convert extracellular stimuli into
intracellular responses, while being located exclusively on cell
surface. However, over the past few decades, the intracellular
location of GPCRs in nuclear membranes was verified, challenging
the classic view of GPCRs. nGPCRs might be specifically or addi-
tionally activated with overlapping and/or unique signaling
events comparative to those of their cell surface counterparts. It
has been hypothesized that the final downstream effects attributed
to a certain GPCR might result from the integration of extracellular
and intracellular signaling pathways.
Studies thus far have led to increased insights into the involve-
ment of nGPCRs and their differential signaling in key physiological
and pathophysiological processes. In addition, the density of some
nGPCRs is known to be increased in several pathological conditions,
highlighting them as putative therapeutic drug targets. Therefore,
the nuclear location of GPCRs challenges our traditional under-
standing of GPCR pharmacology and exponentially increases their
complexity. Comprehensive pharmacological studies are urgently
needed for the development of new optimized drugs with activity on
a desired intracellular response to reach the directed therapeutic
outcome. In addition, further studies are required to understand and
challenge the classic pharmacological view of drugs used in clinical
practice the mechanisms of action of which have been attributed so
far solely to GPCRs located in the cell membrane. Thus, our new
understanding highlights the complex diversity of GPCR pharma-
cology, requiring the inclusion of different locations and/or func-
tions for GPCRs in physiopathology and disease.
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